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11β-Hydroxysteroid Dehydrogenase Type 2 (11βHSD2) catalyses the inactivation of 
cortisol.  In aldosterone target tissues co-expression of 11βHSD2 and 
mineralocorticoid receptors (MR) protects the receptor from activation by 
glucocorticoids.  In the syndrome of Apparent Mineralocorticoid Excess, mutations 
in the HSD11B2 gene cause hypertension, which is thought to be driven by volume 
expansion secondary to sodium retention.  11βHSD2 mice are indeed hypertensive 
but paradoxically volume contracted, suggestive of a urine-concentrating defect.  The 
current studies were designed to evaluate sodium and water homeostasis in 
11βHSD2-/- mice. 
 
11βHSD2-/- mice developed a severe and progressive polyuric-polydipsic phenotype.  
Despite basal polyuria, at <100 days 11βHSD2-/- mice had a functional concentration 
response when challenged with 24 hours water deprivation.  At >180 days the 
exacerbated polyuria was associated with severe medullary injury in the null mice.  
Basal aquaporin 2 (AQP2) abundance was reduced in the 11βHSD2-/- mice at both 
<100 and >180 days.  Moreover, vasopressin 2 receptor (V2R) stimulation failed to 
normalize the impaired response to water deprivation in >180 day null mice.  
Consequently, a renal origin to the polyuria was postulated.  Indeed, mice in which 
11βHSD2 had been selectively targeted in the brain had a normal water turnover.  A 
key finding from these studies is that functional deletion of 11βHSD2 in the brain, 
specifically the nucleus of the solitary tract (NTS), resulted in an increased salt 
appetite.  Moreover, the mice displayed a preference for 1.5% NaCl over water.  
 14 
Blockade of mineralocorticoid receptors (MR) significantly reduced NaCl intake.  
This is the first demonstration of an increased salt appetite in a model with normal 
renal function and in the absence of sodium depletion.  These data implicate 
activation of MR on 11βHSD2 positive neurons in the NTS in the behavioural drive 


























The control of body fluid homeostasis, through the regulation of intravascular blood 
volume and osmolality, is essential for the survival of mammals.  Perturbations of 
plasma osmolality from a tightly regulated set point, approximately 290 mosmol/kg 
H2O in humans, can have detrimental consequences, causing the loss of cellular 
integrity and subsequently the failure of essential physiological processes.  
Consequently, body water homeostasis is tightly regulated such that urinary water 
excretion and water intake are matched.  During situations of high water intake, large 
volumes of dilute urine are formed, thus preventing the dilution of plasma.  
Conversely, during dehydration, small volumes of high osmolality urine prevent the 
concentration of plasma.  These processes ensure that overall body water balance 
remains neutral.  The regulation of sodium and water homeostasis is driven by 
complex neurohormonal systems, which through the concerted modulation of central 
and renal pathways ensure that balance is maintained.  Aldosterone and vasopressin 
(AVP) have pivotal roles in these processes.  Aldosterone activation of 
mineralocorticoid receptors (MR) increases sodium reabsorption in the distal 
nephron and stimulates salt-intake during sodium depletion.  Increased plasma 
osmolality causes the central synthesis and release of AVP, which induces the renal 
conservation of water (Bourque, 2008).  This thesis will focus on the involvement of 
aldosterone and AVP in the deranged salt and water homeostasis observed in 11β-





1.1.  11βHSD2 protects MR from activation by glucocorticoids 
1.1.1.  Mineralocorticoid Receptor 
The MR is a member of the nuclear hormone receptor family, which consists of 
approximately fifty receptors, all of which are ligand-activated transcription factors.  
In common with other members of the family, MR consists of four structurally 
distinct domains: the N-terminal domain, the DNA-binding domain, a hinge region 
and a ligand-binding domain (Pippal and Fuller, 2008).  In the absence of ligand, MR 
is maintained in a transcriptionally inactive state through interactions between the 
ligand-binding domain and chaperone proteins such as heat shock protein 90 (hsp90).  
Whilst held in this inactive conformation, MR is capable of ligand but not DNA 
binding (Couette et al., 1998, Edwards, 2000).  Ligand binding to the ligand-binding 
domain induces conformational changes within the region’s alpha helical structure, 
resulting in the dissociation of chaperone proteins and the exposure of the nuclear 
localization signal (NLS).  Consequently, ligand-activated MR translocates to the 
nucleus (Fejes-Toth et al., 1998, Walther et al., 2005).  Central to the ligand-
dependent activation of MR is a helical sequence referred to as activation function 2 
(AF-2), located at the carboxyl-terminal of the ligand-binding domain (Glass and 
Rosenfeld, 2000).  Ligand-induced conformational changes facilitate the binding of 
AF-2 to transcription coactivators, such as activating signal co-integrator 2 (ASC-2), 
steroid receptor coactivator 1 (SRC-1) and peroxisome proliferator-activated receptor 
gamma coactivator 1 alpha/beta (PGC-1α/β) (Hultman et al., 2005).  Although such 
coactivators have no intrinsic affinity for DNA, their binding to the ligand-binding 
domain induces and enhances MR transcriptional activity (Hermanson et al., 2002).  
The ligand-binding domain is also involved in MR receptor dimerization.  The DNA-
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binding domain is located towards the centre of the MR, and contains eight cysteine 
residues, which bind to two zinc ions, forming zinc fingers.  These interactions are 
fundamental in the stabilization of the DNA-binding domain (Berg et al., 2002), with 
the first zinc finger binding to the minor grove of MR target DNA and the second 
aiding receptor dimerization (Viengchareun et al., 2007).  Following activation, 
dimeric MR binds to hormone response elements (HREs) located within the 
promoter regions of its target genes.  Once bound to DNA, MR acts as a molecular 
scaffold for gene transcription machinery, thus facilitating the process (Viengchareun 
et al., 2007).  In addition to AF-2 located at the carboxyl-terminal of MR, regions 
within the N-terminal domain (AF-1a and AF-1b) are also involved in transcription 
and transrepression.  As with AF-2, these regions modulate MR activity through the 
recruitment of, and interaction with, cofactors (Pascual-Le Tallec and Lombes, 
2005).  The ligand-binding domain of MR bares a high degree of homology to the 
ligand-binding domain of the glucocorticoid receptor (GR) (Figure 1.1).  
Consequently, glucocorticoids bind with the same affinity as mineralocorticoids 
(Arriza et al., 1987).  In addition to regulating transcription, MR cofactors are also 
thought to confer aldosterone specificity upon the receptor.  However, in aldosterone 
target tissues, MR specificity is primarily conferred by its co-expression with the 





The importance of MR in sodium homeostasis is highlighted by gene targeting 
experiments to “knockout” functional expression of the receptor.  MR null mice 
displayed a severe sodium wasting phenotype and consequently died within two 
weeks of birth.  An impaired excretory response to amiloride implicated loss of the 
epithelial sodium channel (ENaC) in the phenotype (Berger et al., 1998).  In contrast, 
spatially regulated deletion of MR in the principal cells of the late connecting tubule 
and collecting duct did not result in natriuresis.  Since plasma aldosterone levels 
were significantly elevated in the null mice it was postulated that upregulation of 
ENaC in the late distal convoluted tubule (DCT2) compensated for the downstream 
loss of the channel.  However, when challenged with a low sodium diet the mice 
were unable to remain in balance despite further increases in plasma aldosterone, 
Figure 1.1:  Schematic diagram illustrating the amino acid sequence homology 
between the mineralocorticoid receptor (MR) and the glucocorticoid receptor 
(GR).  DBD, DNA binding domain.  LBD, ligand binding domain.  Adapted from 
(Pippal and Fuller, 2008). 
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suggesting that ENaC in DCT2 was not sufficient to compensate in this situation 
(Ronzaud et al., 2007).  Temporal induction of MR deletion in the late connecting 
tubule and collecting duct resulted in the same phenotype, confirming that the 
impaired sodium handling was the result of MR deletion rather than developmental 
changes resulting from the absence of the receptor (Ronzaud et al., 2011). 
 
1.1.2.  11βHSD2 confers aldosterone specificity on MR 
In Vitro both aldosterone and cortisol have equal affinities for MR (Arriza et al., 
1987) nevertheless in normal physiological conditions the receptors are selectively 
activated by aldosterone.  This selectivity results from pre-receptor glucocorticoid 
metabolism by the isozymes of 11βHSD in target tissues (Stewart et al., 1987, 
Funder et al., 1988).  Two isoforms of 11βHSD have been cloned, 11βHSD1 and 
11βHSD2.  Both enzymes are members of the short-chain alcohol 
dehydrogenase/reductase (SDR) family, but are encoded by distinct genes (HSD11B1 
and HSD11B2) and have a low sequence homology.  11βHSD1 functions primarily 
as a reductase in vivo, converting inactive cortisone to cortisol (11β-
dehydrocorticosterone to corticosterone in rodents).  Reductase activity is dependent 
on NADP(H) cofactor binding.  Generation of cortisol by 11βHSD1 is involved in 
the regulation of GR activation (Paterson et al., 2005).   
 
HSD11B2 is a five-exon gene located on chromosome 16 in humans (chromosome 8 
in mice), which encodes the 405 amino acid protein 11βHSD2.  11βHSD2 is an 
NAD-dependent dehydrogenase that regulates cortisol inactivation, catalyzing its 
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conversion to the inactive 11-keto metabolite cortisone (corticosterone to 11-
dehydrocorticosterone in rodents) (Figure 1.2) (Agarwal et al., 1995, Albiston et al., 







Figure 1.2:  Inactivation of cortisol by 11βHSD2.  11βHSD2 converts cortisol 
to cortisone (corticosterone to 11-dehydrocorticosterone in rodents).  Since 
cortisone has no affinity at MR this ensures aldosterone specific activation in 
target tissues.  ROMK, potassium channel.  ENaC, epithelial sodium channel.  
Na/K-ATPase, sodium potassium adenosine triphosphate.  
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Despite the low sequence homology between members of the SDR family the protein 
structures of the enzymes are highly conserved (Tsigelny and Baker, 1995).  
Consequently, much of the information about 11βHSD2 structure has been gained 
from homology modeling, predominantly using the x-ray crystal structure of 
11βHSD1 as a template (Yamaguchi et al., 2011a).  The secondary structure of 
11βHSD2 consists of 6 parallel β-sheets flanked by 3 α-helices (Yamaguchi et al., 
2011a) (Figure 1.3).  NAD binds to a highly conserved Gly89XXXGly93XGly95 
motif located within the ligand-binding site of 11βHSD2.  The conserved glycines 
are essential for the attraction of NAD (Yamaguchi et al., 2011b), with their 
substitution resulting in the loss of enzyme function (Weiner and Hurley, 2005).  
Cofactor binding is stabilized through the formation of hydrogen bonds with Asp91, 
Phe94, Tyr232 and Thr267 in the ligand-binding site (Yamaguchi et al., 2011b, 
Yamaguchi et al., 2011a).  Cortisol also binds to the ligand-binding site (Yamaguchi 
et al., 2011a).  11βHSD2 enzymatic activity is dependent on a conserved YXXXK 
motif.  Site directed mutagenesis demonstrated that the mutation of either Tyr-179 of 
Lys-183 within the motif abrogated enzyme activity (Obeid and White, 1992).  
Through inactivation of cortisol, 11βHSD2 confers aldosterone selectivity and 
protects MR from activation by glucocorticoids (Funder et al., 1988).   
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Figure 1.3:  3-dimensional model of dimeric 11βHSD2.  The two monomers 
are shown in dark grey and white.  NAD is shown with carbons-white, cortisol 
is grey.  Other atoms: oxygen-red, nitrogen-blue, phosphorus-orange.  Portions 
with reported modelling problems are shown in red.  Figure taken from 
(Manning et al., 2010) 
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1.1.3.  Localisation of 11βHSD2 
Given its role in protecting MR from activation by glucocorticoids, expression of 
11βHSD2 is enriched in aldosterone target tissues.  Within the cell 11βHSD2 is 
localized to the endoplasmic reticulum (ER) (Odermatt et al., 1999).  Epitope-
tagging the N and C terminal of 11βHSD2 enabled the determination of the 
enzyme’s orientation in the ER.  The catalytic C-terminal was shown to be 
cytoplasmic, whereas the N-terminal transmembrane anchor faced the lumen 
(Odermatt et al., 1999).  Algorithmic modeling was used to predict the membrane 
topology of 11βHSD2, which was proposed to consist of three transmembrane 
helices originating at the luminal N-terminal (Obeyesekere et al., 1997).  In the 
absence of 11βHSD2 MR has a diffuse intracellular expression.  In contrast, 
coexpression with 11βHSD2 resulted in the localization of MR to the ER.  The close 
proximity between enzyme and receptor was shown to be essential for the 
conferment of aldosterone selectivity on MR.  When co-expressed with 11βHSD2 
aldosterone but not cortisol induced nuclear translocation of MR (Odermatt et al., 
2001).  Fundamentally, the discrete location of 11βHSD2 in regions of the kidney 
and brain involved in salt and water homeostasis enables aldosterone regulation of 
extracellular fluid status, which would otherwise be prevented by the promiscuous 
occupation by glucocorticoids of MR. 
 
1.1.3.1.  Expression in the kidney 
In the kidney expression of 11βHSD2 is restricted to the distal nephron.  The 
aldosterone sensitive distal nephron (ASDN), so termed because 11βHSD2 
expression ensures aldosterone specific activation of MR, initiates at the start of the 
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DCT2.  Immunohistochemical evaluation has enabled the localization of 11βHSD2 
along the murine nephron to be determined.  11βHSD2 mRNA expression was 
primarily detected in the principal cells of the connecting tubule and collecting duct.  
Additionally, low levels of mRNA were detected in the terminal DCT (Campean et 
al., 2001).  Consequently, it was postulated that in the murine nephron the 
connecting tubule and collecting duct are the major regions of aldosterone signaling, 
with the terminal DCT playing a secondary role.  Further evaluation utilized mice in 
which the enzyme cre-recombinase was placed under the control of the 11βHSD2 
promoter.  The cre mice were subsequently crossed with mice in which β-
galactosidase activity was driven by cre-recombination (ROSA26).  Therefore tissues 
with active cre-recombinase, and therefore expressed 11βHSD2, were positive when 
X-gal stained.  X-gal staining was most abundant in the connecting tubule and 
collecting duct, and absent in the proximal tubules and glomeruli.  No 11βHSD2 
expression was detected in the DCT (Naray-Fejes-Toth and Fejes-Toth, 2007).  
Together these data suggest that in the murine kidney expression of 11βHSD2 is 
predominant in the connecting tubule and collecting duct, with little to no expression 
in the DCT.  Similarly, immunohistochemical staining has demonstrated the 
abundant expression of 11βHSD2 in the principal cells of the connecting tubule and 
collecting duct in human tissue (Kyossev et al., 1996, Hirasawa et al., 1997).  
However, in contrast to the results from murine kidneys, these studies also 
demonstrated the expression of 11βHSD2 in the thick ascending limb of the loop of 
Henle (Kyossev et al., 1996, Hirasawa et al., 1997), suggesting species differences in 
the expression profiles.  Indeed 11βHSD2 activity has also been detected in the thick 
ascending limb of the rabbit nephron (Bonvalet et al., 1990).  Notably, 11βHSD2 
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expression is consistently absent from more proximal regions of the tubule, 
regardless of species.  Consequently, the distal nephron is involved in the 
aldosterone-mediated fine-tuning of sodium excretion, which is critical in the 
regulation of blood pressure and fluid homeostasis.   
 
1.1.3.2.  Expression in the brain 
In the central nervous system expression of 11βHSD2 is wide spread during 
embryogenesis (Diaz et al., 1998, Holmes et al., 2006b).  During development 
overexposure to glucocorticoids can have deleterious effects on neuronal 
development, resulting in the inhibition of proliferation, migration and 
differentiation.  Prenatally, the broad distribution of 11βHSD2 prevents neuronal 
damage by ensuring that local glucocorticoid concentrations are kept low.  In adult 
mice the expression of 11βHSD2 is restricted to the nucleus of the solitary tract 
(NTS) (Holmes et al., 2006b), although a more diverse distribution has been 
described in other species (Roland et al., 1995, Robson et al., 1998, Geerling et al., 
2006b).  11βHSD2-positive neurons within the NTS are active in sodium-deprived, 
but not replete rats, implicating them in the response to sodium deficiency (Geerling 
et al., 2006a).  Additionally, the NTS has been proposed as a site of integration for 
afferents involved in the regulation of cardiovascular function, specifically arterial 
baroreceptor afferents (Reviewed in (Boscan et al., 2002).  
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1.1.3.3.  Other sites of expression 
In addition to the kidney and brain, 11βHSD2 is also highly expressed in the placenta 
where it protects the foetus from overexposure to maternal glucocorticoids.  
Reductions in placental 11βHSD2 activity result in reduced birth weight (Stewart et 
al., 1995, Dave-Sharma et al., 1998).  Moreover, overexposure to glucocorticoids in 
utero can program detrimental effects postnatally, including hypertension, renal 
damage and altered tubular sodium handing (Dagan et al., 2007, Ortiz et al., 2003).  
This illustrates the importance of glucocorticoid metabolism by placental 11βHSD2 
during fetal development.      
 
Expression of 11βHSD2 has also been documented in the vasculature and bone.  
11βHSD2 is implicated in the response to vasoactive agents.  However, although 
augmented vasoconstriction in response to noradrenaline was recorded in aortae 
isolated from 11βHSD2-/- mice bred on an MF1 background (Hadoke et al., 2001) 
the results were not reproduced when the mice were backcrossed onto a C57Bl/6 
background (Bailey et al., 2008).  Therefore the role of 11βHSD2 in the modulation 
of vascular constriction is unclear.  Within the bone 11βHSD2 modulation of 
glucocorticoid levels is thought to ensure appropriate formation and maintenance.  
Mice in which 11βHSD2 is overexpressed in osteoblasts have a reduced bone mass, 
illustrating the importance of regulated glucocorticoid signaling in bone development 
(Yang et al., 2010). 
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1.2.  11βHSD2 and the renal regulation of sodium and water balance 
In normal physiological conditions the human kidneys filter in the order of 180 l of 
water per day at the glomerulus, of which approximately 99.4% is reabsorped by the 
renal tubules.  Despite this large reabsorption, there is no active transport of water 
within the nephron: rather its movement is driven solely by the reabsorption of 
solute.  In contrast to plasma, filtrate entering the tubule is largely protein free.  The 
glomerular filtration barrier, which consists of three components; the capillary 
endothelial cells, the basement membrane and podocytes, mediates the exclusion of 
protein from the filtrate.  The barrier filters on the basis of charge and size; 
consequently, large negatively charged molecules such as albumin are excluded from 
the luminal fluid.  Accordingly, glomerular disease can be characterized by the 
presence of protein in the urine (D'Amico and Bazzi, 2003). 
 
1.2.1.  The proximal tubule 
The majority (65%) of filtrate reabsorption occurs in the proximal tubule, with the 
movement of water secondary to that of sodium and other osmolytes.  The movement 
of sodium from the luminal fluid into the cell is mediated by a battery of sodium-
coupled exchanges, predominantly sodium-hydrogen exchangers (NHE) expressed 
on the apical membrane (Figure 1.4).  Consequently, the influx of sodium largely 
occurs in exchange for the secretion of hydrogen.  Two isoforms of NHE have been 
identified on the apical membrane: NHE3, which is highly expressed in adults and 
NHE8, the predominant form in neonates.  It is thought that a developmental switch 
between NHE8 and NHE3 occurs during the postnatal renal maturation process 
(Becker et al., 2007).  As in other regions of the nephron, the electrochemical 
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gradient required for the movement of sodium into the cell is generated by Na/K-
ATPases located on the basolateral membrane.  The basolateral membrane of the 
proximal tubule is highly invaginous, bringing membrane bound Na/K-ATPases into 
close proximity with intracellular mitochondria.  This maximizes the surface area 
and energy supply and facilitates the mass reabsorption that occurs in this region 
(Thomas, 2008).   
 
60-70% of filtered water is reabsorbed in the proximal tubule and is mediated by 
aquaporin-1 (AQP1) and aquaporin-7 (AQP7) channels.  AQP1 is located on both 
the apical and basolateral membranes of the cells (Nielsen et al., 1993b).  AQP1 null 
mice were shown to have an impaired concentration response: following a 36-hour 
water deprivation challenge they developed severe dehydration and in extreme cases 
unresponsiveness (Ma et al., 1998).  Although AQP1 is also expressed on the 
descending thin limb of the loop of Henle, free flow micropuncture experiments 
confirmed extensive impairment of osmotic water permeability in the proximal 
tubule of AQP1 null mice, substantiating AQP1 as the main pathway for the 
reabsorption of water in this region of the nephron (Schnermann et al., 1998).  
AQP7, located on the apical membrane of the proximal tubule, also contributes to the 
reabsorption of water, although to a much lesser extent than AQP1.  Based on 
measurements of the water permeability of isolated brush border membrane vesicles 
from AQP7 null mice, AQP7 accounted for ~10% of water reabsorption (Sohara et 
al., 2005).  The remaining ~10% of proximal tubule water reabsorption occurs 
paracellularly.  Since in this region the movement of water and solute are 
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inextricably linked, fluid leaving the proximal tubule is approximately isosmotic to 
plasma despite the daily reabsorption of approximately 120 l of water. 
Since the proximal tubule is devoid of 11βHSD2 (Kyossev et al., 1996, Naray-Fejes-




Figure 1.4:  Proximal tubule cell.  NHE3, sodium-hydrogen exchanger 3.  
AQP1, aquaporin 1.  AQP7, aquaporin 7.  Na/K-ATPase, sodium potassium 
adenosine triphosphatase. 
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1.2.2. The loop of Henle 
1.2.2.1.  The loop of Henle generates a medullary gradient 
As the nephron leaves the cortex and descends into the renal medulla, the 
reabsoption of water and sodium are separated due to the selective permeabilities of 
the ascending and descending limbs of Henle.  In the ascending limb, solutes are 
transported from the luminal fluid into the interstitium by the concerted action of the 
furosemide-sensitive sodium-potassium-chloride cotransporter (NKCC2) on the 
apical membrane, and Na/K-ATPase on the basolateral membrane.  Sodium, 
potassium and chloride are transported from the luminal fluid into the cell via 
NKCC2 in a ratio of 1:1:2 (Brenner and Rector, 2004).  The majority of the 
potassium transported into the cell returns to the luminal fluid via apical membrane 
potassium channels encoded by ROMK, one with a conductance of 30-pS (SK) and 
another of 70-pS (ROMK) (Wang, 1994, Lu et al., 2004).  Therefore, although the 
concentration of potassium in the luminal fluid is substantially lower than that of 
sodium, the recycling of potassium prevents it from limiting sodium transport.  
Consequently, the limiting factor in sodium reabsorption in the ascending limb is the 
delivery of fluid from the proximal tubule.  Increased sodium reabsorption in the 
proximal tubule results in reduced sodium delivery to the ascending limb, and 
therefore limits the generation of the cortico-medullary osmotic gradient.  This 
results in an attenuated osmotic gradient across the collecting duct, and therefore an 
impaired ability to concentrate urine (Schrier, 2003).  The movement of sodium from 
the luminal fluid into the cell is dependent on a favourable sodium gradient; 
consequently, the concentration of sodium within the cell must be kept low.  As in 
the proximal tubule, the sodium gradient is generated by the active extrusion of 
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sodium from the cell by Na/K-ATPase located on the basolateral membrane.  
Moreover, since NKCC2 generates a relatively high concentration of chloride in the 
cell, it also moves down its gradient, out of the cell, via basolateral membrane 
chloride channels (CIC-K1 in the thin- and CIC-K2 in the thick-ascending limb 
(Uchida et al., 1993, Adachi et al., 1994).  Consequently, this sequence of events 
causes the accumulation of NaCl in the medullary interstitium.  Since the ascending 
limb is impermeable to water, these processes lead to the generation of a relatively 
hyperosmotic interstitium and hypoosmotic tubular fluid (Figure 1.5). 
 
 
Figure 1.5:  Ascending limb loop of Henle cell.  NKCC2, furosemide-
sensitive sodium-potassium-chloride cotransporter.  ROMK, renal outer 
medullary potassium channel.  SK, small conductance calcium activated 
potassium channel.  Na/K-ATPase, sodium potassium adenosine triphophatase.  
CIC-K, voltage gated chloride channel.     
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The ascending limb is also a major site of divalent cation reabsorption.  In this region 
60% of filtered magnesium and 20% of filtered calcium is reabsorbed paracellularly, 
driven by the substantial transepithelial voltage gradient predominantly generated by 
NKCC2.  The evaluation of isolated perfused tubules established that transepithelial 
voltages in the ascending limb range from 3-10mV dependent on the species and 
flow rate (Burg, 1982).  The importance of this voltage gradient in divalent cation 
reabsorption was illustrated in isolated perfused thick ascending limbs.  Voltage 
clamp experiments demonstrated that calcium and magnesium reabsorption were 
negligible in the absence of a transepithelial voltage (Bourdeau and Burg, 1979, 
Shareghi and Agus, 1982). Since intra-luminal furosemide increased urinary calcium 
and magnesium in micropuncture experiments, (Quamme, 1981) and decreased the 
transepithelial voltage in isolated perfused tubules (Burg et al., 1973), the pivotal 
role of NKCC2 in paracellular cation transport was confirmed.  
 
1.2.2.2.  Countercurrent multiplication 
It is of note that individual cells in the wall of the ascending limb are only capable of 
sustaining an osmotic gradient of approximately 200 mosmol/kg H2O.  This means 
that at any transverse plane along the medulla the difference between the osmolality 
of the fluid in the ascending limb and in the interstitium is restricted to 200 
mosmol/kg H2O.  However, within the medulla a substantially larger longitudinal 
osmotic gradient exists, extending from the cortico-medullary boundary to the tip of 
the papilla.  This gradient is generated by countercurrent multiplication, a process 
dependent on the anatomical arrangement of the loop of Henle (Figure 1.6) (Lote, 
2000, Brenner and Rector, 2004, Guyton and Hall, 2000). 
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Figure 1.6:  Countercurrent multiplication in the loop of Henle.  Figure 
adapted from (Guyton and Hall, 2000).  Values are in mOsm.  Pink arrows 
represent the transport of Na from the ascending limb into the interstitium.  
Blue arrows represent the movement of water from the descending limb into 
the interstitium.  
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The descending limb of the loop of Henle, (which lies parallel to the ascending limb 
but has a countercurrent tubular flow), has a relatively low permeability to sodium 
but a high permeability to water due to the constitutive presence of AQP1 channels 
on both the apical and basolateral membranes (Nielsen et al., 1995b).  Fluid entering 
the descending limb from the proximal tubule is isosmotic to plasma.  As this fluid 
descends into the medulla, water translocates from it, through AQP1 channels, into 
the relatively hyperosmotic interstitium generated by the ascending limb.  The 
reabsorption of water continues until an osmotic equilibrium has been achieved.  
Consequently, fluid in the descending limb is hyperosmotic relative to that in the 
ascending limb, but isosmotic with the interstitium.  As the hyperosmotic fluid enters 
the ascending limb, NaCl is again transported from it into the interstitium, further 
augmenting its osmolality and decreasing that of the tubular fluid.  This cycle of 
events continues and the longitudinal gradient through the medulla is established.  
Therefore, countercurrent multiplication allows a small transverse osmotic difference 
(a single-osmotic effect of 200 mosmol/kg H2O) to be multiplied into a large 
longitudinal osmotic gradient.  The maximum osmolality achieved along the gradient 
is dependent on the length of the loop of Henle, with osmolalities of 1400 
mosmol/kg H2O being achieved at the tip of long loops in humans (Brenner and 
Rector, 2004).  In rodents osmolalities of over 3000 mosmol/kg H2O are frequently 
reached at the tip of papillae, enabling the production of more concentrated urine 
(Kwon et al., 2009).  Moreover, the separation of solute and water in the loop of 
Henle means that fluid leaving the ascending limb and entering the DCT is 
hypoosmotic relative to plasma, with the degree of hypoosmoticity dependent on the 
length of the loop.  
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Although the accumulation of NaCl in the interstitium is fundamental in the 
concentration of urine, the resultant hypertonic environment imposes severe stress on 
the cells within the renal medulla.  In order to maintain integrity, and a constant 
intracellular environment, cells within the medulla generate organic osmolytes, such 
as sorbitol.  Accumulation of compatible osmolytes increases intracellular 
osmolality, allowing the maintenance of intracellular volume and ultimately 
preventing hypertonicity induced cell death.  Central to this response is the 
transcription factor tonicity-responsive enhancer binding protein (TONEBP) (Woo et 
al., 2002).  During hypertonicity TONEBP mRNA and protein abundance increase.  
This leads to the increased transcription of a battery of genes involved in the 
generation of compatible osmolytes, including aldose reductase, which catalyses the 
conversion of glucose to sorbitol (Lopez-Rodriguez et al., 2004, Cai et al., 2005, 
Miyakawa et al., 1999).  The central role of TONEBP in the maintenance of 
medullary integrity has been illustrated in TONEBP null mice.  In mice deletion of 
TONEBP resulted in the impaired regulation of osmoprotective genes.  Consequently 
the mice the developed severe meduallary atrophy (Lopez-Rodriguez et al., 2004). 
 
1.2.2.3.  The contribution of urea to the medullary gradient 
The accumulation of NaCl in the medulla is pivotal in the generation of the 
medullary osmotic gradient.  However, the concentration of NaCl only accounts for 
approximately half of the medullary hyperosmoticity.  The remainder is largely 
attributable to urea.  Since plasma concentrations of urea are relatively low, 
approximately 5 mmol/L in humans (Hinwood, 1992) and 9 mmol/L in mice (Zhao 
et al., 2006), renal recycling mechanisms exist to establish and maintain high 
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concentrations of urea within the inner medulla.  The pivotal recycling pathway 
involves the movement of urea between the terminal inner medullary collecting duct 
and the thin ascending limb of the loop of Henle.  Urea is freely filtered at the 
glomerulus; therefore the concentration entering the proximal tubule is equal to that 
of the plasma.  50% of filtered urea is reabsorbed in the proximal tubule, moving by 
passive diffusion down its concentration gradient into the medulla.   As the nephron 
descends through the medulla it passes through increasing concentrations of 
interstitial urea.  Consequently, urea moves from the interstitium back into the 
luminal fluid within the descending limb of the loop of Henle.  Luminal fluid 
entering the ascending limb of the loop of Henle has a urea concentration 
approximately equal to that of plasma.  Regions of the nephron distal to the 
descending limb are relatively impermeable to urea.  Since water is reabsorbed from 
the collecting duct, the concentration of urea in the luminal fluid increases as the 
nephron descends back through the medulla.  Consequently, the concentration of 
urea in the luminal fluid in the inner medullary collecting duct can be 50 times 
greater than that of plasma.  In the mouse kidney urea is reabsorbed from the inner 
medullary collecting ducts though urea transporter A1 (UT-A1) on the apical 
membrane and urea transporter A3 (UT-A3) on basolateral plasma membrane 
(Fenton et al., 2002).  Since the ascending limb of the loop of Henle and the inner 
medullary collecting duct are virtually contiguous, urea reabsorbed from the 
collecting duct re-enters the ascending limb of the loop of Henle via the interstitium.  
The low blood flow through the medulla ensured by countercurrent exchange within 
the vasa recta, means that large concentrations of urea are retained in the interstitium.  
Therefore the recycling of urea further increases the osmolality of the interstitium.  
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Moreover, the high concentration of urea within the interstitium prevents the 
induction of osmotic diuresis, which would otherwise be required to excrete the large 
quantities of urea in the urine (Reviewed in (Fenton et al., 2006).   
 
1.2.2.4.  Countercurrent exchange maintains the osmotic gradient 
Once established, the cortico-medullary osmotic gradient is maintained by the unique 
hairpin arrangement of the capillaries within the medulla.  The descending vasa recta 
originate from juxtamedullary efferent arterioles.  Consequently, the sodium 
concentration of blood entering the medulla is approximately equal to that of plasma, 
140 mmol/l.  Like other capillaries within the body the vasa recta have a high 
permeability to both solutes and water; therefore as the capillaries pass through the 
medulla the osmolality of the blood equilibrates with that of the interstitium.  As the 
vasa recta descend into the medulla solutes (mainly sodium and urea) diffuse down 
their concentration gradient from the interstitium into the blood.  In addition water 
leaves the blood through AQP1 channels (Nielsen et al., 1995b).  At the tip of the 
papilla the concentration of blood within the vasa recta is approximately equal to that 
of the interstitium.  In contrast, as the vasa recta ascend towards the cortex the 
osmolality of the interstitium becomes progressively less.  Consequently, solutes are 
reabsorbed into the interstitium, and water moves into the blood.  Hence the 
anatomical arrangement of the vasa recta “traps” solute within the medulla and 
preserves the osmotic gradient.  Moreover, countercurrent exchange provides a 
mechanism by which blood can move into and out of the medulla without disrupting 
the osmotic gradient (Brenner and Rector, 2004). 
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1.2.2.5.  The effect of AVP on the loop of Henle 
Through the stimulation of NaCl reabsorption in the thick ascending limb, AVP 
increases the effects of countercurrent multiplication and enhances AVP induced 
urine concentration in the collecting duct.  The effects of AVP in the thick ascending 
limb are mediated by the activation of vasopressin 2 receptors (V2R).  In situ 
hybridization demonstrated V2R mRNA expression along the thick ascending limb 
(Mutig et al., 2007).  Abundance was highest in the inner medullary stripe and 
declined progressively as the tubules ascended through the cortex.  Activation of 
V2R causes the increased reabsorption of NaCl through the stimulation of the 
NKCC2.  Administration of desmopressin (ddAVP) to adult mice resulted in an 
approximately 2-fold increase in the abundance of phosphosphorylated NKCC2.  
Since the phosphorylated NKCC2 localized at the apical membrane of the thick 
ascending limbs it was postulated that AVP regulation of NKCC2 was similar to that 
of AQP2, with AVP stimulating exocytosis and consequently increased membrane 
expression (Gimenez and Forbush, 2003).  Indeed it was subsequently shown that as 
with AQP2, AVP induced exocytosis of NKCC2 was cAMP dependent, and could be 
blocked by the administration of a protein kinase A (PKA) inhibitor (Caceres et al., 
2009). 
 
1.2.2.6.  The effect of corticosteroids on the loop of Henle 
Studies in adrenalectomized rats demonstrated that the removal of the adrenal 
hormones resulted in reduced sodium reabsorption in the loop of Henle.  
Reabsorption was increased to near control levels by aldosterone but not 
dexamethasone, implicating the mineralocorticoid in the modulation of sodium 
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transport in the loop of Henle (Stanton, 1986).  Recently, immunohistochemical 
analysis has demonstrated significant expression of MR in the thick ascending limb 
(Ackermann et al., 2010); however, since the region of the nephron does not robustly 
express 11βHSD2 (Bujalska et al., 1997), and therefore does not form part of the 
ASDN, the physiological relevance of these findings is uncertain.  Indeed it was 
demonstrated that in intact rats the cellular localization of MR in the thick ascending 
limb is determined by glucocorticoids.  Aldosterone was only capable of inducing 
nuclear translocation of MR in absence of endogenous corticosterone (Ackermann et 
al., 2010). 
 
1.2.3.  The distal convoluted tubule 
1.2.3.1.  The distal convoluted tubule further dilutes filtrate 
5-10% of sodium reabsorption occurs in the DCT.  This region of the nephron can be 
divided into two sections: DCT1 the initial segment in which the majority of sodium 
reabsorption is driven by the thiazide-sensitive transporter (NCC); and DCT2 the late 
segment which also expresses ENaC.  DCT2 marks the start of the ASDN since it is 
the first region of the tubule in which MR and 11βHSD2 are coexpressed 
(Bostanjoglo et al., 1998).  Again, in this section of the nephron the gradient required 
for the movement of sodium is driven by Na/K-ATPases located in the basolateral 
membrane.  In DCT1 Na reabsorption occurs though NCC and is an electroneutral 
process.  In the absence of an electrochemical gradient the secretion of potassium 
through ROMK and BK in this region is minimal (Brenner and Rector, 2004).  
Therefore, in DCT1 the majority of potassium secretion is mediated by K/Cl-
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cotransporters, predominantly in situations when luminal Cl is low or bicarbonate 
excretion is high (Amorim et al., 2003).  In DCT2 ENaC mediates reabsorption of 
sodium.  The reabsorption of sodium through ENaC results in the depolarization of 
the apical membrane and the generation of the electrochemical gradient required for 
potassium secretion.  Consequently in normal conditions the majority of potassium 
secretion occurs in DCT2, through ROMK and BK potassium channels expressed on 
the apical membrane (Figure 1.7).  In this region the rate of potassium secretion is 
dependent in on the reabsorption rate of sodium through ENaC and the activity- and 
expression- of ROMK at the apical membrane (Meneton et al., 2004).  Since DCT 
does not express AQPs it permeability to water is low.  Consequently, the dilution of 









Figure 1.7:  Late distal convoluted tubule cell.  NCC,  thiazide sensitive 
sodium chloride cotranspoter.  ENaC, epithelial sodium channel.  ROMK, 
renal outer medullary potassium channel.  BK, big conductance calcium 
activated potassium channel.  Na/K-ATPase, sodium potassium adenosine 
triphosphatase 
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1.2.3.2.  The effect of AVP on the distal convoluted tubule 
Substantial V2R mRNA expression has been demonstrated in the DCT (Mutig et al., 
2007).  The physiological role of AVP in the DCT was demonstrated in Brattleboro 
rats, a model devoid of endogenous AVP.  In these rats chronic ddAVP 
administration resulted in increased NCC protein abundance (Ecelbarger et al., 
2001a). Subsequently it was shown that ddAVP stimulation of V2R resulted in 
increased NCC phopsphorylation and apical membrane expression (Mutig et al., 
2010, Pedersen et al., 2010).  Plasma levels of AVP are elevated during 
hypovolemia, when increased water reabsorption is desired.  However, since the 
DCT has a low permeability to water, and as such contributes to urinary dilution, it 
seems counterintuitive that sodium reabsorption in this region is increased in 
situations of high plasma osmolality.  It has been postulated that as in the ascending 
limb, sodium reabsorption from the DCT increases the medullary osmotic gradient, 
thereby facilitating AVP-induced water reabsorption from the collecting duct 
(Pedersen et al., 2010). 
 
1.2.3.3.  The effect of corticosteroids on the distal convoluted tubule 
The primary role of aldosterone in the DCT is the modulation of ENaC, through the 
regulation serum- and glucocorticoid-regulated kinase 1 (SGK-1) and the neural 
precursor cell expressed developmentally down-regulated protein (Nedd) type 4-2, 
an E3 ubiquitin ligase.  SGK-1 is expressed in several regions throughout the 
nephron (glomerulus, proximal tubule and distal nephron), however it is only in the 
ASDN where its expression is regulated by aldosterone (Pearce et al., 2000).  Studies 
in rats demonstrated that physiological doses of aldosterone induced the upregulation 
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of SGK-1 expression 30-60 minutes post administration.  This increase was 
associated with decreased urinary sodium excretion, suggesting SGK-1 stimulated 
increased sodium reabsorption in the distal nephron.  Moreover, administration of a 
glucocorticoid receptor antagonist demonstrated that the effects of aldosterone were 
mediated by the activation of MR (Bhargava et al., 2001).  Initial evidence for the 
role of SGK-1 in regulation of ENaC expression came from studies in Xenopus 
oocytes.  Co-expression of SGK-1 with ENaC increased the ENaC mediated sodium 
current approximately 7-fold, relative to expression of ENaC alone.  Since SGK-1 
alone had no effect on sodium transport it was concluded that its effect was mediated 
through increased ENaC activity (Chen et al., 1999).  This conclusion was further 
substantiated through the evaluation of SGK-1 knockout mice.  Although the mice 
were phenotypically normal when receiving a standard sodium diet (2.5g Na+/kg), 
when challenged with sodium restriction (0.15g Na+/kg) they displayed an impaired 
ability to appropriately conserve sodium.  Consequently, they had an attenuated 
blood pressure and glomerular filtration rate in spite of elevated plasma aldosterone 
levels (Wulff et al., 2002).  Despite its pivotal role in the control of ENaC mediated 
sodium reabsorption, SGK-1 is not thought to phosphorylate the channel directly; 
rather its posttranslational effects are mediated by the phosphorylation and 
subsequent inhibition of Nedd4-2.  The α, β and γ subunits of ENaC contain a PY 
motif in their carboxyl-terminal domains.  These motifs are the point of interaction 
for Nedd4-2, which ubiquitinates the channel, targeting it for internalization and 
lysosomal degradation.  Since ubiquitination is central in the membrane retrieval of 
ENaC, this causes its accumulation at the apical membrane (Debonneville et al., 
2001, Staub et al., 1996).   
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In addition, glucocorticoids regulate α ENaC transcription through the activation of a 
glucocorticoid receptor response element (GRE) in the genes promoter region.  In 
contrast to the posttranslational modification, modulation of transcription occurs 
independently of SGK-1 activation (McTavish et al., 2009). 
 
Since 11βHSD2 is not expressed in DCT1 the region is insensitive to aldosterone 
(Campean et al., 2001).  Therefore aldosterone modulation of NCC is restricted to 
DCT2.  In vivo microperfusion studies demonstrated that both mineralocorticoids 
and glucocorticoids are capable of NCC modulation.  Both aldosterone and 
dexmethasone replacement in adrenalectomized rats resulted in increased NCC 
mediated sodium reabsorption (Velazquez et al., 1996).  Moreover the effects were 
shown to be the result of increased channel expression.  Additionally, aldosterone 
has been shown to modulate the serine theronine kinase with-no-lysine 4 (WNK4).  
WNK4 inhibits NCC mediated sodium reabsorption by reducing trafficking of the 
channel to the plasma membrane (Yang et al., 2003, Wilson et al., 2003).  The 
inhibition NCC trafficking is likely mediated by WNK4 phosphorylation of the 
channel since catalytic inhibition of the kinase prevented the suppression of NCC 
activity (Wilson et al., 2003).  Aldosterone is thought to remove the inhibitory 
effects of WNK4 on NCC through the activation of SGK-1.  In oocytes SGK-1 was 
shown to phosphorylate WNK4 and consequently increase the activity of NCC 
(Rozansky et al., 2009).  Therefore, aldosterone stimulation of SGK-1 would result 
in increased NCC activity.  In addition to removing the inhibitory effects of WNK4, 
chronic administration of aldosterone to has been shown to increase NCC protein 
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expression (Kim et al., 1998).  These data illustrate that aldosterone can augment 
sodium reabsorption DCT2 via the regulation of NCC and ENaC.   
 
1.2.4.  The collecting duct 
1.2.4.1. The collecting duct regulates the fine tuning of urine concentration 
The generation of the longitudinal osmotic gradient in the medulla is fundamental to 
the modulation of urine concentration in response to changes in plasma osmolality.  
This fine-tuning of urine concentration occurs in the collecting duct and is regulated 
by AVP.  AVP acts to increase the water permeability of the collecting duct in both 
the short and long term.  In the short term, AVP induces the translocation of AQP2 
from intracellular vesicles to the apical membrane (Nielsen et al., 1995a).  This 
response occurs rapidly, with increase water permeability measurable 5-30 minutes 
after exposure to peritubular AVP (Kuwahara and Verkman, 1989, Wall et al., 
1992).  Chronic AVP stimulation, as occurs during 24-hour water deprivation 
challenges, causes the increased expression of AQP2 in the collecting duct (Nielsen 
et al., 1993a).  In vitro this was shown to be mediated by the increased transcription 






1.2.4.2.  The effect of AVP on the collecting duct 
In the principal cells of the collecting duct AVP binds to the G-protein coupled 
receptor (GPCR) V2R, located on the basolateral membrane (Figure 1.8).   
 
 
Figure 1.8:  Vasopressin activation of V2R increases apical AQP2.  AVP, 
vasopressin.  V2R, vasopressin 2 receptor.  AC, adenylate cyclase.  ATP, 
adenosine triphosphate.  cAMP, cyclic monophosphate.  PKA, protein kinase 
A.  P, phosphorylated.  AQP2, aquaporin 2.  AQP3, aquaporin 3.  AQP4, 
aquaporin 4.  
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Activation of these receptors causes the stimulatory G-protein, Gs, to translocate to, 
and activate, adenylate cyclase.  Activation of adenylate cyclase causes an increased 
synthesis of cAMP from intracellular ATP and consequently the activation of PKA 
(Boone and Deen, 2008, Fushimi et al., 1997).  In addition, the regulatory subunits of 
PKA in the collecting duct are also bound to the PKA anchoring protein 18δ 
(AKAP18δ). AKAP18δ anchors PKA in AQP2 expressing intracellular vesicles, 
allowing the regulated and spatially orchestrated phosphorylation of AQP2 following 
AVP binding to V2R (Henn et al., 2004).  In 1993 when Fushimi et al., cloned and 
characterized AQP2 in the rat collecting duct they identified a cAMP dependent 
PKA phosphorylation site (Fushimi et al., 1993).  Further analysis using site-directed 
mutagenesis demonstrated that PKA phosphorylation of Ser-256, stimulated 
translocation of AQP2 from intracellular vesicles to the apical membrane (Fushimi et 
al., 1997).  Moreover, the PKA inhibitor H89 prevented AVP-induced translocation 
(Katsura et al., 1997).  Consequently, it was postulated that AVP-induced 
phosphorylation of Ser-256 by PKA was essential for apical membrane expression of 
AQP2.  In view of these data, it was somewhat surprising that intracellular AQP2 
was shown to be phosphorylated in the kidneys of hydrated rats (Nishimoto et al., 
1999).  This finding was resolved by Kamsteeg et al., who demonstrated that the 
phosphorylation of three out of four monomers of tetrameric AQP2 was required for 
its apical membrane expression (Kamsteeg et al., 2000).  Although these studies 
were originally performed in Xenopus oocytes, the importance of Ser-256 in AQP2 
regulation was recently corroborated in vivo, using a mouse model of congenital 
progressive hydronephrosis.  In these mice a single base change resulted in the 
substitution of Ser-256 to Leu-256, which rendered the residue nonphosphorylatable.  
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As a result AQP2 did not accumulate at the apical membrane and the mutant mice 
developed severe polyuria and hydronephrosis (McDill et al., 2006).  Following its 
translocation to the apical membrane, AQP2 enables water to move down its osmotic 
gradient into the cell.  Aquaporin-3 (AQP3) and aquaporin-4 (AQP4) channels 
located on the basolateral membrane then allow the movement of water from the 
cells into the interstitium.  Although both AQP3 and AQP4 are constitutively 
expressed on the basolateral membrane, AQP3 expression is increased following 
chronic AVP stimulation, as occurs during water deprivation challenges (Ecelbarger 
et al., 1995, Terris et al., 1996).  Conversely, water deprivation and chronic AVP 
stimulation have no effect on AQP4 expression (Terris et al., 1996).  Once plasma 
osmolality has been restored, circulating levels of AVP decrease, and AQP2 
endocytosis predominate over exocytosis (Knepper and Nielsen, 1993). 
 
The reabsorption of urea from the inner medullary collecting duct is increased by 
AVP.  In situations of antidiuresis, the increased reabsorption of urea into the 
interstitium facilitates the concentration of urine.  Evaluation of inner medullary 
collecting ducts isolated from UT-A1/3 knockout mice demonstrated the absence of 
AVP sensitive urea transport (Fenton et al., 2004).  Therefore UT-A1 and UT-A3 
mediate AVP sensitive urea reabsorption in the inner medullary collecting duct.  The 
fundamental role of urea recycling in urine concentration was confirmed by the 
demonstration of polyuria in UT-A1/3 null mice when on a normal protein diet.  
Since polyuria was abolished by protein restriction, it was proposed that in the 
absence of urea recycling, diuresis was required to excrete the high luminal 
concentrations of urea (Fenton et al., 2004). 
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1.2.4.3.  The effect of corticosteroids on the collecting duct 
In addition to AVP, the other major hormonal regulator of the collecting duct is 
aldosterone.  Aldosterone stimulation increases sodium reabsorption through its 
action at the MR, which upon ligand binding acts as a transcription factor.  
Consequently, aldosterone’s action at MR located in the principal cells of the 
collecting duct causes the increased transcription of proteins involved in sodium 
reabsorption.  Such proteins included the α, β and γ subunits of ENaC, and the α1 and 
β1 subunits of Na/K-ATPase and SGK-1.  Since 90% of filtered sodium is 
reabsorbed in regions prior to the collecting duct, aldosterone’s action in this region 
of the nephron is responsible for the fine-tuning sodium excretion (Brenner and 
Rector, 2004).   
 
In the collecting duct the movement of sodium is a two-step process, sodium enters 
the cell via ENaC located on the apical membrane, it is then actively pumped into the 
interstitium by Na/K-ATPases located on the basolateral membrane.  The entry of 
sodium through ENaC is the rate-limiting step.  Aldosterone regulation of sodium 
reabsorption occurs in two phases.  Initially (1-4 hours post stimulation) the effects 
are predominantly mediated by SGK-1, whereas in the later phase (>4 hours post 
stimulation) increased expression of Na/K-ATPase and ENaC becomes the primary 
mechanism (McCormick et al., 2005).  The regulation of ENaC in the collecting duct 
is as previously described for the DCT (Section 1.2.3). 
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Additionally, aldosterone had been shown to modulate the expression of AQP2 in the 
collecting duct.  In vitro administration of aldosterone was shown to have biphasic 
effect on AQP2 expression.  Following AVP stimulation, aldosterone initially caused 
a reduction in AQP2 protein expression, whereas prolonged treatment resulted in 
increased AQP2 abundance.  The effects of aldosterone on AQP2 were blocked by 
MR antagonism, implicating the activation of the receptor in the response.  In 
contrast concurrent administration of aldosterone with AVP resulted in a reduction in 
AQP2 mRNA expression at all of the time points.  These data suggest that the long-
term effects of aldosterone on AQP2 protein abundance occurred independently of 
changes in mRNA expression and were rather mediated by increased mRNA 
translation.  Since aldosterone had no effect on AQP2 protein expression in the 
absence of AVP it was postulated to play a modulatory role, acting to buffer the 
effects of AVP (Hasler et al., 2003).   
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1.3.  11βHSD2 and the central regulation of sodium and water balance 
The kidneys modulate water and sodium excretion in order to maintain plasma 
osmolality at a set point of ~290 mosmol/kg H2O.  To enable this, plasma osmolality 
must be detected and information relayed to the kidneys.  Moreover, extra-renal 
mechanisms such as thirst and/or salt appetite, also act to normalize water balance 
and plasma osmolality. 
 
1.3.1.  AVP synthesis and release 
1.3.1.1.  Central control of AVP release 
Changes in plasma osmolality are primarily detected by osmoreceptors located in the 
organum vasculosum lamina terminals (OVLT), a region of the brain not protected 
by the blood brain barrier, thus enabling a rapid response to perturbations in 
osmolality.  The osmoreceptors are extremely sensitive: a 1% increase in plasma 
osmolality results in a rapid increase in plasma AVP concentration (Dunn et al., 
1973).  Electrophysiological approaches confirmed the involvement of the OVLT in 
osmosensation.  Application of hyperosmotic fluid to isolated OVLT neurons evoked 
membrane depolarization; moreover there was a linear correlation between 
osmolality and firing rate (Ciura and Bourque, 2006).  Additionally, functional 
magnetic resonance imaging in humans demonstrated that infusion of hypertonic 
saline resulted in activation of the third ventricle (illustrated by an increased blood-
oxygen-level dependent (BOLD) signal), which contains the OVLT, and the 
sensation of thirst (Egan et al., 2003).   
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To be classified as osmoreceptors, activation of osmosensitive neurons must trigger a 
functional response, which acts to normalize plasma osmolality, for example the 
secretion of AVP.  Lesions of the OVLT abolished the correlation between plasma 
osmolality and AVP release (Thrasher et al., 1982).  Neurons from the OVLT have 
been demonstrated to project to both the supraoptic- and paraventricular- nuclei of 
the hypothalamus (SON and PVN respectively) (Camacho and Phillips, 1981).  
Additionally, the neurons that project from the OVLT to the SON are activated by 
hypertonic fluid (Nissen et al., 1993).  As a result, changes in plasma osmolality are 
detected by the osmoreceptors in the OVLT, and relayed to the SON and PVN where 
AVP is synthesized.   
 
AVP, a nine amino acid cyclic peptide, is produced in magnocellular neurosecretory 
cells located within the PVN and SON of the hypothalamus (Harding et al., 1995) 
(Figure 1.9).  Evaluation of AVP-secreting cells within the SON of rats demonstrated 
increase neuron firing in response to augmented plasma osmotic pressure.  Moreover 
there was a linear correlation between plasma osmotic pressure and the firing rate of 
AVP cells, indicative of the controlled and graded release of AVP in response to 
increased plasma osmolality.  Reducing plasma osmotic pressure by water loading 
reduced neuron firing (Brimble and Dyball, 1977), suggestive of basal AVP release 
during resting conditions, enabling a rapid response to perturbations in plasma 
osmolality.  Once synthesized, the AVP precursor is stored in membrane bound 
vesicles, which are transported along axons to the posterior pituitary, in which AVP 
is stored and then subsequently released into circulation. 
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Considerable levels of AVP accumulate within the posterior pituitary, such that basal 
secretion could be maintained for a month without additional synthesis.  During 
dehydration these stores deplete rapidly; after approximately three days of water 
deprivation stored AVP levels would have reduced to about 90% (Laycock, 2010).  
Consequently, the rate of AVP synthesis and delivery to the posterior pituitary must 
increase to match demand.  In response to dehydration, AVP mRNA expression 
increases followed by augmented protein synthesis, processes that take 
approximately two hours to complete.  Therefore large AVP stores in the posterior 
pituitary are required for the rapid and sustained response to dehydration.  Since the 
posterior pituitary is not protected by the blood brain barrier AVP is released directly 
through fenestrations into the circulation (Zingg et al., 1986, Gainer et al., 1977). 
 
Figure 1.9:  AVP is synthesized in the hypothalamus and then released into 
circulation by the posterior pituitary.  SON, supraoptic nuclei of the 




1.3.1.2.  The effect of corticosteroids on AVP release 
Glucocorticoids are involved in the regulation of AVP synthesis and release.  
Hyperadrenocorticism is associated with an impaired release of AVP in response to 
plasma hypertonicity (Biewenga et al., 1991).  Moreover, postmortem analysis of 
patients who had been receiving glucocorticoid therapy showed an attenuation of 
AVP immunoreactive neurons in their PVN and SON relative to controls (Erkut et 
al., 1998).  The AVP gene contains a GRE.  Binding of GR to this region caused a 
reduction in AVP promoter activity and consequently attenuated levels of AVP (Kim 
et al., 2001).  These data support an inhibitory role for glucocorticoids in the 
regulation of AVP.  In contrast, non-suppressible AVP release has been documented 
in experimental models of glucocorticoid deficiency (Boykin et al., 1978, Saito et 
al., 2000). 
 
1.3.2.  Thirst 
In conjunction with reduced water excretion, increased water intake, through the 
stimulation of thirst, also acts to normalize augmented plasma osmolality.  As with 
AVP secretion, the sensation of thirst is triggered by the activation of osmoreceptors 
located in the OVLT.  Small increases in plasma osmolality (1-2%) elicit thirst, 
which continues to increase in parallel with plasma hypertonicity.  In addition to 
altered plasma osmolality, water intake is also stimulated by changes in blood 
volume, and blood pressure. 
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The role of the OVLT in the initiation of fluid intake was demonstrated by lesion 
studies, in which the destruction of the region reduced water consumption in 
response to increased plasma osmolality (Thrasher et al., 1982).  Given that water 
intake is terminated prior to the restoration of plasma osmolality a feed-forward 
mechanism is implied, such that the anticipation of rehydration prevents excessive 
fluid consumption.  Such a mechanism was demonstrated in dehydrated dogs: fluid 
intake stopped prior to the dilution of plasma (Thrasher et al., 1981).  These data 
suggest first that the act of drinking, rather than fluid intake per se, regulates thirst: 
and second that osmoreceptors located outside of the brain detect water intake.  In 
line with this hypothesis, the NTS and the area postrema (AP) receive vagal inputs 
from the abdominal viscera (Norgren and Smith, 1988).  In rats the destruction of 
these neuronal fibres resulted in the over consumption of water (Curtis and Stricker, 
1997).  
 
Volume contraction also stimulates water intake, indeed the loss of blood in the 
absence of plasma hypertonicity initiates fluid consumption and AVP release 
(Stricker and Sved, 2000).  Fluid intake in response to hypovolemia is initiated in 
part in response to neuronal inputs from cardiac baroreceptors.  Afferents from 
baroreceptors project to the NTS, triggering fluid intake.  Destruction of cardiac 
baroreceptors prevented water intake in response to reduced venous return in dogs 
(Quillen et al., 1990).  Similarly, the placement of an arterial balloon, which 
prevented the detection of hypovolemia, blunted water intake in rats (Kaufman, 
1984).  However, despite this, in rats the destruction of the NTS did not prevent 
water intake or AVP secretion induced by volume contraction (Schreihofer et al., 
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1994).  These data suggest that although baroreceptor activation is involved in the 
initiation of thirst, it is not essential for the response to volume contraction.   
 
Finally, thirst is also stimulated by hypotension.  The administration of β-
adrenoreceptor agonists to rats caused a significant reduction in blood pressure and a 
concominant increase in water intake (Lehr et al., 1967). 
 
1.3.3.  Salt appetite 
1.3.3.1.  Salt appetite: the innate drive to consume sodium 
Sodium is the predominant extracellular cation and therefore the main determinant of 
plasma osmolality.  As such its intake and excretion must be tightly regulated in 
order to maintain balance.  The excretion of sodium is largely mediated by the 
kidneys, whereas the motivation to consume sodium (“salt appetite”) is driven by 
complex central circuits which respond to both hypovolemia and sodium depletion.  
Wilkins and Richter obtained clinical evidence for the existence of an intrinsic salt 
appetite in 1940.  Their seminal case study described a child suffering from adrenal 
insufficiency.  As a result of the condition he synthesized low levels of aldosterone 
and was unable to conserve sodium renally.  To compensate for the unregulated loss 
of sodium he developed an augmented salt appetite, actively seeking and ingesting 
high levels of the mineral.  When admitted to hospital and placed on a regular diet 
the child died (Wilkins and Richter, 1940), illustrating that the maintenance of 
sodium balance is essential for survival. 
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Experimentally, salt appetite is modeled by inducing sodium depletion, commonly 
through adrenalectomy (which causes renal sodium wasting) (Fregly and Waters, 
1966) or sodium deprivation challenges (Liedtke et al., 2011).  The trigger for 
increased sodium intake is not, however, hyponatremia but rather volume 
contraction; indeed reductions in plasma sodium in the absence of volume 
contraction do not stimulate sodium appetite.  In contrast to the thirst response to 
hypovolemia, which occurs within hours of volume contraction, the onset of salt 
appetite is relatively delayed, sometimes occurring days after the stimulus, and often 
over corrects the deficit (Geerling and Loewy, 2008). 
 
1.3.3.2.  The effect of corticosteroids on salt appetite. 
The involvement of adrenal hormones in salt appetite was elucidated from 
investigations in adrenalectomized rats.  Removal of the adrenal gland resulted in 
death, unless the rats were given a sodium-supplemented diet.  When given access to 
salt solution and water the rats chose to drink vast quantities of the sodium solution.  
Therefore, they were able to intrinsically compensate for the renal inability to 
conserve sodium (Richter, 1936).  Subsequently, it was proved that the salt appetite 
stimulated by adrenalectomy was a consequence of sodium deficiency.  
Adminstration of aldosterone, to restore renal sodium reabsorption, reduced NaCl 
intake in adrenalectomized rats.  There was, however, a U shaped correlation 
between NaCl intake and the dose of aldosterone administered.  Minimum 
consumption was observed at the concentration of aldosterone closest to the rate at 
which it is secreted from the adrenal gland of intact rats.  At this concentration it 
could be postulated that sodium balance was restored.  However, at 
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supraphysiological doses aldosterone stimulated NaCl consumption (Fregly and 
Waters, 1966).  Aldosterone is the only hormone that has been demonstrated to 
selectively stimulate salt intake: unlike other hormones, e.g. angiotensin II (angII), it 
has minimal effects on water intake (Geerling and Loewy, 2006).  Despite this, the 
demonstration that supraphysiological concentrations are required to induce sodium 
ingestion (Fregly and Waters, 1966) suggests that aldosterone acts to increase 
sodium appetite, rather than being the primary stimulus for it.  This hypothesis is 
corroborated by the demonstration that glucocorticoids and intracerebroventricular 
(i.c.v.) angII exacerbated aldosterone’s effect (Ma et al., 1993, Fluharty and Epstein, 
1983) 
 
1.3.3.3.  The role of 11βHSD2 in salt appetite. 
MR are located on the neurons of the NTS.  The coexpression of 11βHSD2 ensures 
that the receptors are selectively activated by the mineralocorticoid.  Recent work 
suggests that 11βHSD2-positive neurons in the NTS play a key role in the central 
response to sodium deficiency.  Firstly, 11βHSD2 neurons were shown to be active 
in sodium-deprived but not replete rats (Geerling et al., 2006a).  In vivo 
investigations into the role of 11βHSD2 in salt appetite have been hampered by the 
inability to selectively inhibit the enzyme in the NTS.  Therefore, although 
subcutaneous glycyrrhizic acid (to inhibit 11βHSD2) resulted in augmented salt 
appetite in rats (Cooney and Fitzsimons, 1996), it is impossible to discern whether 
the intake was secondary to altered renal sodium handling.  Increased salt appetite 
has been documented in a patient with a partial loss of 11βHSD2 activity.  
Significantly, the increased salt intake was postulated to exacerbate the potentially 
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mild hypertensive effects of attenuated enzyme activity in the kidney (Ingram et al., 
1996). 
 
1.4.  The Syndrome of Apparent Mineralocorticoid Excess 
1.4.1.  Clinical loss of 11βHSD2. 
In humans the loss of 11βHSD2 function causes the syndrome of apparent 
mineralcorticoid excess (AME).  Characterized by features associated with 
hyperaldosteronism and augmented activation of MR (salt-dependent hypertension, 
hypokalemic alkalosis and plasma volume expansion), AME was first described by 
Werder et al., in 1974 (Werder E et al., 1974).  Paradoxically, sufferers also 
exhibited hypoaldosteronism (Ulick et al., 1979) suggesting the involvement of non-
aldosterone mediated activation of MR.  Polyuria has also been documented (Stewart 
et al., 1996).  Subsequent evaluation demonstrated that the severity of the condition 
could be augmented by cortisol administration and improved by dexamethasone, a 
synthetic glucocorticoid with negligible activity at MR (Stewart et al., 1988).  Based 
on these data it was postulated that AME resulted from the illicit occupation and 
activation of MR by glucocorticoids due to defective 11βHSD2.  Genetic analysis of 
patients suffering from AME confirmed that HSD11B2 was mutated.  To date >35 
different genotypes have been identified, the mutations of which, (with the exception 
of L114,Δ6nt, R74G and P75,Δ1nt), are all located on exons 3, 4 and 5 of HSD11B2 
(Draper and Stewart, 2005, Morineau et al., 2006) (Figure 1.10).  In 1990 a second 
variant of AME (AME type 2) was described (Ulick et al., 1990).  Sufferers of this 
condition presented with a milder phenotype and a delayed onset of hypertension, 
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which typically developed in early adulthood (Li et al., 1998).  In these patients 
mutations in HSD11B2 resulted in only partial reductions in 11βHSD2 enzyme 
activity.  This has led to the classification of AME as a continuum disorder (Li et al., 
1998) with the extent of the enzyme deficiency correlating with the severity of the 
phenotype.  
 
In addition to being congentital disease AME can be acquired, typically by the 
overconsumption of licorice and carbenoxolone (an antiulcer drug).  Since 
glycrrhizic acid (the active component of licorice) and carbenoxolone inhibit 
11βHSD2, abuse of these substances results in hypertension and hypokalemia 
(Mantero et al., 1996). 
 
 
Figure 1.10:   Schematic of the HSD11B2 gene mutations causative in AME.  
The five exons are represented by boxes, the introns are lines.  Numbers above 
the exons are the amino acid numbers.  Adapted from (Morineau et al., 2006) 
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1.4.2.  Experimental evaluation of the origins of AME 
Attempts to resolve the effects of loss of 11βHSD2 function into specific organ 
function (brain/kidney) have compared the effects of i.c.v. and subcutaneous (s.c.) 
drug delivery.  I.c.v. infusion of aldosterone induced hypertension in unilaterally 
nephrectomized rats.  Moreover, the concentrations required to increase blood 
pressure were significantly lower than those needed when aldosterone was 
administered s.c.  The pressor effects of aldosterone were attenuated by MR 
antagonism, implicating the receptor in the response (Gomez-Sanchez and Gomez-
Sanchez, 1986).  Similarly, i.c.v. carbenoxolone (to inhibit 11βHSD2 in the brain) 
increased blood pressure in rats and the hypertensive effects of oral carbenoxolone 
were prevented by the concurrent i.c.v. infusion of an MR antagonist (Gomez-
Sanchez and Gomez-Sanchez, 1992).  Given that MR antagonism prevented the 
hypertensinogenic effects of carbenoxolone, it is likely that the increased blood 
pressure reflects reduced protection of MR by 11βHSD2 in the brain.  Despite these 
data, the fact that blood pressure was normalized in an AME patient by kidney 
transplantation (Palermo et al., 2000) suggests that the hypertension was renal in 
origin. 
 
In addition, s.c. but not i.c.v. aldosterone was shown to induce polyuria in 
unilaterally nephrectomized rats (Gomez-Sanchez, 1986).  Similarly, i.c.v. 
carbenoxolone, to inhibit 11βHSD2 in the brain, did not alter urine flow in rats, 
whereas oral administration resulted in a two-fold increase.  In support of a renal 
origin to the polyuria, the increased urine flow was not normalized by the i.c.v. 
administration of an MR antagonist (Gomez-Sanchez and Gomez-Sanchez, 1992).  
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However, caution must be taken when interpreting these data given the unselective 
nature of carbenoxolone, which also inhibits 11βHSD1 (Hult et al., 1998). 
 
1.4.3.  A mouse model of AME 
Although evaluation of AME sufferers has provided useful information regarding the 
consequences of defective 11βHSD2, investigations are hampered by 1) the rarity 
and severity of the disease and 2) the limits of clinical experiments in patients.  Less 
than 100 cases of AME have been documented worldwide, making large clinical 
investigations of the disorder unfeasible.  Moreover, the condition is predominantly 
found in children, often with fatal manifestations, (Mantero et al., 1996) further 
limiting clinical studies.  Therefore, research into the consequences of mutated 
HSD11B2 has been greatly aided by the development of genetically modified mice.   
 
Homologous recombination permits the discrete targeting of genes within a genome.  
In past two decades this technology has been used to generate “knockout” mice, in 
which the gene of interest is rendered functionally inactive.  Consequently, the in 
vivo function of the gene product can be evaluated (Figure 1.11).  This technique was 
used to generate 11βHS2D2-/- mice. 
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Figure 1.11:  Gene targeting in mice.  Electroporation is used to introduce the 
targeting vector in embryonic stem (ES) cells.  In a few cells homologous 
recombination will occur such that the mutation is transferred into the genome.  
Cells in which homologous recombination has occurred are identified using 
positive-negative selection.  Blastocysts containing the targeted cells are then 
implanted in the foster mother, the offspring of which are chimeric.  Crossing 
of the chimeric mice with wildtype mice leads to the generation of gene 
targeted mice.  Figure taken from (Hansson, 2007) 
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Mice in which 11βHSD2 have been deleted provide an excellent experimental model 
of AME, having many of the clinical features of the disease (hypertension, 
hypokalemia and polyuria) (Bailey et al., 2008, Kotelevtsev et al., 1999).  Neonatal 
mortality was observed in the null mice, ∼50% died within two days of birth.  The 
mice had a low urinary sodium/potassium ratio, suggesting that increased urinary 
potassium excretion contributed to the hypokalemia.  To evaluate whether the altered 
electrolyte handling was attributable to increased glucocorticoids the effect of 
dexamethasone was assessed.  Dexamethasone, which suppresses corticosterone, 
normalized urinary sodium/potassium ratios.  The involvement of glucocorticoids in 
the phenotype was confirmed by the observation urinary sodium/potassium ratios 
returned to the basal level following corticosterone replacement.  Consequently, 
overactivation of MR was postulated to contribute to the phenotype. Structural 
changes within kidney were also described, notably hypertrophy and hyperplasia 
within the distal tubule.  Since chronic sprionolactone did not normalize the renal 
structure, the involvement of non-MR stimulated pathways in the damage was 
postulated. Notably, heterozygous mice were phenotypically normal (Kotelevtsev et 
al., 1999).  
 
Additionally, time course investigation has provided insights into the etiology of the 
hypertension observed in AME (Bailey et al., 2008).  Initially the augmented blood 
pressure was renal in origin, driven by increased ENaC activity and impaired sodium 
excretion.  However, at later time points sodium excretion was normalized in 
correlation with decreased ENaC activity.  The observation that urinary excretion of 
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catecholamines was increased in 11βHSD2-/- mice, and that antagonism of α1-
adrenoreceptor normalized blood pressure, implicated sympathetic overdrive in the 
hypertension. 
 
A key finding from this study was the separation of water and sodium retention in 
the model (Bailey et al., 2008).  Although the mice were hypertensive at all time 
points, they were also paradoxically volume contracted.  The uncoupling of sodium 
and water retention was indicative of a urine-concentrating defect, indeed the mice 
were polyuric, producing high volumes of low osmolality urine.  
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1.5.  Aim of PhD 
The studies detailed in this thesis were undertaken to evaluate water and sodium 
turnover in 11βHSD2-/- mice.  It was hypothesized that loss of enzyme in the activity 
the kidney would result in the derangement of water and sodium excretion.  In 
addition the evaluation of mice in which hsd11b2 had been selectively targeted in the 
brain and kidney allowed the separation of central and renal effects of 11βHSD2. 










Chapter 2:  Evaluation of Renal Water and Electrolyte Handling in 
Conscious 11βHSD2-/- Mice 
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2.1.  Introduction 
The syndrome of Apparent Mineralocorticoid Excess is characterized by 
glucocorticoid-mediated activation of MR, as a result of impaired 11βHSD2 
function.  Cardinal features of the condition include hypokalemia, 
hypoaldosteronism and hypertension.  Although 11βHSD2 is expressed in several 
tissues throughout the body, including the brain and vascular endothelium, it is 
postulated that the hypertension in the condition is renal in origin, driven by the 
impaired renal excretion of sodium (van Uum et al., 1998, Ferrari and Krozowski, 
2000).  
 
In the kidney, as in other aldosterone target tissues, 11βHSD2 acts to protect the MR 
from activation by glucocorticoids.  In the principal cells of the distal nephron 
activation of MR causes the increased activity of ENaC and Na/K-ATPase, and 
consequently increased sodium reabsorption.  Therefore, it is postulated that in AME 
hypertension is driven by sodium retention and the concurrent volume expansion 
(Ferrari and Krozowski, 2000).  This hypothesis is in accord with the Guytonian 
view of the blood pressure regulation, summarized in Figure 2.1.  In this model the 
retention of sodium causes the retention of fluid, volume expansion and consequently 
increased cardiac output.  As a result of this, peripheral resistance increases, causing 
an increase in mean arterial blood pressure.  In an attempt to normalize blood 
pressure, urinary sodium excretion is increased (referred to as pressure natriuresis) 







Clinically, the confirmation of the molecular mechanisms involved in the 
development of hypertension in AME has been hampered by the rarity of the disease.  
Nevertheless, the limited data available do support a renal component to the 
augmented blood pressure.  Firstly, the urinary sodium/potassium concentration ratio 
was suppressed in a patient with AME, indicative of augmented sodium retention 
and potassium excretion.  These data are cohesive with the effects of MR stimulation 
in the distal nephron.  Indeed, since dexamethasone increased, and hydrocortisone 
decreased, the urinary sodium/potassium concentration ratio, glucocorticoid 
Figure 2.1:  The Guytonian view of blood pressure regulation, (adapted 
from (Bongartz et al., 2005). 
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activation of MR was implicated in the phenotype.  The impaired renal handling of 
sodium and potassium in the patient resulted in hypokalemia and hypertension 
(Stewart et al., 1988).  Secondly, blood pressure and plasma potassium 
concentrations were normalized by a kidney transplantation operation in a patient 
with AME (Palermo et al., 2000), suggesting that in this instance hypertension was 
the result of impaired renal function. 
 
Identification of the molecular mechanisms causative in AME has been facilitated by 
the generation of hsd11b2 null mice (Kotelevtsev et al., 1999).  When originally bred 
on an MF1 background the phenotype of the 11βHSD2-/- mice was shown to closely 
parallel the clinical condition: hypertension, hypokalemia and suppressed plasma 
aldosterone levels were observed.  Moreover, the urinary sodium/potassium ratio was 
attenuated in the null mice and could be normalized by dexamethasone, suggestive of 
glucocorticoid mediated over-activation of MR in the distal nephron.  However, the 
high neonatal mortality in the model, when maintained on an MF1 background, 
prevented the more thorough evaluation of the mechanisms involved in the impaired 
renal electrolyte handling.  Subsequently, the mice were backcrossed onto a C57Bl/6 
background, which resulted in a milder phenotype and increased survival.  This 
enabled the more detailed evaluation of mechanisms causative in AME.  
 
Temporal evaluation of the progression of hypertension in the 11βHSD2-/- mice 
provided key insights into its development.  Although sodium retention and 
increased ENaC function were reported at early time points (35 and 60 days) this did 
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not persist.  At 80 days decreased ENaC function and natriuresis were observed, 
suggesting that at this age hypertension was not the result of sodium retention.  
Moreover, volume contraction was observed in the null mice at all points assessed, 
suggestive of a urine-concentrating defect, and the uncoupling of sodium and water 
retention at early time points (Bailey et al., 2008).  Although it is likely that a 
transient volume expansion is causative in the development of hypertension at the 
time points prior to those assessed, at the point of evaluation a new steady state of 
volume contraction was observed, suggesting that alternative mechanisms contribute 
to the sustainment of hypertension.  
 
Therefore, the studies detailed in this chapter were designed to evaluate the effect of 
hsd11b2 deletion on the renal handling of water, sodium and potassium in conscious 
mice.  Initial experiments confirmed that the polyuric phenotype, previously 
observed in the 11βHSD2-/- when bred on an MF1 background, persisted on an 
inbred C57Bl/6 background.  A key aim was to establish whether the deranged water 
handling was progressive, and whether the ability to concentrate urine in response to 
a water deprivation challenge was impaired.  Finally, a detailed evaluation of 
electrolyte excretion was performed to provide an insight into the renal handling of 
sodium and potassium in conscious 11βHSD2-/- mice. 
Hypothesis 
1. Global deletion of 11βHSD2 results in a urine-concentrating defect.   
2. Loss 11βHSD2 function in the kidney results in polyuria, with polydipsia 
arising as a secondary consequence in order to maintain balance.   
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2.2.  Methods 
2.2.1.  Animals 
Experiments were performed on male C57Bl/6 and 11βHSD2-/- mice aged <100 and 
>180 days (representing mice aged 50-70 and 180-250 days respectively).  These 
time points were selected on the basis of pilot histopathological analysis (performed 
by Dr David Brownstein, data not shown).  Since the 11βHSD2-/- mice used in these 
studies were generated from null-null crosses, wildtype littermates were not available 
for comparison.  Therefore, throughout the studies detailed, C57Bl/6 mice were used 
as controls given that this is the background strain of the null mice (n=4-7 
throughout).  
 
2.2.2.  Metabolic cage studies 
Mice were individually housed in metabolic cages (model 3600M021, Tecniplast 
Ltd, UK) for the duration of the experiments under 12-hour light and dark cycles in a 
room with controlled temperature (~23°C) and humidity (~25%).  Throughout the 
study mice had free access to powdered rodent maintenance (RM1) diet (0.7% 
potassium and 0.3% sodium, Special Diet Services Ltd, UK) and water, unless 
otherwise specified.   
 
2.2.2.1.  Evaluation of basal renal function and urine concentrating ability 
Following 3-4 days acclimatization, baseline measurements of body weight, urine 
output, food and water intake were made over 4 days, after which water was 
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removed for 24 hours to assess urine concentrating ability.  Following a 1 week 
recovery period, a second 24-hour water deprivation was performed, immediately 
prior to which the synthetic V2R agonist desmopressin (ddAVP; 1µg/kg s.c, Sigma-
Aldrich, UK) was administered.  
 
2.2.2.2.  Evaluation of the response to acute V2R stimulation 
The origin of the polyuria was evaluated in separate cohorts of mice.  Following a 3-
4 day acclimatization period, baseline measurements were made over 4 days, during 
which time the mice had ad libitum access to food and water.  Throughout this period 
urine output and water intake were measured at 6 and 24 hours on each day.  On the 
fifth day mice were treated with ddAVP (1µg/kg s.c.).  Urine output and water intake 
were measured at 6 and 24 hours post administration.  Additional experiments were 
performed to control for the effects of s.c. injection (30µl saline s.c.). 
 
2.2.2.3.  Evaluation of the response to water restriction 
To evaluate the contribution of polydispsia to the polyuria, water restriction studies 
were performed.  After acclimatization and baseline measurements, as described in 
section 2.2.1.1, 11βHSD2-/- mice were presented with a restricted water intake 
(5ml/24hr) over a 4 day period.  This volume was selected based on the consumption 
of aged matched C57Bl/6 mice in the study detailed in 2.2.1.1.  
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2.2.3.  Analysis 
Urine volume (UV) was determined gravimetrically, assuming a density equal to that 
of water; urine flow rates are expressed as ml/24hr.  Water intake was calculated 
similarly.  Water balance was calculated by subtracting the average daily urine flow 
rate (ml/24hr) from the average daily water intake (ml/24hr).  Cumulative water 
balance, expressed in ml, was the sum of the individual daily water balances over the 
4-day baseline period.  Daily consumption of food (g/24hr) was used to calculate 
sodium intake, which was expressed in mmol/24hrs.  
 
Urinary sodium and potassium concentrations were measured using flame 
photometry (Model BWB-1 Performance Plus Flame Photometer, Spectonic 
Analytical Instruments, UK) or an electrolyte analyzer (AVI 9180 Electrolyte 
analyzer, Roche, UK).  For flame photometry 200µl of urine was mixed with 9800µl 
diluent solution (1ml diluent (approximately 1% w/v Brij-35, BWB Technologies, 
UK) in 1000ml deionised water) prior to analysis.  Four point standard curves were 
generated using sodium and potassium standard solutions (BWB Technologies, UK) 
and used for electrolyte quantification.  For the electrolyte analyzer, urine samples 
were diluted 1 in 5 in deionised water and then 1 in 3 in 120mM NaCl.  Cumulative 
sodium balance over the 4-day baseline period was calculated in a similar fashion to 
water balance.  Sodium excretion was subtracted from sodium intake and balance 
expressed in mmol/24hrs.   
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Urine osmolality was measured in a 40µl sample by freezing point depression 
(Osmometer, OM801, Vogel, Germany).   
 
Urinary calcium, magnesium and phosphate were measured by the Clinical Analysis 
Core Service at the University of Edinburgh, using commercially available 
colourmetric assays.  Urinary aldosterone was measured by Dr Emad Al-Dujaili 
using a previously described ELISA (Al-Dujaili et al., 2009). 
 
2.2.4.  Statistics   
Data are presented as means ± standard error of the mean (S.E.M.) except for 
cumulative data, which are medians ± range.  Statistical significance was evaluated 
using a one-way ANOVA and Tukey post-test, or a Kruskal-Wallis test with Dunn’s 
post-test as appropriate to compare significance between groups. 
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2.3.  Results 
2.3.1.  Water homeostasis in 11βHSD2-/- mice 
2.3.1.1.  Basal water handling and urine concentrating ability 
To examine the effect of hsd11b2 deletion on water turnover, water intake and urine 
flow were evaluated in <100 and >180 day old mice.  At <100 days 11βHSD2-/- mice 
drank significantly more water (Figure 2.2.A) and produced significantly more urine 
(Figure 2.2.B) than aged matched C57Bl/6 controls.  Urine osmolality was 
significantly lower in the <100 day 11βHSD2-/- mice than the <100 day C57Bl/6 
mice (Figure 2.2.C).  The elevated water turnover meant that cumulative water 
balance was significantly higher in the 11βHSD2-/- than the C57Bl/6 mice at <100 
days (Figure 2.2.D).  
 
At >180 days, the null mice displayed exacerbated polyuria (Figure 2.2.B) and 
polydipsia (Figure 2.2.A).  24-hour urine flow was four times greater in 11βHSD2-/- 
mice the age matched C57Bl/6 controls (Figure 2.2.B).  Polyuria was associated with 
a significant polydipsia (Figure 2.2.A); and consequently the mice maintained a 
cumulative water balance not significantly different from the C57Bl/6 controls 
(Figure 2.2.D).  Throughout the baseline period, both 11βHSD2-/- and C57Bl/6 mice 
remained in a positive water balance.  This likely reflects insensible water losses, 
such as the evaporation that occurs during respiration.  Using the methods detailed it 
was not possible to measure insensible water losses.  Urine osmolality was lower in 
the >180 day 11βHSD2-/- mice than the age matched C57Bl/6 mice, suggesting an 
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impaired urine concentrating ability (Figure 2.2.C).  Consequently, urine-





Figure 2.2:  Water turnover in C57Bl/6 (white) and 11βHSD2-/- (black) mice 
aged <100 and >180 days.  (A) Water intake.  (B) Urine Flow.  (C) Urine 
Osmolality.  (D) Cumulative Water Balance calculated over the four-day 
baseline period.  Data are means ± S.E.M. except for (D) which are medians ± 
range.  Statistical analysis was performed using a one-way ANOVA with 
Tukey post-test (A, B, C) or Kruskal-Wallis test with Dunn’s post-test (D) as 
appropriate.  ***P<0.001, **P<0.01, *P<0.05, compared to age matched 
controls. ###P<0.001 compared to younger mice within the same genotype.   
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At <100 days 11βHSD2-/- mice concentrated their urine to the same extent as age 
matched C57Bl/6 controls, with no significant difference between urine flow (Figure 
2.3.A) or urine osmolality (Figure 2.3.B).  In corroboration with a functional 
concentration response, weight loss (used as an indicator of body fluid loss) and 
water balance were not significantly different between the two groups at this age 
(Figures 2.3.C and 2.3.D).   
 
In contrast, at >180 days urine concentrating ability was impaired in 11βHSD2-/- 
mice.  Urine flow rate remained significantly higher (Figure 2.3.A), and osmolality 
significantly lower (Figure 2.3.B) than the C57Bl/6 controls during the water 
deprivation challenge.  11βHSD2-/- mice at this age lost significantly more weight 
(Figure 2.3.C) and water balance was more significantly negative (Figure 2.3.D) 






Figure 2.3:  Response to water deprivation in C57Bl/6 (white) and  
11βHSD2-/- (black) mice at <100 and >180 days (A) Urine Flow.  (B) Urine 
Osmolality.  (C) Weight Loss.  (D) Water Balance.  Data are means ± S.E.M. 
Statistical analysis was performed using a one-way ANOVA with Tukey 
post-test.  ***P< 0.001 compared to age matched controls. ###P<0.001, 
##P<0.01, compared to younger mice within the same genotype.   
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To establish the mechanisms of the impaired urine concentrating ability in  
11βHSD2-/- mice, the response to a water deprivation challenge following the 
administration of ddAVP, a V2R specific AVP analogue, was evaluated.  ddAVP 
failed to rescue the phenotype; >180 day old 11βHSD2-/- mice continued to produce 
significantly higher volumes of more dilute urine during water deprivation challenge.  
Again, a substantially greater weight loss and an attenuated water balance reflected 
an augmented loss of body fluid in the >180 day 11βHSD2-/- mice (Table 2.1). 
 
<100 Days >180 Days  
C57Bl/6 11βHSD2-/- C57Bl/6 11βHSD2-/- 
UV (ml/24hr) 0.4 ± 0.1 0.6 ± 0.1 0.8 ± 0.1 1.5 ± 0.2ab 
UOsm (mOsm) 6928 ± 1327 2923 ± 388.7a 4505 ± 262.6 2292 ± 203.7 
Δ  Weight (g) -1.7 ± 0.1 -1.8 ± 0.1 -1.6 ± 0.2 -2.4 ± 0.4 
Water Balance 
(ml/24hr) 
-0.4 ± 0.1 -0.6 ± 0.1 -0.8 ± 0.1 -1.5 ± 0.2ab 
 
Table 2.1:  Response to water deprivation following s.c. ddAVP administration.  
UV, urine flow.  UOsm, urine osmolality.  Δ Weight, change in body weight.  
Water Balance, calculated as the difference between water intake and urine flow 
over 24hrs. Data are means ± S.E.M.  Statistical analysis was performed using one-
way ANOVA and a Tukey post-test.   a=P<0.01 compared to age matched controls, 
b=P<0.001 compared to younger mice of the same genotype.  
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2.3.1.2.  The response to acute V2R stimulation 
Chronic stimulation of V2R, as occurs during a 24-hour water deprivation challenge, 
is thought to facilitate water reabsorption by stimulating de novo synthesis of AQP2 
in the collecting duct.  In contrast, acute V2R stimulation is associated with increased 
translocation of pre-existing AQP2 from intracellular vesicles to the apical 
membrane (Nielsen et al., 1993a, Nielsen et al., 1995a).  Therefore, to evaluate 
specifically the response to acute V2R stimulation, the urine concentration response 
to ddAVP administration during free access to water was assessed in >180 day 
C57Bl/6 and 11βHSD2-/- mice.  Prior to the administration of ddAVP 11βHSD2-/- 
mice produced significantly higher volumes of urine (Figure 2.4.A) and drank 
significantly more water (Figure 2.4.B) than the C57Bl/6 controls.  ddAVP 
administration resulted in anuria for up to 6 hours in the C57Bl/6 control mice 
(Figure 2.4.A).  In contrast ddAVP had no effect on water intake during the 0-6 hour 
period (Figure 2.4.B).  ddAVP significantly reduced urine flow in the 11βHSD2-/- 
mice between hours 0-6.  However, the concentration response was impaired relative 
to the C57Bl/6 mice, and anuria was not observed (Figure 2.4.A).  As with the 
C57Bl/6 controls, water intake was not significantly altered by treatment with 
ddAVP (Figure 2.4.B).  By 24 hours urine flow had restored to basal levels in both 
groups of mice (Figure 2.4.A).  In saline control experiments s.c. administration of 
saline had no effect on urine flow or water intake in either group of mice (Table 2.2). 
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Figure 2.4:  The effect of ddAVP on (A) Urine Flow and (B) Water Intake in 
11βHSD2-/- (black) and C57Bl/6 (white) mice.  Measurements were made 
during a baseline period (filled bars) and following ddAVP administration 
(1µg/kg s.c.) (hashed bars).  0-6 are rates recorded between hours 0-6.  6-24 
are rates recorded between hours 6-24.  Data are means ± S.E.M.  Statistical 
analysis was performed using a one-way ANOVA and Tukey post-test.  
***P<0.001, *P<0.5 compared to C57Bl/6 controls in same period.  #P<0.5 





0-6 hours 6-24 hours  
C57Bl/6 11βHSD2-/- C57Bl/6 11βHSD2-/- 
 Basal ddAVP Basal ddAVP Basal ddAVP Basal ddAVP 
UV 
(µ l/min) 




4.8±0.4 5.9±0.5 11.6±0.9 11.7±1.1 1.7±0.2 2.0±0.2 8.7±1.2 8.3±1.3 
Table 2.2:  The effect of saline on urine flow (UV) and water intake (Water In) in 
11βHSD2-/- and C57Bl/6 mice.  Measurements were made during a baseline period 
and following saline administration (30µl s.c.).  0-6 are rates recorded between 
hours 0-6.  6-24 are rates recorded between hours 6-24.  Data are means ± S.E.M.  
Statistical analysis was performed using a one-way ANOVA. 
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2.3.1.3.  The response to water restriction 
Next the contribution of polydipsia to polyuria was evaluated in 11βHSD2-/- mice by 
the restriction of water intake to control levels.  During the baseline period 
11βHSD2-/- mice produced significantly higher volumes (Figure 2.5.A) of more 
dilute (Figure 2.5.B) urine than age-matched controls.  Restriction of water intake 
caused a reduction in urine flow rate to a level that was not significantly different 
from that of the C57Bl/6 mice (Figure 2.5.A).  Urine osmolality increased 
significantly during water restriction, however it remained significantly lower than 
that of the C57Bl/6 controls (Figure 2.5.B).   
 
 
Figure 2.5:  The effect of water restriction on (A) Urine Flow and (B) Urine 
Osmolality in C57Bl/6 (white) and 11βHSD2-/- (black) mice. Data are means ± 
S.E.M.  Statistical analysis was performed using a one-way ANOVA and Tukey 
post-test.  **P<0.001 compared to C57Bl/6 mice during the baseline period. 
##P<0.001 compared to 11βHSD2-/- mice during the baseline period.   
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2.3.2.  Electrolyte homeostasis in 11βHSD2-/- mice 
In view of the postulated role of increased sodium retention and potassium excretion 
in AME, the urinary excretion of the electrolytes was assessed in conscious 
11βHSD2-/- and C57Bl/6 control mice.  Surprisingly, sodium excretion was 
significantly higher in the null mice than aged-matched C57Bl/6 mice at both <100 
and >180 days (Figure 2.6.A).  Since there was no significant difference in sodium 
intake (<100 day C57Bl6 0.54±0.009 versus <100 day 11βHSD2-/- 0.53±0.02 
mmol/24hrs P>0.05, >180 day C57Bl6 0.55±0.01 versus >180 day 11βHSD2-/- 
0.56±0.02 mmol/24hrs P>0.05) cumulative sodium balance was more negative in 
11βHSD2-/- mice than the C57Bl/6 controls at both ages (Figure 2.6.B).  Within 
genotypes sodium excretion increased in an age dependent manner: a higher 
natriuresis was observed in >180 day mice than the <100 day mice in both the 
control and null groups (Figure 2.6.A).  This progressive increase in excretion was 
reflected in the sodium balance data: cumulative balance was more negative in the 
>180 day mice than the <100 day mice of the same genotype (Figure 2.6.B).  
Potassium excretion rates were not significantly different in the 11βHSD2-/- and 
C57Bl/6 mice (Figure 2.6.C).  As a result, urinary sodium/potassium concentration 
ratios were significantly higher in the null mice than the C57Bl/6 controls at <100 
and >180 days (Figure 2.6.D).  Crucially, urinary aldosterone excretion rates were 
suppressed in the 11βHSD2-/- mice at <100 (C57Bl/6 4.0±0.2 versus 11βHSD2-/- 
0.8±0.05 pmol/24hr, P<0.0001 using an unpaired t-test) and >180 days (C57Bl/6 
6.2±0.9 versus 11βHSD2-/- 0.7±0.1 pmol/24hr, P<0.0001 using an unpaired t-test).  
These data suggested that loss of 11βHSD2 function resulted in hypoaldosteronism, 
in line with previous clinical and experimental observations. 
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Figure 2.6:  Sodium and potassium handling in C57Bl/6 (white) and 
11βHSD2-/- (black) mice at <100 and >180 days.  (A) Sodium Excretion.  (B) 
Cumulative Sodium Balance over the four-day baseline period.  (C) Potassium 
excretion.  (D) Urinary Sodium/Potassium Concenrtration ratio.  Data are 
means ± S.E.M., except for (B) which are medians ± range.  Statistical analysis 
was performed using a one-way ANOVA and Tukey post-test (A, C, D) or 
Kruskal-Wallis test with Dunn’s post-test (B) as appropriate.  ***P<0.001, 
**P<0.01, compared to age matched controls. ###P<0.001, #P<0.05 compared 
to younger mice of the same genotype.  
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Previous evaluation of renal function in 11βHSD2-/- mice was performed in 
anesthetized mice, in which the administration of pharmacological agents was used 
to assess tubular function (Bailey et al., 2008).  Since the current studies were 
performed in conscious mice, the evaluation of the acute response to exogenous 
markers of tubular function was not possible.  Therefore, in an attempt to localize the 
natriuresis in the 11βHSD2-/- mice to a specific region of the nephron, the urinary 
excretion of phosphate, calcium and magnesium was evaluated.  This provided an 
insight into the function of proximal tubule and loop of Henle respectively.  
Phosphate excretion was significantly higher in the 11βHSD2-/- mice than the 
C57Bl/6 controls at <100 days.  By 180 days the excretion rate had decreased 
significantly to a level that was not significantly different from the age matched 
C57Bl/6 mice.  The urinary excretion rates of calcium and magnesium were not 
significantly different between the 11βHSD2-/- and age-matched control C57Bl/6 





<100 Days >180 Days  
C57Bl/6 11βHSD2-/- C57Bl/6 11βHSD2-/- 
Phosphate Excretion  
(µmol/24hr) 
16.1±3.4 96.9±21.0a 26.4±8.1 38.7±8.4b 
Calcium Excretion  
(µmol/24hr) 
3.1±0.2 1.6±0.3 3.4±0.3 3.5±1.0 
Magnesium Excretion  
(µmol/24hr) 
40.3±2.2 25.4±0.9 32.8±5.2 44.5±4.5 
Table 2.3:  Urinary excretion rates of phosphate, calcium and magnesium in 
C57Bl/6 and 11βHSD2-/- mice aged <100 and >180 days.  Data are means ± 
S.E.M.  Statistical analysis was performed using one-way ANOVA and a 
Tukey post-test.  Urine collections were made over a 4-day baseline period.  
a=P<0.01 when compared to age matched controls.  b=P<0.05 when compared 
to younger mice of the same genotype. 
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2.4.  Discussion 
The syndrome of apparent mineralocorticoid excess is characterized by 
glucocorticoid-mediated activation of MR, the result of impaired 11βHSD2 function 
(Ferrari and Krozowski, 2000).  Previous evaluation of 11βHSD2-/- mice found them 
to hypertensive but paradoxically volume contracted from an early age (Bailey et al., 
2008).  In accord with the Guytonian view of hypertension, it is likely that a transient 
volume expansion was involved in the initiation of hypertension, at time points prior 
to those evaluated (Guyton et al., 1984, Guyton and Hall, 2000).  However, by 35 
days compensatory mechanisms seem to have resulted in the resetting of fluid status 
to a volume depleted state.  Consequently, alternative mechanism may be involved in 
the maintenance of hypertension.  Hypertension in the absence of volume expansion 
was also found in the mouse of model of Cushing’s syndrome, a condition driven by 
hypercortisolism.  In this model of chronic exposure to excess glucocorticoids, 
hypertension developed despite severe polyuria and volume contraction (Dunbar et 
al., 2010).  To evaluate the consequence of deranged glucocorticoid metabolism on 
water and sodium homeostasis, water and sodium turnover and urine concentrating 
ability were assessed in 11βHSD2-/- mice.  The mice were evaluated at two ages, 
<100 days and >180 days, to determine whether the phenotype described was 
progressive.  Through the evaluation of urinary divalent cation and phosphate 
excretion an indication of tubular function was obtained. 
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2.4.1.  Basal water turnover is elevated in 11βHSD2-/- mice 
11βHSD2-/- mice displayed a significant and progressive polyuria, producing large 
volumes of low osmolality urine.  Urine flow was closely paralleled by water intake; 
consequently at >180 days 11βHSD2-/- mice were able to maintain a cumulative 
water balance not significantly different from the C57Bl/6 control mice.  Despite 
being polyuric during free access to water, at <100 days the null mice had a 
functional concentration response to water deprivation.  In contrast, at >180 days the 
11βHSD2-/- mice continued to produce significantly larger volumes of more dilute 
urine following water removal, illustrative of a urine-concentrating defect.  
Therefore, the severity of the phenotype increased in a temporal manner.  Water 
turnover was exacerbated at >180 days, and at this age polyuria was associated with 
an impaired response to water deprivation, indicative of a nephrogenic diabetes 
insipidus (D.I.) like phenotype. 
  
2.4.2.  Renal components to the polyuria in >180 day 11βHSD2-/- mice 
Clinically, D.I., a disease characterized by severe polyuria and polydipsia, can be 
central or renal in origin depending on whether it is associated with an impaired 
central release of AVP, or an impaired renal response to AVP (Ball, 2007).  To 
determine the origin of the condition ddAVP is administered in conjunction with a 
water deprivation challenge.  If ddAVP normalizes urine-concentrating ability an 
impaired synthesis and release of AVP is assumed.  In contrast, if ddAVP does not 
restore urine-concentrating ability an impaired renal response to V2R activation is 
assumed (Lavin, 2009).  The failure of ddAVP to normalize urine-concentrating 
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ability in >180 day 11βHSD2-/- mice suggested a nephrogenic component to the 
phenotype.   
 
The evaluation of urine concentrating ability during a 24-hour water deprivation 
challenge provided an insight into the renal response to chronic AVP stimulation.  In 
an attempt to resolve the acute response to V2R stimulation, the response to ddAVP 
administration was evaluated in polyuric 11βHSD2-/- mice during free access to 
water.  In contrast to the C57Bl/6 control mice, 11βHSD2-/- mice were unable fully to 
concentrate their urine following ddAVP administration; anuria was not observed.  
These data support the hypothesis that an impaired response to V2R stimulation 
contributes to the polyuria in 11βHSD2-/- mice. 
 
In an attempt to confirm a nephrogenic origin to the polyuria, the role of polydispia 
was assessed.  Water restriction studies were performed in >180 day 11βHSD2-/- 
mice.  Although water restriction normalized urine flow, urine osmolality remained 
significantly lower in the >180 day 11βHSD2-/- mice than the C57Bl/6 controls.  
These data suggest that the polyuria was not entirely driven by augmented water 
intake.  Similar results were obtained in UTA1/3-/- mice, in which polyuria is driven 
by impaired renal handling of urea.  Water restriction in UTA1/3-/- mice did not 
normalize water turnover (Fenton et al., 2004).  In contrast, in mice with 
constitutively active Gαq, in which polyuria occurs as a consequence of primary 
polydipsia, restriction of water intake did normalize urine concentrating ability 
(Wang et al., 2006).   
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2.4.3.  Basal sodium excretion is augmented in 11βHSD2-/- mice 
An unexpected finding in this chapter is that urinary sodium excretion was 
significantly higher in 11βHSD2-/- mice than the age-matched controls at both <100 
and >180 days.  Since there was no significant difference in sodium intake between 
the two groups, these data reflect the impaired tubular reabsorption of sodium.  This 
is in contrast to the tradition view of AME, in which the impaired renal natriuretic 
capacity of sodium is causative in hypertension, following which a steady state of 
balance and therefore normal excretion would be assumed.  
 
Previously, a transient, age-dependent impairment of the intrinsic renal natriuretic 
capacity of 11βHSD2-/- mice has been demonstrated.  Using renal clearance 
techniques it was established that the fractional excretion of sodium was lower in 
11βHSD2-/- mice than C57Bl/6 controls at <60 days.  However, at 80 days natriuresis 
was observed in the null mice, and by 120 days the fraction excretion of sodium had 
normalized (Bailey et al., 2008).  Notably, the 11βHSD2-/- mice displayed significant 
hypertension at all ages.  These data demonstrated that, although sodium retention 
may have been involved in the initiation of hypertension, at older ages elevated 
blood pressure persisted despite normal, and indeed elevated, sodium excretion.  In 
combination with the data discussed in section 2.4.1, in which elevated basal water 
excretion was documented in the null mice, and in view of the previously described 
volume contraction (Bailey et al., 2008), these data suggest that alternative 
mechanisms for the increased blood pressure must be considered.  Although 
paradoxical, several lines of evidence support the notion that, in models of 
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glucocorticoid excess, hypertension occurs independently of sodium and water 
retention.   
 
Mineralocorticoid induced hypertension is dependent on the retention of sodium, 
therefore the elevation of blood pressure can be prevented by sodium restriction: the 
same is not true for glucocorticoid induced hypertension.  In rats, cortisone induced 
hypertension was equivalent regardless of whether the animals were maintained on a 
high or low sodium diet.  This was in contrast to mineralocorticoid induced 
hypertension, which was prevented by the administration of a low sodium diet 
(Knowlton and Loeb, 1957).  Moreover, several studies in rats have demonstrated 
that chronic glucocorticoid induced hypertension persisted despite the induction of 
polyuria, natriuresis and a negative sodium balance (Okuno et al., 1981, Haack et al., 
1977, Li et al., 2008).  Studies in adrenalectomized rats demonstrated that although 
corticosterone reduced the urinary sodium/potassium ratio, the effect was entirely 
due to increased potassium excretion: sodium excretion was not altered.  This was in 
contrast to aldosterone, which induced kaliuresis and antinatriuresis.  Moreover, 
corticosterone was shown to modulate the response to aldosterone, reducing the 
steroids antinatriuretic capacity.  These studies highlighted the complexity of the 
steroids’ actions on renal electrolyte handling (Kenyon et al., 1984b).  Similarly, in a 
comparable mouse model of glucocorticoid excess, chronic ACTH treatment resulted 
in hypertension despite the development of polyuria and natriuresis (Dunbar et al., 
2010).  Together, these data support the hypothesis that glucocorticoid induced 
hypertension is not dependent on renal sodium retention.  
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In an attempt to delineate the cause of natriuresis in 11βHSD2-/- mice, phosphate, 
calcium and magnesium excretion were assessed.  Phosphate reabsorption primarily 
occurs in the proximal tubule (Strickler et al., 1964) mediated by Na/Pi 
cotransporters expressed on the apical membrane (Biber et al., 1996).  Consequently, 
changes in phosphate excretion can be used as an assessment of proximal tubule 
sodium reabsorption, with increased excretion reflective of impaired reabsorption 
(Schneider et al., 1973).  Therefore, the demonstration of phosphaturia in the 
11βHSD2-/- mice is suggestive of impaired sodium reabsorption in the proximal 
tubule.  These data are cohesive with those obtained from mice chronically treated 
with ACTH.  Moreover, chronic ACTH administration was also shown to reduce 
NHE8 expression, further supporting the hypothesis that glucocorticoid excess 
results in reduced sodium reabsorption in the proximal tubule (Dunbar et al., 2010).    
 
The thick ascending limb of the loop of Henle is a major site of divalent cation 
reabsorption, as discussed in section 1.2.2.1.  In this region of the nephron cation 
reabsorption occurs paracellularly, driven by the transepithelial voltage gradient 
generated by NKCC2 (Bourdeau and Burg, 1979, Shareghi and Agus, 1982, 
Quamme, 1981).  Therefore, calcium and magnesium excretion rates are indicative 
of NKCC2 mediated sodium reabsorption.  The demonstration that calcium and 
magnesium excretion rates were not significantly different in the 11βHSD2-/- and 
C57Bl/6 mice suggests that sodium reabsorption in the loop of Henle was not altered 
in the null mice. 
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It is possible that impaired sodium reabsorption in the proximal tubule is a 
compensatory response to functional changes in the distal nephron.  Previously, 
deranged ENaC function was documented in anesthetized 11βHSD2-/- mice.  
Notably, at early time points increased ENaC activity was associated with sodium 
retention (Bailey et al., 2008).  It is postulated that in the 11βHSD2-/- mice adaptive 
changes occur in the proximal tubule in an attempt to normalize sodium excretion.  
Support for this hypothesis came from the evaluation of genetically modified mice in 
which the human GR was overexpressed in the collecting duct.  Although 
overexpression of GR resulted in increased ENaC expression in the collecting duct, 
urinary sodium excretion was not altered in the mice.  The maintenance of sodium 
balance was enabled by the compensatory downregulation of proteins involved in 
sodium reabsorption in proximal regions of the nephron (Nguyen Dinh Cat et al., 
2009).  These data suggest that the overactivation of GR in one region of the nephron 
can induce adaptive changes in other regions.  Since the localization of 11βHSD2 is 
restricted to the distal nephron, it is conceivable that the discrete overactivation of 
GR in this region results in a transient increase in ENaC function, which is 
subsequently compensated for by reductions in sodium reabsorption in more 
proximal regions of the tubule.  
 
Crucially, these data highlight the importance of comparing functional data obtained 
in anesthetized mice with that from conscious mice.  The evaluation of the response 
to pharmacological agents in anesthetized mice enables the dissection of nephron 
function in specific regions of the tubule.  However, as highlighted in the current and 
previously published studies (Bailey et al., 2009, Dunbar et al., 2010), these acute 
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experiments, in which renal function is challenged by the infusion of saline solutions 
and pharmacological manipulations, are not entirely reflective of chronic renal 
function.  Therefore, the combined of evaluation of data obtained from anesthetized 
and conscious mice is required to gain a thorough understanding of renal function.   
 
Paradoxically, despite the increased natriuresis, previous evaluation demonstrated 
hypernatremia in the 11βHSD2-/- mice (Bailey et al., 2008).  The reason for this 
apparent discrepancy is uncertain; however it was also observed in the ACTH treated 
mice (Bailey et al., 2009, Dunbar et al., 2010).  The demonstration of osmotically 
inactive sodium storage in the skin generates interesting hypotheses.  Predominantly, 
the observation that the chronic sodium deprivation resulted in the mobilization of 
sodium from osmotically inactive skin reservoirs suggests that extra-renal 
mechanisms may be involved in the modulation of plasma sodium concentrations 
(Schafflhuber et al., 2007).  In this context the evaluation of total body sodium 
content in the 11βHSD2-/- mice is of interest.   
 
2.4.4.  Basal potassium excretion is normal in 11βHSD2-/- mice 
Despite the differences in sodium handling, a striking consistency in models of 
mineralocorticoid and glucocorticoid induced hypertension is hypokalemia 
(Knowlton and Loeb, 1957).  Indeed, hypokalemia is a key characteristic of AME 
(New et al., 1977) and has previously been reported in the 11βHSD2-/- mice (Bailey 
et al., 2008, Kotelevtsev et al., 1999).  In normal situations the fine-tuning of 
potassium balance occurs in the distal nephron, specifically in the connecting tubule 
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and collecting duct.  Within the principal cells of the collecting duct potassium 
secretion is directly coupled to sodium reabsorption through ENaC, and is therefore 
under the influence of aldosterone.  Through the increased expression of ENaC at the 
apical membrane and Na/K-ATPase at the basolateral membrane, aldosterone 
increases potassium excretion (Reviewed in (Unwin et al., 2011).  However, despite 
these effects, potassium excretion was not significantly different in the 11βHSD2-/- 
and C57Bl/6 mice.  
 
Aldosterone induced hypokalemia, in the absence of increased potassium secretion, 
has been documented in several experimental models.  In dogs chronically infused 
with aldosterone, hypokalemia but not increased urinary excretion of potassium was 
documented (Pan and Young, 1982).  Comparable observations were made in DOCA 
treated pigs (Grekin et al., 1980) and aldosterone treated rabbits (Dawborn and Ross, 
1967).  In these studies fecal potassium levels were also measured, thus excluding it 
as a route of potassium loss.  An explanation for these paradoxical findings was 
proposed by Young (Young, 1988).  In addition to increasing potassium secretion, 
aldosterone can induce its movement from extracellular to intracellular 
compartments (Young and Jackson, 1982).  Moreover, there was a positive 
correlation between plasma aldosterone levels and the redistribution of potassium.  
Since low plasma potassium has an antikaliuretic effect, this model can be used to 
explain hypokalemia in the absence of kaliuresis (Young, 1988).  Although less 
thoroughly studied, glucocorticoid excess may induce similar effects.  
Glucocorticoids excess was associated with increased Na/K-ATPase activity in the 
kidneys of adrenalectomized rats (Hendler et al., 1972) and in the erythrocytes from 
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patients with Cushing’s syndrome (Gall et al., 1971).  In human erythrocytes, 
glucocorticoid induced Na/K-ATPase activity resulted in increased intracellular 
concentrations of potassium (Kaji et al., 1981).  These data suggest that like 
mineralocorticoids, glucocorticoids may induce the redistribution of potassium.  The 
analysis of potassium distribution in 11βHSD2-/- mice would provide information on 
whether the previously observed hypokalemia (Bailey et al., 2008, Kotelevtsev et al., 
1999) arose as a consequence of increased intracellular potassium. 
  
In view of the fact that potassium excretion was not different between the   
11βHSD2-/- and C57Bl/6 mice at either age, the urinary ratio of sodium/potassium 
paralleled that of sodium excretion.  Consequently, the ratio was augmented in the 
11βHSD2-/- mice at both <100 and >180 days.  The reason for the disparity between 
these data, and those obtained in the 11βHSD2-/- mice on an MF1 background, is not 
clear (Kotelevtsev et al., 1999).  However, since the age of the conscious mice 
evaluated in the original study was not specified, it is possible that the urinary 
excretion data was obtained prior to the postulated compensatory changes in tubular 
sodium handling, discussed in section 2.4.3.  Moreover, urinary potassium excretion 
rates were not detailed, raising the possibility that the attenuated sodium/potassium 
ratio was entirely attributable to decreased sodium excretion.  Whether the attenuated 
ratio persisted in older mice is of interest.  Without the thorough temporal evaluation 
of patients with AME, it cannot be determined whether similar changes in renal 
sodium and potassium handling occur clinically.  Given the rarity and severity of the 
disease these studies are unlikely.  
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Chapter 3:  Evaluation of Renal Function and Structure in 11βHSD2-/- 
mice 
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3.1.  Introduction 
The studies described in this chapter were designed to evaluate the cause of the 
deranged water handling observed in the 11βHSD2-/- mice. The investigations 
detailed in section 2.3 suggested a nephrogenic origin to the increased water 
turnover.  To assess this in more detail, renal function, with a focus on the collecting 
duct, was evaluated in the 11βHSD2-/- mice.  In addition, the effect of increased urine 
flow on renal structure was also assessed. 
  
3.1.1.  AVP-AQP2 cascade in 11βHSD2-/- mice 
The association between impaired glucocorticoid homeostasis and altered water 
turnover is well established.  In both clinical and experimental studies, glucocorticoid 
deficiency is associated with an attenuated ability to dilute urine.  Mechanistically, 
fluid retention is the result of increased AQP2 expression, secondary to non-
suppressible AVP release (Boykin et al., 1978, Saito et al., 2000, Agus and 
Goldberg, 1971).  Conversely, in conditions of chronic glucocorticoid excess, such as 
Cushing’s syndrome, polyuria and polydipsia occur (Tierney, 2004).  Although the 
phenotype persists in experimental models of glucocorticoid overexposure, little 
work has been done to determine the molecular mechanisms underlying the increased 
urine flow.  Notably, studies in rats chronically treated with dexamethasone found no 
difference in AQP2 expression (Li et al., 2008), suggesting that glucocorticoid 
excess may not merely be the antithesis of glucocorticoid deficiency.  However, the 
studies detailed in section 2.3 demonstrated that in addition to being polyuric, the 
11βHSD2-/- mice had an impaired concentration response following ddAVP 
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administration, during both water deprivation and ad libitum water intake.  These 
data were suggestive of deranged AQP2 function in the null mice.  In view of the 
results in 2.3, and the role of the collecting duct in the fine-tuning of water balance, 
the studies detailed were designed to provide an insight into the function of the 
collecting duct in 11βHSD2-/- mice.   
 
3.1.2.  Renal Structure in 11βHSD2-/- mice 
Medullary atrophy is commonly observed in mouse models of polyuria, documented 
in V2R and AQP2 deficient mice amongst others (Yun et al., 2000, Yang et al., 
2006).  The murine kidney may be particularly susceptible to polyuria-induced injury 
since extensive medullary atrophy is infrequently reported in sufferers of congenital 
D.I.  (van Lieburg et al., 1999).  In rare instances non-obstructed hydronephrosis, 
occurring secondarily to the increased urine flow has been described (van Lieburg et 
al., 1999, Yoo et al., 2006).  In humans nephrogenesis continues throughout 
gestation, consequently the kidneys tend to be mature at birth.  In contrast, rodent 
kidneys are not fully developed at birth, with changes in tubular structure occurring 
postnatally (Speller and Moffat, 1977).  Subsequently, postnatal insults can impair 
renal development, which may explain the increased propensity to polyuria-induced 
injury in mice.  In accord with these hypothesizes, our MRI analysis has 
demonstrated extensive medullary atrophy in 11βHSD2-/- mice at >180 days (Figure 
3.1).  To evaluate whether the medullary injury was the cause or consequence of 
increased water turnover, gross and fine renal structure were evaluated in the 







1. Polyuria in 11βHSD2-/- mice is nephrogenic in origin  
2. Increased urine flow is primarily the result of impaired collecting duct 
function, specifically an impaired AQP2 response to V2R stimulation 
3. As in other murine models of polyuria, the increased urine flow at >180 days 
causes renal injury, which exacerbates the phenotype further 
 
 
Figure 3.1.A:  MRI analysis of renal structure in a C57Bl/6 (left) and 
11βHSD2-/- mouse aged >180 days.   
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3.2.  Methods 
3.2.1.  q-PCR analysis 
3.2.1.1.  Isolation of RNA 
Following decapitation kidneys were resected from mice, cut in half through the 
papilla and snap frozen on dry ice.  Kidney sections were stored at -80°C until 
analysis.  Initially kidney halves were cut into smaller sections, on dry ice using a 
scalpel.  RNA extraction was then performed using an RNeasy mini kit (Qiagen, UK) 
following the manufacturers protocol.  Kidney halves were homogenized using a 
hand held homogenizer (Bio-Gen PRO200, Pro Scientific, USA) in 800µl RLT 
Buffer.  Following homogenization a further 800µl RLT Buffer was added.  Samples 
were centrifuged at 13000rpm for 3 minutes and a 600µl aliquot of supernatant 
mixed with 600µl of 70% ethanol by inversion.  700µl of this solution was then 
loaded into RNeasy mini columns, which were centrifuged at 13000rpm for 15 
seconds.  The flow-through was discarded and the step repeated with the remaining 
700µl of solution.  350µl RW1 buffer was added to the RNeasy column, which was 
centrifuged at 13000rpm for 15 seconds and the flow through discarded.  10µl DNase 
1 stock solution was then added to 70µl RDD buffer and the 80µl solution added to 
the RNeasy column.  Following a 15-minute incubation at room temperature, an 
additional 350µl of RW1 buffer was added to the column, which was span at 
13000rpm for 15 seconds, the flow-through was discarded.  500µl RPE buffer was 
then added to the column, which was centrifuged at 13000rpm for 2 minutes.  The 
RNeasy column was then transferred into a fresh collection tube and an additional 
minute centrifugation undertaken to remove any residual solution.  To elute the RNA 
from the column 50µl RNase-free water was added, the column places in a sterile 
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1.5ml eppendorf tubes (Eppendorf, UK) and centrifuged at 13000rpm for 1 minute.  
A microvolume spectrophotometer (Nanodrop, ThermoScientific, UK) was used to 
determine the concentration of the isolated RNA.  RNA quality was assessed by 
electrophoresis on 1% agarose gels made with 0.5% TBE buffer.  High quality 
extractions were determined by the presence of a band at 2kb and 5kb representing 
18s and 28s ribosomal RNA respectively.  An intensity ratio of 1:2 was used as 
confirmation that the RNA was intact. 
 
3.2.1.2.  Generation of cDNA 
Reverse transcription of the RNA was performed using a High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, UK) following the manufacturers 
protocol.  500ng of RNA was used per reaction.  Amplification was performed using 
thermal cycler (Vertiti 96-Well Thermal Cycler, Applied Biosystems, UK) using the 
following protocol, 10 minutes at 25°C, 120 minutes at 37°C, 5 minutes at 85°C.  
cDNA quality was confirmed by an end-point pcr using primers directed against 
11βHSD1. 
  
3.2.1.3.  q-PCR analysis of mRNA abundance 
q-PCR assays were generated using the universal probe library kit (Roche, UK) 
following the manufacturers protocol.  All reactions contained 200nM primer, 
100nM Probe, 5µl Roche probe mastermix, 2.8µl Roche water and 2µl cDNA.  
cDNA was diluted 1 in 40 in Roche water prior to analysis.  Standard curves were 
generated using a stock cDNA, consisting of equal aliquots of all the cDNA samples 
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that were to be compared to the curve.  Seven point curves (1 in 10, 1 in 20, 1 in 40, 
1 in 80, 1 in 160, 1 in 320 and 1 in 640 dilutions) were used for quantification.  All 
samples and standards were evaluated in triplicate.  q-PCR reactions were performed 
using a light cycler (LightCycler 480 Real-Time PCR system, Roche, UK).  
Quantification was performed using the second derivative maximum method.  
 
3.2.1.4.  Primers and analysis 
Primers were designed using ProbeFinder version 2.45 for Mouse, (Roche 
Diagnostics, UK).  Primer sequences were as detailed in Table 3.1.  For analysis all 
values were normalized to the abundance of house-keeping genes.  At <100 days 
values were normalized to an average of three house-keeping genes (18s, TBP and 
PPIA) since there was no significant difference in their average abundance between 
the two cohorts at this age (C57Bl/6 155.9±7.9 versus 11βHSD2-/- 156.4±2.5 P>0.05, 
unpaired t-test).  In contrast, at >180 days the abundance of TBP and PPIA were 
substantially different between the C57Bl/6 and 11βHSD2-/- mice, therefore the 
values were normalized to 18s, the abundance of which was not significantly 
different between the two cohorts (C57Bl/6 174.2±7.5 versus 11βHSD2-/- 145.0±17.4 
P>0.05, unpaired t-test).  All data are presented as a percentage of the mean value 
recorded in C57Bl/6 mice (n=8). 
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 Left Primer Right Primer 
18S ctcaacacgggaaacctcac cgctccaccaactaagaacg 
TBP gggagaatcatggaccagaa gatgggaattccaggagtca 
PPIA acgccactgtcgcttttc gcaaacagctcgaaggagac 
AQP2 tagccctgctctctccattg gagcagccggtgaaatagat 
AQP3 ctggggaccctcatcctt tggtgaggaagccaccat 
AQP4 tggaggattgggagtcacc tgaacaccaactggaaagtga 
NKCC2 tgggttgtcaacttctgcaa gctccgggaaatcaggtagt 
UT-A gaaatgccggaagaaaagg tcattgggtttttcaatcttca 
Caspase-3 tgaagacattttggaattaatgga tcaccatggcttagaatcaca 
HIF-1α gcactagacaaagttcacctgaga cgctatccacatcaaagcaa 
TonEBP tcagacaagcggtggtga agggagctgaagaagcatca 
 
Table 3.1: RT-PCR primers.  Designed using ProbeFinder version 2.45 for 
Mouse, Roche Diagnostics, UK. 
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3.2.2.  Western blot analysis of AQP2 
3.2.2.1.  Protein extraction and quantification 
An isolation solution was made composed of 250mM sucrose (BDH Laboratory 
supplies, VWR, USA) and 10mM triethanolamine (Sigma-Aldrich, UK).  On the day 
of protein extraction five Complete Protease Inhibitor Cocktail Tablets (Roche 
Applied Science, UK) and 2.5ml phenylmethanesulfonyl fluoride (pmsf, Sigma-
Aldrich, UK) solution (50mg pmsf in 25ml isopropyl ethanol) were added to 50ml 
isolation solution.  1.5ml of the solution was then added, on ice, to each kidney.  Due 
to the limited number of 11βHSD2-/- mice available, in the free access to water 
groups kidney halves were evaluated.  Kidneys were cut in half through the papilla to 
ensure proportional representation of medulla and cortex.  The kidneys were 
homogenized in 2ml ependorf tubes containing metal beads using a mixer mill 
(MM301 Ball Mill, Retsch, UK).  The resultant solution was centrifuged at 2000rpm 
for 1 minute.  Final protein concentration was assessed using a BCA Protein Assay 
kit (Pierce Biotechnology, USA) following the manufacturer’s protocol.  In brief, 
25µl of sample, standard, or blank were added to a clear 96 well plate (IWAKI, R&L 
Slaughter Ltd, UK) in duplicate.  Mixing BCA reagents A and B in a ratio of 50:1 
made a working reagent, 200µl of which was added to each sample.  Following a 30 
minute incubation at 37°C the plate was allowed to cool to room temperature and 
then absorbance measured at 562nm (OPTI Max Tunable Microplate Reader, 




3.2.2.2.  Electrophoresis 
For western blot analysis 1µg/µl protein stock solutions were made in 5x laemmli 
buffer.  Samples were heated at 95°C for 5min prior to electrophoresis, which was 
performed at 150mV for 1 hr, on 10% SDS-PAGE gel.  8-16µg of protein was 
loaded per lane.  Following a 20 minute incubation of the gel in transfer buffer, 
proteins were electrotransferred to a hydrophobic polyvinylidene difluoride (PVDF) 
membrane (Amersham Hybond-P, GE Healthcare, UK) using a semi-dry method 
(10mV for 30 minutes).  Subsequently, the blot was incubated in PBST-0.1% 
containing 5% nonfat dry milk at room temperature for 1 hour.  Membranes were 
incubated over night with a primary antibody against AQP2 (Cell Signaling 
Technology, USA) at 1/1000 dilution at 4°C overnight.  The membranes were 
washed 3x 5 minutes in PBST-0.1%, and then incubated with a secondary antibody 
(goat anti-rabbit, Santa Cruz, USA) for 2 hours at room temperature.  Membranes 
were again washed 3x 5 minutes in PBST-0.1% and developed using ECL (Thermo 
Scientific, UK).  For quantification membranes were stripped and re-probed with a 
primary antibody against GAPDH (Santa Cruz, USA).  Membranes were washed 1x 
5 minutes in PBST-0.1% and then incubated for 1 hour at 40°C in stripping buffer.  
Following this, membranes were washed 3x 5 minutes in PBST-0.1% and re-probed 
with anti-GAPDH, following the same method as detailed above.   
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3.2.2.3.  Buffers and Gels 
Laemelli loading buffer: 2% sodium dodecyl sulphate (SDS), 80% glycerol,  
1M Tris-Base, bromophenol blue, 0.1M dithiothreitol 
(DTT) 
Tank buffer: 0.025M Tris-Base, 0.192M Glycine, 0.1% SDS, pH 8.3 
Transfer Buffer: 0.25M Tris-Base, 0.192M Glycine, 0.1% SDS, 20% 
methanol 
Striping Buffer:  0.1% SDS, 1% Tween, 0.2M Glycine 
Running Gel: 1.5M Tris-Cl pH 8.8, 0.1% SDS, 10% acrylamide, 
0.05% tetramethylethylenediamine (TEMED), 0.067% 
ammonium peroxodisulphate (APS) 
Stacking Gel: 0.12M Tris-Cl pH 6.8, 0.1% SDS, 4% acrylamide, 
0.05% TEMED, 0.067% APS,  
 
3.2.2.4.  Analysis 
Densitometric analysis was performed using the gel analyzer tool within the Image-J 
software analysis program.  All AQP2 densitometries were normalized to the 
corresponding densitometries of GAPDH.  The ratio of AQP2/GAPDH was then 
used for statistical analysis.  The individual dehydrated blot values were expressed as 
a percentage of the average value measured in the hydrated blots from the 
corresponding group (n=4-6). 
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3.2.3.  Plasma AVP radioimmunoassay 
Trunk blood was collected from decapitated mice and centrifuged at 10000rpm for 5 
minutes at 4°C in order to isolate the plasma from the hematocrit.  Plasma samples 
were acidified with 2M hydrochloric acid (HCl), 0.25ml per 1ml of plasma.  AVP 
was then extracted from the plasma samples using Sep-Pak C18 cartridges (Water 
Associates, USA).  Initially the cartridges were conditioned using 5ml methanol.  
5ml of distilled water was then used to equilibrate the cartridge.  Subsequently, the 
plasma samples were added to the cartridges, all samples were diluted with distilled 
water so that the final volume added to the cartridges was 1ml.  The cartridges were 
then washed with 5ml 1% acetic acid, in order to remove any retained interferences.  
Finally, the AVP was eluted into glass test tubes using 2ml methanol.  The samples 
were then dried under nitrogen gas and reconstituted in 200µl assay buffer (50mM 
Tris pH 7.4 (12.14g Tris in 1l deionised water, 10ml 5M HCl, 3.5g neomycin 
sulphate, 1.75g human serum albumin, pH was adjusted to 7.4 and then made up to 
2l with deionised water)).  For the assay 50µl AVP standard or plasma extract was 
mixed with 25µl antibody (1:20000 dilution so final dilution in each assay tube was 
1:80000) and 25µl 125I-AVP ([125I]Tyr2,Arg8] Perkin Elmer, UK) in 
radioimmunoassay cups (Sarstedt, UK) in duplicate at 0°C.  For the standard curve a 
stock of AVP (4pg/50ml) serially diluted 1:2 to give concentrations of 2, 1, 0.5, 0.25, 
0.125 pg/50µl.  The radioimmunoassay tubes were then centrifuged at 2000rpm for 1 
minute and incubated at 4°C for 48 hours.  Following the incubation 300µl of 
charcoal suspension (6.07g Tris in 500ml deionised water, 5ml 5M HCl, 2g 
neomycin sulphate, 1.85g EDTA, 5g BSA.  The pH was adjusted to 7.4 and then the 
solution made up to a final volume of 1l using deionised water.  For the charcoal 
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solution 0.062g dextran T70 (Amersham Biosciences, Sweden) was dissolved in 5ml 
buffer, this was then mixed with 95ml buffer and 0.6g Norit charcoal (Norit N.V, 
The Netherlands)) was added to each tube.  The tubes were then centrifuged at 
3000rpm for 15 minutes following which the supernatant was aspirated off.  The 
charcoal free pellet was then counted using a scintillation-gamma counter (1470 
Wallac Wizard Gamma Counter, GMI, USA) (n=2-5).   
 
3.2.4.  Gross renal structural analysis 
Following resection, kidneys were fixed in 10% formalin (Sigma-Aldrich, UK) for 
up to 48-hours and then transferred to 70% ethanol for long term storage.  Both poles 
of the kidneys were removed using a scalpel, leaving mid transverse sections 
approximately 2mm wide.  The central sections were imaged using a microscope 
(Lecia DFC320, Lecia Micorsystems, Germany) at magnification 1.25.  A ruler with 
mm graduations was included on each image as a scale reference (n=5-6).   
 
3.2.5.  Fine renal structural analysis 
Mid transverse sections were embedded in paraffin.  4µm sections were cut and 
stained with hematoxylin and eosin (H+E, Histology Core Service, University of 
Edinburgh).  Images were captured using a microscope (Zeiss Axioscope, Zeiss, 
USA) at magnification 40.  The amount of glomeruli in ten H-E stained sections per 
mouse (n=5 per group) were counted to evaluate nephron loss.  Post-acquisition 
morphometric analysis was performed to quantify total tubule, luminal and basement 
membrane areas in >180 day old mice.  The number of nuclei per tubule was also 
 112 
assessed.  Since there was no qualitative difference in the tubules from <100 day 
C57Bl/6 and 11βHSD2-/- mice they were not quantified.  Quantification was 
performed in a blinded fashion using the Image-J software analysis program.  Areas 
were measured using the free hand tool and nuclei counted using the multi-point 
selection tool.  Up to 10 sections from 3 mice per group were evaluated, totaling 
>600 tubules per group.     
 
3.2.6.  Analysis of urinary urea and albumin 
Urinary urea was measured using a commercially available colourmetric assay kit 
(QuantiChrom, BioAssay Systems, USA).  In brief, urine samples were diluted 50 
fold in deionised water.  A working reagent consisting of equal volumes of reagent A 
and B was mixed no more than 20min prior to performing the assay.  5µl of diluted 
urine and 200µl of working reagent were added to each well of a clear 96 well plate 
(IWAKI, R&L Slaughter Ltd, UK).  A standard (5mg urea/dL) and blank (deionised 
water) were also included on each plate.  All samples were assessed in duplicate.  
Following 20 minutes incubation at room temperature a plate reader (OPTI max 
tunable microplate reader, Molecular Devices, UK) was used to measure colour 
intensity using an optical density of 430 nm.  Urinary urea concentrations were 
converted to excretion rates using the appropriate urine flow rate, and then expressed 
in mg/24hr (n=4).  Urinary albumin was measured by the Clinical Analysis Core 




3.2.7.  Analysis of renal cell death 
As above, mid transverse-paraffin embedded renal sections were cut into 4µm slices 
using a microtome.  The sections were transferred to micro slides (SuperFrost Plus 
Microslides, VWR, USA) and dried overnight at 37°C.  Terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) staining was used to assess DNA 
fragmentation, and therefore cell death.  In this technique dUTPs are incorporated 
into the fragmented DNA by the enzyme terminal deoxynucleotidyl transferase.  
Since the dUTPs are labeled with fluorescence (fluorescein-12-dUTP), fragmented 
DNA can be imaged using a fluorescence microscope.  TUNEL staining was 
performed using DeadEnd Fluorometric TUNEL System kit (Promega, UK), 
following the manufacturers protocol.  Initially, slides were immersed in xylene to 
deparaffinize the sections (2x 5 minutes).  A 5-minute wash in 100% ethanol was 
then performed.  Sections were then rehydrated by immersion in decreasing 
concentrations of ethanol (100, 95, 85, 70 and 50%) for 3 minutes each.  The sections 
were then washed in 0.85% NaCl for 5 minutes followed by 5 minutes in phosphate 
buffered saline (PBS).  Sections were fixed by 15-minute immersion in 4% 
methanol-free formaldehyde solution in PBS and then washed in twice PBS for 5 
minutes.  The sections were then permeabilized by incubation for 10 minutes with 
20µg/ml.  Following permeabilization the sections were washed in PBS for 5 
minutes, fixed by immersion in 4% methanol-free formaldehyde solution in PBS for 
5 minutes, and again washed in PBS for 5 minutes.  Sections were then incubated for 
10 minutes with 100µl of equilibration buffer.  50µl of terminal deoxynucleotidyl 
transferase, recombinant (rTdT) incubation buffer was then added to the sections.  
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The slides were covered with plastic coverslips to ensure even distribution of the 
buffer and the slides incubated in a humidified chamber at 37°C for 60 minutes.  The 
coverslips were then removed and the reaction terminated by immersing the slides in 
2x saline-sodium citrate (SSC) for 15 minutes.  Finally the slides were washed 3 
times in PBS (5 minutes each) and counterstained with propidium iodide.  Following 
the second fixation step one section was incubated with DNase I to cause DNA 
fragmentation, this slide acted as the positive control.  For the negative control 
addition of rTdT was omitted from one section. 
 
TUNEL stained sections were imaged using a laser scanning microscope with a 
moving stage (Zeiss, USA) at 40x magnification.  A 3x3 square scan-area at the base 
of the papilla was selected for analysis since this was region was excluded from the 
region of medullary damage.  Quantification of positive nuclei was performed using 
the Image-J software analysis program.  Positive (green) nuclei were counted using 
the multipoint selection tool, and then expressed as a percentage of total nuclei (red 
and green). 
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3.3.  Results 
The mRNA abundance of AQP2 was compared in kidneys from hydrated C57Bl/6 
and 11βHSD2-/- mice.  AQP2 mRNA abundance was significantly lower in the 
11βHSD2-/- mice than aged-matched C57Bl/6 mice at both <100 and >180 days 
(Figure 3.2.A and Figure 3.2.B respectively). 
 
 
Figure 3.2:  AQP2 abundance in hydrated C57Bl/6 (white) and 11βHSD2-/- 
(black) mice at (A) <100 and (B) >180 days.  Data are means ±S.E.M.  Statistical 
analysis was performed using an unpaired t-test, **P<0.01. 
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To evaluate whether attenuated AVP contributed to the decreased abundance of 
AQP2 in the null mice, plasma AVP levels were assessed.  Measuring plasma AVP 
in mice is challenging and data were not obtained from each mouse; consequently the 
data presented must be interpreted as preliminary only.  Nevertheless, plasma AVP 
tended to be higher in the 11βHSD2-/- mice than the C57Bl/6 at both <100 and >180 






Figure 3.3.A:  Basal plasma AVP concentrations in C57Bl/6 (white) and 
11βHSD2-/- (black) mice at <100 and >180 days.  
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AQP3 and AQP4 mRNA abundance were evaluated to examine the involvement of 
the basolateral collecting duct water channels in the polyuria observed in 11βHSD2-/- 
mice.  AQP3 abundance was significantly lower in the 11βHSD2-/- mice than the 
C57Bl/6 controls at both <100 (Figure 3.4.A) and >180 (Figure 3.4.B) days.  In 
contrast AQP4 abundance was normal in the null mice at <100 days (Figure 3.4.C) 
but significantly lower than in the C57Bl/6 controls >180 days (Figure 3.4.D).  
Figure 3.4:  Abundance of basaolateral collecting duct AQPs in C57Bl/6 (white) 
and 11βHSD2-/- (black) mice.  (A) AQP3 at <100 days.  (B) AQP3 at >180 days.  
(C) AQP4 at <100 days.  (D) AQP4 at >180 days.  Data are means ± S.E.M.  
Statistical analysis was performed using an unpaired t-test,  ***P<0.001. 
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The reabsorption water from the collecting duct is dependent on the corticomedullary 
osmotic gradient generated by the loop of Henle.  In view of the central role of 
NKCC2 in this process, its abundance was evaluated in the C57Bl/6 and 11βHSD2-/-
mice.  Renal abundance of NKCC2 was not different in the C57Bl/6 and 11βHSD2-/- 
mice at <100 days (Figure 3.5.A).  In contrast, at >180 days renal NKCC2 
abundance was significantly lower in the 11βHSD2-/- mice than the aged match 
C57Bl/6 mice (Figure 3.5.B). 
 
Figure 3.5:  Abundance of NKCC2 in C57Bl/6 (white) and 11βHSD2-/- (black) 
mice at (A) <100 day and (B) >180 days.  Data are means ± S.E.M.  Statistical 
analysis was performed using an unpaired t-test,  ***P<0.001. 
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Given that impaired renal handling of urea has been implicated in glucocorticoid 
induced polyuria (Li et al., 2008) the renal mRNA abundance of UT-A was assessed 
in the 11βHSD2-/- and C57Bl/6 mice.  Since the UT-A gene encodes UT-A1 and UT-
A3 its evaluation gave an indication of the abundance of the urea transporters 
(Fenton et al., 2002).  UT-A abundance was substantially reduced in 11βHSD2-/- 
mice at <100 days.  Abundance was ~50% lower in the null mice than the aged 
matched controls (Figure 3.6.A), but this did not reach statistical significance 
(P=0.16).  At >180 days UT-A abundance was significantly lower in the null mice, a 
~70% reduction was observed in the 11βHSD2-/- mice compared to the aged matched 
controls (Figure 3.6.B).  The physiological relevance of these data was determined 
by the evaluation of urinary urea.  Urinary excretion of urea was significantly higher 
in the 11βHSD2-/- mice than C57Bl/6 controls at both <100 and >180 days (Figure 
3.6.C).  Since food intake was not significantly different between the two cohorts at 
either <100 or >180 days (<100 days C57Bl/6 4.1±0.1 versus 11βHSD2-/- 4.1±0.1 
and >180 days C57Bl/6 4.2±0.1 versus 11βHSD2-/- 4.3±0.2 g/24hr), increased 
protein intake did not contribute to the increased urinary excretion of urea. 
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Figure 3.6:  Abundance of UT-A and urea excretion in C57Bl/6 (white) and 
11βHSD2-/- (black) mice.  (A) UT-A at <100 days.  (B) UT-A at >180 days.  (C) 
Urinary urea excretion.  Data are means ± S.E.M.  Statistical analysis was 
performed using an unpaired t-test or one-way ANOVA with Tukey post-test as 
appropriate, ***P<0.001, *P<0.05 compared to age matched C57Bl/6 controls. 
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In view of the attenuated AQP2 mRNA abundance in hydrated 11βHSD2-/- mice, 
semi-quantitive immunoblotting was used to assess the role AQP2 in the impaired 
response to water deprivation in >180 day 11βHSD2-/- mice.  As previously 
described (Frokiaer et al., 1999), AQP2 presented as 29kDa and 35-50kDA bands, 
representing non-glycosylated and glycosylated forms of the channel respectively.  
Consistent with a functional concentration response, water deprivation resulted in an 
increase in AQP2 protein abundance in C57Bl/6 mice (Figure 3.7.A and Figure 
3.7.C).  This was ∼2 fold in both groups (Figure 3.8.A).   
 
In <100 day 11βHSD2-/- mice, the water deprivation challenge caused a ∼3 fold 
increase in renal AQP2 abundance (Figures 3.7.A and 3.8.A).  In contrast the AQP2 
response to water deprivation was blunted in the >180 day 11βHSD2-/- mice (Figure 






Figure 3.7:  Semiquantitive immunoblots showing the effect of water 
deprivation on AQP2 protein abundance in kidneys from C57Bl/6 
and 11βHSD2-/- mice at <100 (A+B) and >180 (C+D) days.  




Figure 3.8:  The effect of water deprivation on AQP2 protein abundance in 
kidneys from C57Bl/6 (white) and 11βHSD2-/- (black) mice aged <100 and >180 
days.  All data were normalized to GAPDH.  Data are the individual 
densitometry values of the water-deprived kidney bands expressed as a 
percentage of the mean value for the hydrated kidney bands in the corresponding 
group.  100% is therefore no difference in abundance, whereas 200% is a 2-fold 
increase.  Data are means ± S.E.M.  Statistical analysis was performed using a 
one-way ANOVA. 
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3.2.2.  Renal structure in 11βHSD2-/- mice 
Kidney morphology was evaluated to assess whether renal injury correlated with 
increased water turnover in 11βHSD2-/- mice.  Despite being polyuric, the kidneys of 
11βHSD2-/- appeared normal at <100 days.  At the gross level there was no obvious 
structural difference between the kidneys from C57Bl/6 and 11βHSD2-/- mice 
(Figure 3.9.A and Figure 3.9.B respectively).  Similarly, at the fine level, tubular 
structure was normal in <100 day C57Bl/6 and 11βHSD2-/- mice (Figure 3.10.A and 
Figure 3.10.B respectively).  The tubules were densely packed and the lumens 
narrow in both cohorts.  By >180 days severe renal injury was evident in all of the 
kidneys evaluated from 11βHSD2-/- mice.  At this age the kidneys displayed severe 
medullary atrophy, exposed papilla and dilated renal pelvises (Figure 3.9.D).  Given 
that kidneys from >180 day C57Bl/6 mice were structurally normal (Figure 3.9.C), 
this was not merely an effect of aging.  At the fine level, tubular structure was 
damaged in >180 day 11βHSD2-/- mice (Figure 3.10.D).  Varying degrees of tubular 
dilation were observed, with membrane blebbing and debris within the lumen evident 
in the most severely dilated tubules (Figure 3.10.D). 
 
Glomeruli number was assessed to evaluate whether the renal injury was associated 
with nephron loss.  Glomeruli number was not significantly different between the 
C57Bl/6 and 11βHSD2-/- mice at either <100 and >180 days (Figure 3.11.A).  Since 
glomeruli number was not reduced in the 11βHSD2-/- mice, urinary albumin 
excretion was evaluated as an assessment of glomeruli function.  Urinary albumin 
excretion was substantially higher in <100 day 11βHSD2-/- mice than the age-
matched C57Bl/6 controls.  By >180 days the excretion rate had increased further, to 
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levels that were significantly higher than both aged matched C57Bl/6 mice and the 
<100 day 11βHSD2-/- mice.  In contrast, there was no difference in albumin excretion 
between the C57Bl/6 mice at <100 and >180 days. (Figure 3.11.B)  
 
 
Figure 3.9:  Histological evaluation of gross renal structure.  Mid transverse 
sections approximately 2mm thick from <100 day C57Bl/6 (A), <100 day 
11βHSD2-/- (B), >180 day C57Bl/6 (C) and >180 day 11βHSD2-/- (D) mice were 




Figure 3.10:  Histological evaluation of tubular structure.  H+E stained sections 
were evaluated from <100 day C57Bl/6 (A), <100 day 11βHSD2-/- (B), >180 day 
C57Bl/6 (C) and >180 day 11βHSD2-/- (D) mice. 
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Figure 3.11:  Evaluation of glomeruli number and function in C57Bl/6 (white) 
and 11βHSD2-/- (black) mice aged <100 and >180 days.  (A) Glomeruli 
Number.  (B) Urinary Albumin Excretion.  Data are means ± S.E.M.  Statistical 
analysis was performed using a one-way ANOVA and Tukey post-test.  
*P<0.05 compared to age matched controls.  #P<0.05 compared to younger 
mice within the same genotype. 
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To quantify the qualitative observations, morphometric analysis was performed on 
tubules from >180 day C57Bl/6 and 11βHSD2-/- mice.  Consistent with the 
qualitative observations, luminal area was significantly larger in the 11βHSD2-/- mice 
than the C57Bl/6 controls (Figure 3.12.A).  As a result of this, total tubule area was 
also significantly higher in the 11βHSD2-/- mice (Figure 3.12.B).  Basement 
membrane width was not significantly different between the C57Bl/6 and   
11βHSD2-/- mice (Figure 3.12.C), indicative of an absence of hypertrophy.  
However, hyperplasia was evident, the number of nuclei per tubule was significantly 
higher in the 11βHSD2-/- mice than the control C57Bl/6 mice (Figure 3.12.D).  
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Figure 3.12:  Morphometric evaluation of tubules from >180 day old C57Bl/6 
(filled triangles) and 11βHSD2-/- (open squares) mice.  (A) Luminal Area.  (B) 
Tubular Area.  (C) Basement Membrane Width.  (D) Nuclei per Tubule.  Data 
are individual measurements with the median value indicated by the vertical line.  
Statistical analysis was performed using a Mann-Whitney test *P<0.05, 
***P<0.001. 
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In an attempt to identify the cause of medullary atrophy observed in > 180 day old 
11βHSD2-/- mice, TUNEL staining was used to evaluate apoptotic cell death.  As 
shown in Figure 3.13.A, there was no significant difference in the amount of TUNEL 
positive nuclei in C57Bl/6 and 11βHSD2-/- mice at either <100 or >180 days.  There 
was, however, a significant increase in the amount of TUNEL positive nuclei 
observed in each group at >180 days compared to the younger mice of the same 
genotype.  The amount of TUNEL positive nuclei at >180 days was 
uncharacteristically high in both groups of mice (C57Bl/6 61±16 versus 11βHSD2-/- 
46±11 %), indicative of false positive staining, as previously characterized in murine 
kidneys (Pulkkanen et al., 2000).   An additional assessment of cell death was 
therefore utilized.  q-PCR analysis of Caspase-3 mRNA abundance demonstrated 
that there was no significant difference in the amount of renal apoptotic cells in 








Figure 3.13: Evaluation of apoptotic cell death in C57Bl/6 (white) and 
11βHSD2-/- (black) mice.  (A) TUNEL staining.  Caspase-3 mRNA abundance 
in (B) <100 and (C) >180 day mice.  Data are means ± S.E.M.  Statistical analysis 
was performed using a one-way ANOVA and tukey post-test or an unpaired t-
test as appropriate.  ***P<0.001 when compared to <100 day mice of the same 
genotype. 
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It has been postulated that in mice, polyuria and the resultant tubular dilation can 
cause reductions in local blood flow (Oppermann et al., 2007).  To evaluate whether 
the medullary atrophy in >180 day 11βHSD2-/- mice was the result of local hypoxia, 
hypoxia inducible factor 1, alpha subunit (HIF-1α) mRNA abundance was assessed.  
Abundance of HIF-1α was not significantly different between 11βHSD2-/- and 
C57Bl/6 mice at either <100 (Figure 3.14.A) or >180 days (Figure 3.14.B). 
 
 
Figure 3.14:  Abundance of HIF-1α in C57Bl/6 (white) and 11βHSD2-/- (black) 
mice at (A) <100 day and (B) >180 days.  Data are means ± S.E.M.  Statistical 
analysis was performed using an unpaired t-test.   
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In view of the role of TonEBP in the maintenance of medullary cellular integrity its 
abundance was evaluated in C57Bl/6 and 11βHSD2-/- mice at <100 (Figure 3.15.A) 
and >180 (Figure 3.15.B) days.  There was no significant difference in the abundance 






Figure 3.15:  Abundance of TonEBP in C57Bl/6 (white) and 11βHSD2-/- (black) 
mice at (A) <100 day and (B) >180 days.  Data are means ± S.E.M.  Statistical 
analysis was performed using an unpaired t-test.   
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3.4.  Discussion 
3.4.1.  Evaluation of basal renal function in 11βHSD2-/- mice 
3.4.1.1.  Basal collecting duct function 
In accordance with other models of glucocorticoid excess, 11βHSD2-/- mice have an 
increased water turnover, displaying both polyuria and polydipsia.  Notably water 
restriction and ddAVP administration failed to normalise urine concentrating ability, 
suggestive of a nephrogenic D.I. like phenotype.  Clinically, nephrogenic D.I. is 
caused by mutations in the genes encoding AQP2 and V2R.  ∼95% of cases arise 
from X-linked mutations in the gene encoding V2R, which render the kidney 
insensitive to the actions of AVP.  The remaining ∼5% of cases are caused by 
autosomal recessive mutations in the gene encoding AQP2, with the mutations 
causing the retention of the channel in the ER and subsequently its degradation 
(Nielsen et al., 2007, Bichet, 1996).  The demonstration that AQP2 mRNA 
abundance was lower in hydrated 11βHSD2-/- mice than the aged matched controls, 
at both <100 and >180 days, suggests that attenuated levels of the channel contribute 
to the increased urine flow.   
 
The importance of AQP2 in basal water handling has been demonstrated through the 
evaluation of genetically modified mice.  In humans point mutation T126M within 
the AQP2 gene causes the retention of the channel in the ER and consequently 
nephrogenic D.I.  The generation of “knock-in” mice expressing this form of the 
channel illustrated the importance of the AQP2 in urine-concentrating ability.  
Although the mice appeared normal at birth they rapidly became dehydrated, failed 
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to thrive, and consequently died within a week (Yang et al., 2001).  Since neonatal 
mortality was not observed in the polyuric AQP3 (Ma et al., 2000) and AQP4 (Ma et 
al., 1997) knockout mice, these studies highlighted the importance of apical AQP2 as 
the rate-limiting barrier in the modulation of basal urine concentration.   
 
The reabsorption of water through AQP2 is dependent on its translocation from 
intracellular vesicles to the apical membrane.  Although conclusions about the 
localisation of AQP2 cannot be drawn from the current studies, the demonstration 
that basal levels of AQP2 were reduced in the 11βHSD2-/- mice may explain the 
attenuated response to acute ddAVP stimulation during free access to water, 
discussed in section 2.3.  In the acute setting, administration of ddAVP failed to 
induce anuria in the null mice.  It is postulated that the intracellular AQP2 reservoir 
in the 11βHSD2-/- mice was not sufficient to induce a full concentration response 
following acute V2R stimulation.   
 
Since the AQP2 gene does not contain a GRE (Tchapyjnikov et al.), it is unlikely 
that the decreased mRNA abundance of the channel in the 11βHSD2-/- mice is the 
direct result of decreased glucocorticoid inactivation.  As discussed in section 1.2.4.1 
AQP2 expression and localisation are regulated by AVP.  Acutely, AVP induces the 
trafficking of intracellular AQP2 to the apical membrane, whereas chronic 
stimulation results in the increased abundance of the channel (Nielsen et al., 1993a, 
Nielsen et al., 1995a).  To evaluate the role of AVP in the regulation of AQP2 in the 
11βHSD2-/- mice, plasma AVP concentrations were assessed during hydration.  The 
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data presented suggest that there was a trend towards increased plasma AVP in the 
null mice.  These data are in contrast to the known inhibitory effect of 
glucocorticoids on AVP transcription (Kim et al., 2001, Jard, 1991) and the 
demonstration of non-suppressible AVP release in glucocorticoid deficient models 
(Boykin et al., 1978, Saito et al., 2000).  However, the evaluation of patients with 
Cushing’s syndrome found that basal plasma AVP levels were not significantly 
different from the control subjects.  Moreover, the AVP response to a water 
deprivation test was augmented in the Cushing’s patients.  Despite this, basal 
polyuria and an impaired response to ddAVP administration were also documented 
(Knoepfelmacher et al., 1997).  These data suggest that chronic glucocorticoid 
excess is associated with a renal insensitivity to AVP.   
 
Further support for this hypothesis came from the demonstration that AQP3, but not 
AQP4, abundance was decreased in the 11βHSD2-/- mice at <100 days.  Chronic 
stimulation of V2R, as occurs during a water deprivation challenge, increases renal 
AQP3 abundance.  In contrast AQP4 is not regulated by V2R stimulation (Terris et 
al., 1996).  Therefore, the observation that AQP3, but not AQP4, abundance was 
decreased in the 11βHSD2-/- mice is cohesive with a renal escape from AVP 
stimulation.  Despite this, in an experimental model of AVP escape AQP3 abundance 
was increased, despite attenuated levels of AQP2 (Ecelbarger et al., 1997, Ecelbarger 
et al., 2001b).  The reason for the separation of AQP2 and AQP3 regulation was not 
determined.  However, since the studies were performed over a relatively short 
period of time, the increase in AQP3 may have been an initial compensatory 
response to decreased apical AQP2.  In line with this hypothesis is the demonstration 
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that in inducible AQP2-/- mice, increased abundance of AQP3 was reported six weeks 
following the induction of AQP2 deletion (Yang et al., 2006).  Whether the increase 
in expression was a transient effect was not determined.   
 
Crucially, the normal expression of AQP4 in the null mice at <100 days suggests that 
the difference in the abundances of AQP2 and AQP3 were not merely reflective of 
medullary atrophy, as might be assumed at >180 days.   
 
The mechanism underlying AVP escape has not been fully determined.  However, 
prolonged AVP stimulation has been shown to decrease V2R mRNA abundance, 
binding capacity and cAMP production (Tian et al., 2000, Saito et al., 2001) 
implicating impaired receptor function in the phenomenon.  Additionally, proteomic 
evaluation of the vasopressin escape model demonstrated the increased expression of 
several proteins involved in V2R internalisation, adding support to the hypothesis 
that altered V2R signalling contributes to the insensitivity to AVP (Hoorn et al., 
2005).  Within the time frame of this thesis it was not possible to assess V2R receptor 
abundance and function, evaluation of which would provide an insight into whether 
the apparent renal insensitivity to AVP stimulation in the 11βHSD2-/- mice was the 
result of decreased receptor function. 
 
Although the data presented suggest that plasma AVP was increased in the null mice, 
the low number of mice available for analysis means that caution should be taken 
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when drawing conclusions from these experiments.  Evaluation of plasma AVP in 
mice is hampered by both the low volume of plasma available for analysis and the 
difficultly of obtaining non-stressed samples.  Acute stress was shown to increase the 
activity of AVP positive neurons in the hypothalamus (Zhao and Ai, 2011), 
implicating the release of the neurohormone in the stress response.  In the current 
studies plasma samples were obtained from decapitated mice.  Since carbon dioxide 
has been shown to have profound affects on plasma AVP concentrations (Reed et al., 
2009) the mice were not anesthetised prior to decapitation, consequently, minimal 
stress was unavoidable.  In an attempt to reduce the effect of stress on the data, 
values more than two standard deviations from the mean were excluded from 
analysis, thus limiting the number of useable mice per cohort.  Ideally, the data 
would be verified using plasma samples obtained from conscious, unrestrained mice.  
However, this technique is not without problems; hypovolemia is a powerful 
stimulus for AVP release.  Since the plasma volume of mice is particularly low, 
plasma AVP concentrations directly correlate to the amount of blood withdrawn.  
Therefore, effort must be taken to simultaneously replace any blood removed 
(Professor Peter Bie, personal communication).  
 
Although the cause of the deranged water handling in 11βHSD2-/- was not 
determined, it is likely that the severe hypokalemia documented in the model 
contributes to the phenotype (Bailey et al., 2008, Kotelevtsev et al., 1999).  The 
effect of hypokalemia on renal water handling has been extensively studied.  In rats 
chronic hypokalemia is associated with polydipsia, polyuria and decreased renal 
AQP2 abundance (Berl et al., 1977, Marples et al., 1996, Amlal et al., 2000), in line 
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with the phenotype observed in the 11βHSD2-/- mice.  Similarly, in rats chronically 
treated with aldosterone, decreased apical AQP2 and polyuria were documented.  It 
is likely that the altered water handling in this model occurred secondarily to the 
resultant hypokalemia, however this was not confirmed (de Seigneux et al., 2007).  
In hypokalemic rats, urine-concentrating defects were reversed by the administration 
of a normal potassium diet (Marples et al., 1996).  Whether the normalisation of 
plasma potassium would have the same effect in 11βHSD2-/- mice is of interest. 
 
3.4.1.2.  Generation of the osmotic gradient 
As discussed in section 1.2.2 the loop of Henle is responsible for the generation of 
the corticomedullary osmotic gradient.  The dissipation of this gradient would impair 
the reabsorption of water from the collecting duct regardless of the function of the 
AVP-AQP2 cascade.  The demonstration that NKCC2 mRNA abundance was not 
significantly different between the 11βHSD2-/- mice and C57Bl/6 controls at <100 
days suggests that the polyuria observed at this age is not the result of an impaired 
osmotic gradient.  In contrast the mRNA abundance of NKCC2 was significantly 
lower in the null mice at <180 days.  Therefore, the impairment of the cortico-
medullary gradient may contribute to the exacerbated urine flow in >180 day 
11βHSD2-/- mice.  Indeed, the attenuation of the osmotic gradient may explain the 
reduced sensitivity to AVP in the null mice at this age.  However, as with AQP3 and 
AQP4, the contribution of the extensive medullary atrophy, observed at >180 days in 
11βHSD2-/- null mice, should taken into consideration when interpreting these data.   
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In the inner medulla, the longitudinal osmotic gradient is partly attributable to the 
accumulation of urea.  The demonstration that urea excretion was elevated, and    
UT-A mRNA abundance decreased, in the null mice at both <100 and >180 days 
implies an impaired medullary concentration of urea.   
 
Chronic glucocorticoid excess is associated with altered renal handling of urea.  
Studies in rats on a low protein diet demonstrated that 7-day dexamethasone 
administration resulted in the increased fractional excretion of urea.  In contrast, the 
same effect was not observed following acute (2-day) glucocorticoid administration, 
suggesting that prolonged elevations of glucocorticoids are required to alter tubular 
urea transport (Knepper et al., 1975).  The augmented excretion of urea, induced by 
glucocorticoid excess, has been implicated in the development of the polyuria 
frequently observed in the models.  In rats, chronic dexamethasone treatment 
resulted in polyuria and an impaired concentration response to water deprivation, a 
similar phenotype to that observed in the 11βHSD2-/- mice.  Evaluation of renal 
transporter abundance demonstrated the decreased expression of UT-A1 and UT-A3.  
Since the abundance of AQP2 was not altered, the polyuria was attributed to the 
impaired medullary concentration of urea (Li et al., 2008).  Detailed evaluation of 
urea transporter expression following glucocorticoid treatment provided a causative 
mechanism for the increased urea excretion.  Protein expression of UT-A1 was found 
to be significantly higher in adrenalectomized rats than sham-operated controls.  
Glucocorticoid replacement resulted in the attenuation of UT-A1 expression to 
control levels, thus supporting the hypothesis that glucocorticoids are involved in the 
suppression of UT-A1 (Naruse et al., 1997).  Subsequent studies showed that 
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dexamethasone treatment resulted in inhibition of UT-A promoter 1 activity in cell 
culture (Peng et al., 2002).  Investigations in mice in which β-­‐galactosidase (β-gal) 
was placed under the control of the UT-A promoter illustrated the physiological 
reference of these in vitro findings.  Administration of dexamethasone to the mice 
resulted in a reduction in β-gal activity in the inner medulla, and contemporaneously 
a decrease in UT-A1 and UT-A3 mRNA (Fenton et al., 2006).  The demonstration 
that UT-A mRNA abundance was lower in 11βHSD2-/- mice than aged matched 
C57Bl/6 controls is in line with these observations, and suggests that decreased 
expression of UT-A1 and UT-A3 may contribute to the polyuria. 
 
Given that the deletion of 11βHSD2 provides glucocorticoids with unrestricted 
access to MR, it could be postulated that glucocorticoid activation of MR is causative 
in the augmented urea excretion observed in null mice.  However, in 
adrenalectomized rats, dexamethasone induced reductions in UT-A1 protein 
abundance were not attenuated by spironolactone (Gertner et al., 2004).  These data 
suggested that the effects of glucocorticoids were not mediated by the 
mineralocorticoid receptor, and were more likely the result of glucocorticoid receptor 
activation.  This hypothesis was supported by the observation that the glucocorticoid 
receptor antagonist, RU-486, prevented dexamethasone-induced inhibition of the 
UT-A1 promoter in vitro (Peng et al., 2002).   
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3.4.1.3.  The AQP2 response to water deprivation 
In view of the apparent role of AQP2 in the increased urine flow in 11βHSD2-/- mice, 
its involvement in the response to water deprivation was assessed.  Protein levels of 
AQP2 were ∼2 fold higher in dehydrated C57Bl/6 mice than their hydrated 
counterparts at both <100 and >180 days.  In line with a functional response to water 
deprivation, the abundance of AQP2 was also higher in dehydrated than hydrated 
11βHSD2-/- mice at <100 days.  In contrast, at >180 days the abundance of AQP2 
following water removal was only marginally higher than that measured during free 
access to water, implicating the channel in the impaired response to water 
deprivation at this age.  It is a limitation of these studies that comparable AQP2 
mRNA abundance data was not obtained from dehydrated mice.  Consequently, the 
cause for the reduced protein expression during dehydration cannot be determined.  
However, assuming a close correlation between mRNA and protein expression, it is 
postulated that the augmented AQP2 response to water deprivation in the <100 day 
11βHSD2-/- mice is the result of attenuated basal expression. 
 
As discussed in 1.2.4.2 phosphorylation of Ser-256 induces the translocation of 
intracellular AQP2 to the apical membrane.  Ser-256 is one of four AVP-regulated 
phosphorylation sites on the AQP2 gene, all of which reside in the carboxyl terminal 
tail.  Although less thoroughly characterised, Ser-261, Ser-264 and Ser-269 are also 
involved in determining the localisation of AQP2.  Clathrin-coated pits mediate 
endocytosis of AQP2, a process that is dependent on membrane scission by the 
GTPase dynamin (Sun et al., 2002).  Co-immunoprecipitation studies demonstrated 
that 256D and 269D (D representing aspartic acid, which mimics phosphorylation) 
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had an attenuated interaction with dynamin compared to wildtype AQP2.  Moreover, 
internalisation of the constitutively phosphorylated forms of the channel was slower 
than that of the wildtype, suggesting that apical membrane accumulation of AQP2 
when phopshorylated at Ser-256 and Ser-269 is in part due to impaired endocytosis 
(Moeller et al., 2010).  The use of phospho-specific antibodies to evaluate the 
phosphorylation state of AQP2 would provide an insight into whether impaired 
shuttling of AQP2 to the apical membrane contributed to the attenuated response to 
water removal in the >180 day 11βHSD2-/- mice.   
 
3.4.2.  Evaluation of renal structure in 11βHSD2-/- mice 
The kidneys from <100 day 11βHSD2-/- mice were structurally normal at both the 
gross and tubular level despite significant polyuria.  In contrast at >180 days 
extensive renal damage was observed in the null mice.  At the gross level severe 
medullary atrophy was documented, to the extent that the papilla was exposed.  
Similarly, tubular structure was damaged in the >180 day 11βHSD2-/- mice.  The 
tubules displayed varying degrees of dilation, as a result of which the total tubular 
area was increased in the 11βHSD2-/- mice.  Basement membrane width was not 
significantly different between the C57Bl/6 and 11βHSD2-/-, suggesting that there 
was no hypertrophy, however, hyperplasia was evident, with increased nuclei per 
tubule. 
 
Glomeruli number was not significantly different between the 11βHSD2-/- and 
C57Bl/6 mice at either <100 or >180 days.  However, despite this increased urinary 
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excretion of albumin was documented in the null mice at both ages, indicative of 
glomeruli damage.  Albumin, which is synthesized by the liver, accounts for 
approximately 60% of total plasma protein in humans.  The kidneys filter roughly 
0.99% of plasma albumin, the majority of which is taken up by proximal tubule cells, 
such that in healthy individuals the final urinary concentration is <100mg/24hr.  The 
glomerular barrier is both size and charge selective.  Since albumin has a relatively 
large radius and negative charge it is predominantly restricted from the filtrate (Lund 
et al., 2003).  The demonstration that albumin excretion was augmented in 
11βHSD2-/- mice at <100 days, and had increased substantially by >180 days is 
suggestive of glomeruli injury in the null mice. 
 
Hypertension, as documented in 11βHSD2-/- mice (Bailey et al., 2008, Kotelevtsev et 
al., 1999) is associated with endothelial dysfunction and glomerular hyperfiltration.  
Therefore the augmented albumin in the urine of 11βHSD2-/- mice may be the result 
of hypertension induced glomeruli damage.  Alternatively, the albuminuria could be 
the result of over exposure to glucocorticoids during development.  Although acute 
glucocorticoid administration has been shown to reduce glomerular disease and 
proteinuria, through a reduction in local inflammation (Leech et al., 2000), prenatal 
glucocorticoid exposure has been frequently documented to result in postnatal renal 
injury.  Within the placenta 11βHSD2 acts to protect the foetus from over exposure 
to maternal glucocorticoids (Reviewed in (Yang, 1997).  Since the 11βHSD2-/- mice 
in the current investigations were generated from null-null crosses, the effects of 
over exposure to glucocorticoids in utero must be considered when interpreting the 
results.   
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Maternal glucocorticoid administration during gestation has been demonstrated to 
cause renal injury in mice (Dickinson et al., 2007) and rats (Ortiz et al., 2003, Singh 
et al., 2007).  In these studies renal injury was classified as a reduction in glomeruli 
number.  Moreover, increased glomerulosclerosis was observed (Ortiz et al., 2003).  
Although glomeruli number was not different between the two cohorts in the current 
studies, it is possible that damage to glomerular barrier, occurring as a consequence 
of in utero glucocorticoid exposure, may have contributed to the albuminuria in 
11βHSD2-/- mice.  
 
To evaluate whether apoptotic cell death contributed to the medullary injury TUNEL 
staining was performed.  Although there was no significant difference in the amount 
of TUNEL positive nuclei counted in the C57Bl/6 and 11βHSD2-/- mice at either 
<100 or >180 days, the amount of positive nuclei recorded in both cohorts at >180 
day was surprisingly high.  It has previously been documented that false positive 
staining is particularly prevalent in the murine kidney (Pulkkanen et al., 2000).  
Therefore, a second assessment of apoptosis was utilised.  Caspase-3 is a key protein 
in the execution of apoptosis, involved in the many of the proteolytic events central 
to programmed cell death.  Moreover, its mRNA expression has been used to 
evaluate apoptosis in murine renal injury models (Zhang et al., 2006).  Evaluation of 
the renal caspase-3 mRNA demonstrated that there was no difference in abundance 
between the 11βHSD2-/- and C57Bl/6 control mice at either <100 or >180 days.  
These data suggested that increased apoptosis may not have been the cause of 
medullary atrophy. 
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To evaluate whether hypoxia contributed to the loss of tissue, renal HIF-1α 
abundance was assessed.  HIF-1α expression increases during hypoxia, and through 
the induction of protective genes, aids cellular survival when oxygen levels are low.  
The involvement of HIF-1α in murine renal hypoxia has been illustrated using 
genetically modified mice.  Mice heterozygous for HIF-1α had an exacerbated 
response to ischemia-reperfusion injury, assumedly because the protective effects of 
the gene were reduced (Hill et al., 2008).  Since HIF-1α abundance was not different 
in the 11βHSD2-/- and C57Bl/6 mice it is unlikely that hypoxia contributed to the 
renal injury.  Similarly, TonEBP abundance was not different between the two 
cohorts, suggesting that an impaired response to medullary hypertonicity was not 
causative in the renal injury.  Notably, these studies are limited by the evaluation of 
mRNA abundance at only two time points: one prior to, and one after, the 
development of extensive renal injury.  The evaluation of mRNA abundance at 
intermittent time points would provide a more thorough understanding of the 
mechanisms involved in initiation the medullary atrophy. 
 
Extensive renal injury has been documented in several polyuric mouse models, 
suggesting that increased urine flow may contribute to the medullary damage. 
Support for this hypothesis came from the evaluation of inducible AQP2-/- mice.  
Within six weeks of AQP2 gene excision, extensive medullary atrophy was 
observed.  At this time urine flow was ~25ml/24hrs, ~2 fold greater than that 
observed in the 11βHSD2-/- mice at >180 days (Yang et al., 2006).  These data 
support the notion that increased urine flow is involved in the development of 
medullary atrophy, perhaps with the extent of the polyuria determining the time 
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course of damage.  This may explain the absence of injury in the <100 day 
11βHSD2-/- mice, in which the polyuria was less severe.  The more detailed analysis 
of the temporal correlation between renal structure and urine flow rate in the 
11βHSD2-/- mice would provide an insight into whether there is threshold for 
polyuria induced renal injury.   
 
The reason that the murine kidney is particularly susceptible to flow induced injury 
has not been determined, however an interesting hypothesis has been proposed by 
Schnermann’s laboratory (Oppermann et al., 2007).  Following furosemide 
administration it was demonstrated that renal blood flow was reduced (assessed 
using doppler probes).  Since furosemide induced the vasodilation of isolated 
perfused arterioles it was postulated that the reductions in blood flow were secondary 
to diuresis.  It was proposed that increased urine flow resulted in increased 
intratubular pressure, tubular dilation, compression of peritubule capillaries and 
consequently reductions in local blood flow.  The demonstration that furosemide 
induced reductions in blood flow were attenuated by renal decapsulation supported 
the hypothesis.  Since the amount of nephrons per kidney weight is substantially 
higher in mice than humans, this theory could explain why medullary injury is less 
commonly observed clinically in nephrogenic D.I.  The use of doppler probes to 
measure total and medullary perfusion in the 11βHSD2-/- mice would provide 










Chapter 4:  Separation of the role of 11βHSD2 in the kidney and brain 
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4.1.  Introduction 
The studies detailed in this chapter were designed to evaluate and separate the role of 
11βHSD2 in the kidney and brain in the regulation of salt and water homeostasis.   
To specifically assess the contribution of the enzyme in these organs to the 
phenotype observed in the global 11βHSD2-/- mice, two strains of transgenic mice 
already established in the Centre for Cardiovascular Science were utilized.  Firstly, to 
assess the role of renal 11βHSD2, global null mice in which hsd11b2 had been 
selectively reintroduced into the kidney were evaluated (referred to as ‘KRDKO 
mice’).  Secondly, selective targeting of hsd11b2 in the brain was achieved by cre-
lox recombination (referred to as ‘brain 11βHSD2-/- mice’). 
 
4.1.1.  11βHSD2-/-/ApoE-/- kidney rescue mice 
The studies detailed were conducted to evaluate the role of 11βHSD2 in the kidney.  
Ideally, the experiments would have been performed in mice in which hsd11b2 had 
been selectively targeted in the ASDN: using AQP2 driven cre-recombinase to 
selectively delete floxed hsd11b2 in this region of the nephron.  However, given the 
availability of the KRDKO mice, the opportunity to gain an insight into the role of 
renal 11βHSD2 was capitalised. Within the Centre for Cardiovascular Science an 
11βHSD2-/-/ApoE-/- double-knockout mouse (DKO) has been generated (Deuchar et 
al., 2011).  This model was created primarily to evaluate the contribution of 
11βHSD2 to lesion development in atherosclerosis.   
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Deletion of 11βHSD2 with apolipoprotein-E (ApoE) resulted in exacerbated 
atherosclerosis, with accelerated lesion formation that was not dependent on the 
administration of a high fat diet.  In an attempt to separate the effects of 11βHSD2 
deletion from the resultant hypertension, amiloride and eplerenone were 
administered to the mice.  Since amiloride blocks ENaC it was used to target the 
hypertension, whereas the MR antagonist eplerenone was used to evaluate the 
consequences of receptor over-activation.  Amiloride but not eplerenone caused a 
significant reduction in blood pressure; however eplerenone was more effective at 
reducing lesion formation.  These data therefore suggested that the effects of 
11βHSD2 deletion on atherosclerosis were independent of hypertension in the double 
knockout mice (Deuchar et al., 2011).  To substantiate further this conclusion, 
double knockout mice in which 11βHSD2 had been selectively introduced back into 
the kidney were generated.  In view of the postulated renal origin to the altered salt 
and water homeostasis in the global 11βHSD2-/- mice, the KRDKO mice made 
available to study the role of 11βHSD2 in renal function.  The model was used to 
assess the role of renal 11βHSD2, in the absence of 11βHSD2 in the brain.  
 
Homologous recombination was used to “knock-in” 11βHSD2 in the kidney.  In this 
model the hsd11b2 transgene was placed under the control of the AQP2 promoter.  
Consequently 11βHSD2 was selectively expressed in cells that express AQP2.  
Within the kidney AQP2 is localised to the collecting duct (Fushimi et al., 1993).  
Since the DCT is devoid of AQP2, 11βHSD2 expression was not reinstated in this 
region of the nephron.  As previously stated, in the mouse nephron 11βHSD2 may 
also be expressed in the DCT (Campean et al., 2001).  Extra renal expression of 
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AQP2 has also been characterised in humans (Mobasheri et al., 2005) and mice 
(Yang et al., 2006).  In mice AQP2 transcript and protein expression have been 
demonstrated in the testis, vas deferens and inner ear (Yang et al., 2006).  This is in 
contrast to humans in which expression has also been described in discrete regions of 
the central nervous system (Mobasheri et al., 2005).  Therefore, in the KRDKO mice 
any alterations in water and sodium homeostasis are likely the result of renal, rather 
than extra-renal, 11βHSD2.      
 
ApoE-/- mice are not hypertensive (Hartley et al., 2000, Nogueira et al., 2007) and 
have a normal water intake at <12 months (Raber et al., 2000).  Therefore it was 
postulated that the targeting of ApoE would not contribute in a major way to any 
renal phenotype in the double knockout mice.  Nevertheless, to control for the loss of 
ApoE, ApoE-/- mice were evaluated along with DKO and KRDKO mice in the 
studies detailed. 
 
4.1.2.  Nestin.Cre.HSD2Flx mice 
To assess specifically the contribution to the phenotype observed in the global 
11βHSD2-/-, of 11βHSD2 in the brain, cre-lox recombination was used.  Selective 
targeting of hsd11b2 in the brain was achieved by a conventional breeding strategy 
in which nestin.cre mice (mice in which the enzyme cre-recombinase is under the 
control of the nestin promoter) were crossed with hsd11b2.floxed mice (mice in 
which loxP sites were inserted in the intronic regions prior to exon 2 and after exon 5 
of the hsd11b2 gene).   
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Cre-recombinase, a 38kDa enzyme isolated from bacteriophage p1, catalyzes the 
recombination of DNA between two identical 34 base-pair loxP sites (referred to as 
‘floxed’ regions).  Although such loxP sites frequently occur in the bacteriphage 
genome, their endogenous expression is statistically unlikely in the mouse, therefore 
favouring specific recombination of the targeted floxed gene.  When inserted in the 
same orientation, cre-recombinase excises the sequence of DNA flanked by the loxP 
sites (Figure 4.1).   
 
Figure 4.1:  The use of Cre-Lox technology to create tissue specific knockout 
mice.  LoxP sites flank a region of the target gene.  This region will be excised in 
cells that express the enzyme cre-recombinase.  In cells without cre-recombinase 
the target gene remains functional.  Here, β-galactosidase is included as an 
internal control.  Cells in which the target gene has been deleted will stain positive 
for X-gal.  In contrast an absence of X-gal staining represents the absence of gene 
targeting. 
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Since cre-recombinase is not endogenously expressed in mammals, spatial regulation 
of its activity and therefore gene deletion can be achieved through the use of tissue-
specific promoters (Kos, 2004).  In the studies detailed, cre-recombinase expression 
was driven by the nestin promoter.  Nestin, originally identified in neuroepithelial 
stem cells, is a class 6 intermediate filament protein (Lendahl et al., 1990).  Within 
the central nervous system nestin is expressed in both glial cells and neurons (Shi et 
al., 2008).  In mice nestin is highly expressed in the central nervous system 
throughout embryogenesis.  Expression is evident from the seventh day of gestation, 
mainly in proliferative zones and becoming more wide spread throughout 
embryogenesis.  Postnatal nestin expression decreases in correlation with decreased 
neuronal proliferation (Dahlstrand et al., 1995).  The relevance of this for the current 
study is that nestin-cre driven recombination, occurs throughout neuronal 
development, and will delete 11βHSD2 expression wherever nestin is expressed.  In 
embryogenesis, this will target 11βHSD2 in the cerebellum, thalamus and 
hypothalamus (Brown et al., 1996, Holmes et al., 2006b).  However, in adult mice 
the expression of 11βHSD2 in the brain is exquisitely localised to the NTS (Holmes 
et al., 2006b).  This is in contrast to rats in which a more widespread localization has 
been described (Geerling et al., 2006b, Roland et al., 1995, Robson et al., 1998).  
Consequently the selective targeting of 11βHSD2 in the mouse brain provides the 
unique opportunity to evaluate, in the adult, the role of the enzyme in the NTS.  
Since the NTS has been implicated in salt appetite (Geerling et al., 2006a), this was 
evaluated along with sodium and water homeostasis in the model.  
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 Hypothesis  
1. Rescue of renal 11βHSD2 function in KRDKO mice will normalize water 
turnover and blood pressure 
2. Mice in which 11βHSD2 has been selectively targeted in the brain, 
specifically the NTS, will have normal renal function 





4.2.  Methods 
4.2.1.  Animals 
All experiments were performed on male mice aged ~180 days since this was the age 
at which the phenotype was most severe in the global 11βHSD2-/- mice. 
 
4.2.1.1.  KRDKO mice 
DKO mice were generated as described previously (Deuchar et al., 2011).  Targeting 
of 11βHSD2 in the kidney was performed using homologous recombination, with 
expression of human 11βHSD2 placed under the control of the AQP2 promoter.  The 
crossing of these mice, with DKO mice resulted in the generation of the KRDKO 
mice (Armour, 2010).  Renal enzyme activity assays were performed to assess how 
effective the 11βHSD2 transgene induction was in the kidneys of KRDKO (Danielle 
Armour, personal communication).  It was demonstrated that 11βHSD2 activity was 
partially restored in the KRDKO mice.  Renal enzyme activity in the KRDKO mice 
was ~30% that of the ApoE-/- mice.  In the experiments detailed n=3-9 throughout. 
 
4.2.1.2.  Brain 11βHSD2-/- mice 
Mice in which the hsd11b2 gene has been flanked with loxP sites (referred to as 
‘floxed 11βHSD2’) were used as controls.  Floxed mice were generated by Taconic, 
UK.  Nestin.Cre mice were obtained from the Jackson Laboratory, USA (Tronche et 
al., 1999).  In the experiments detailed n=3-9 throughout. 
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4.2.2.  Evaluation of blood pressure in conscious KRDKO mice 
Tail cuff plethysmography was used to measure systolic blood pressure in conscious 
restrained mice.  Initially, the mice underwent a training regime to allow 
acclimatization to the restraint tube and the warming chamber.  Training was 
performed over five consecutive days prior to the experimental recordings.  
Vasodilation of the tail vein was induced by warming the mice to 37˚C in the 
warming chamber.  Mice were then restrained in a Perspex tube and tail cuff 
plethysmography performed.  On each training day eight consecutive blood pressure 
measurements were taken per mouse, being completed over a ten-minute period.  
Throughout the experimental protocol blood pressure recordings were made over 
five consecutive days.  Eight measurements were made per mouse per day, again 
over ten minutes; these values were then averaged to give one reading per mouse per 
day.  Since there was no difference between the pressures obtained on the inflate or 
deflate cycle the blood pressures presented represent combined recordings.  For 
analysis daily measurements were combined to give a five-day average per mouse.  
Experiments were performed in a blinded fashion to prevent experimental bias.   
 
4.2.3.  Evaluation of renal function 
Mice were anesthetized using thiobutabarbital sodium salt hydrate (100mg/kg i.p. 
Inactin hydrate, Sigma-Aldrich, UK) and prepared surgically for renal clearance.  A 
tracheotomy was performed using polyethylene tubing (P90, Smiths-Medical, UK).  
A saline-filled polyethene cannula (P10 polyethene tubing, Smiths-Medical, UK) 
was inserted into the right jugular vein for the infusion of a saline solution.  The 
carotid artery was cannulated with heparinised-saline filled polyethene tubing (P10 
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polyethylene tubing, Smiths-Medical, UK), which was connected to a pressure 
transducer (disposable blood pressure-transducer, AD Instruments, UK).  Mean 
arterial blood pressure was measured throughout the experiment (PowerLab, AD 
Instruments, UK).  Finally, a supra-pubic incision was made and the bladder 
cannulated (P10 into P50 polyethylene tubing, Smiths-Medical, UK) for urine 
collection.  Following surgery animals were infused i.v. (0.2ml/hr per 10g AL2000 
model, World Precision Instruments, USA) with a solution containing 120mM NaCl, 
15mM NaHCO3 5mM KCl, 0.5% FITC-Inulin (Fluorescence Isothiocyanate, Sigma-
Aldrich, UK).  Following a 60-minute equilibrium period, a 20µl arterial blood 
sample was taken for haematocrit analysis.  Following a further 40-minute period, a 
second blood sample was taken for haematocrit analysis.  The haematocrit values 
presented represent the average of both measurements.  Terminal blood was 
collected at the end of the experiment for the measurement of plasma sodium and 
potassium concentration (AVI 9180 Electrolyte Analyzer, Roche, UK).  Values 
outside the range of the analyzer were assigned maximum or minimum range values 
as appropriate.  In the experiments detailed in KRDKO mice, following the second 
haematocrit sample amiloride (2mg/kg i.v. Sigma-Aldrich, U.K) was administered.  
After a 10 minute acclimatization period a second 40 minute urine collection was 
made, after which terminal blood was collected.  
 
4.2.4.  Evaluation of water and sodium turnover in brain 11βHSD2-/- mice 
Metabolic cage studies were performed to evaluate basal sodium and water handling 
as detailed in 2.2.2.1.  In brief, following four days acclimatization, baseline 
measurements were made over four days.  Subsequently water was removed from the 
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mice for 24-hours to assess urine concentrating ability.  Throughout the study water 
and food intake and urine output were measured.  Mouse body weight was monitored 
daily. 
 
4.2.5.  Evaluation of salt appetite in brain 11βHSD2-/- mice 
Metabolic cage studies were performed to evaluate salt appetite.  In these 
investigations mice had ad libitum access to two drinking bottles, one of which 
contained water, the other 1.5% NaCl.  Bottle position was rotated every 24 hours to 
ensure that side preference did not influence the results.  Following four days 
acclimatization, baseline measurements were made over seven days.  During this 
period water, NaCl and food intake, urine output and body weight were measured 
daily. 
 
4.2.6.  Evaluation of the role of MR in salt appetite in brain 11βHSD2-/- mice 
The role of mineralocorticoid receptor activation in salt appetite was evaluated in a 
separate cohort of mice using the antagonist spironolactone.  Spironolactone was 
distributed (0.5g, Sigma-Aldrich., UK) in an elastomer matrix (2g, Silastic MDX4-
4210 medical grade elastomer, Dow Corning, UK).  The pellets were cured overnight 
at 37˚C.  After confirming salt preference, as detailed above, spironolactone pellets 
were implanted subcutaneously under isoflurane anaesthetic.  A small incision was 
made in the neck and the pellet inserted.  The wound was closed using auto-wound 
clips (Clay Adams, USA).  Our previous work shows that the pellets release 
 159 
spironolactone over a two week period and achieve a plasma concentration that 
would completely block MR (Bailey et al., 2009). 
 
4.2.7.  Enzyme Activity Assay 
These assays were independently performed by Dr Caitlin Wyrwoll and Dr Danielle 
Armour.  In brief, tissues were homogenised in Krebs Buffer and centrifuged at 4°C 
for 5 minutes at 2000 rpm.  The supernatant was collected and protein concentration 
determined using a Bradford-base protein assay (Bio-Rad Protein Assay, Bio-Rad 
Laboratories, USA).  0.1 mg/ml homogenate was used per assay.  Assay reactions 
contained 100µM co-factor (NAD+, Sigma-Aldrich, UK), 100nM substrate (1,2,6,7-
3H-corticosterone, GE Heathcare Life Sciences, Anachem, UK) and 18µg tissue 
homogenate.  Following 3 minutes incubation the reactions were terminated by the 
addition of HPLC grade ethyl acetate.  Once settled, the aqueous phase of the 
reaction mix was isolated, dried down under oxygen-free nitrogen and resuspended 
in absolute ethanol.  Thin layer chromatography assays were performed to determine 
the conversion of 3H-corticosterone to dehydrocorticosterone, illustrative of 
11βHSD2 activity.  For the foetal assays, to increase the levels of enzyme activity, 
assays were performed on pooled samples from a litter, with 5-7 litters evaluated per 
group per tissue. 
 
4.2.8.  Analysis 
Analysis was performed as detailed (section 2.2.3).  In the salt appetite studies 
sodium preference was calculated by expressing the amount of 1.5% NaCl consumed 
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during a 24-hour period as a percentage of the total volume of fluid consumed.  
Sodium balance was evaluated by calculating the difference between combined 
sodium intake and urinary sodium excretion as detailed (section 2.2.3).  Urinary 
protein, electrolyte and osmolar excretion were assessed as detailed (section 2.2.3).   
FITC-Inulin clearance was used to calculate glomerular filtration rate (GFR) as 
detailed (Lorenz, 2002).  All dilutions were made using HEPES buffer at pH7.4, 
since the fluorescence is pH sensitive.  Urine samples were diluted 1:100, plasma 
samples were diluted 1:1000.  A seven point standard curve was generated for 
analysis.  All samples were assessed in duplicate.  Once loaded into a black 96 well 
plate (Microfluor Solid Microplate, Thermo Scientific, UK) fluorescence was 
measured using a Wallac Multilabel HTC counter (model 1420, Perkin Elmer, USA) 
with excitation at 485nm and emission at 538nm.  GFR was calculated using the 
standard equation below, in which UV represents urine flow and UInu and PInu inulin 
concentrations in urine and plasma respectively.   
 
GFR = UInuUV/PInu 
 
4.2.9.  Statistics 
Data are presented as mean ± S.E.M. except for cumulative data, which are medians ± 
range.  Statistical analysis was performed using an un-paired t-test, one-way 
ANOVA or Mann-Whitney test with Tukey post-test to compare between groups as 
appropriate.   
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4.3.  Results 
4.3.1.  Blood pressure and renal sodium handling in KRDKO mice 
To assess the role of 11βHSD2 in the kidney in the regulation of blood pressure, tail 
cuff plesmography was performed on ApoE-/-, DKO and KRDKO mice over a five-
day period.  Global deletion of 11βHSD2 in the ApoE-/- mice resulted in 
hypertension.  Systolic blood pressure was significantly higher in the DKO mice than 
the control ApoE-/- mice.  Blood pressure was partially rescued by 11βHSD2 
transgene induction in the kidney.  Blood pressure was significantly lower in the 
KRDKO mice than the DKO mice, but remained significantly higher than that of the 
ApoE-/- mice (Figure 4.2.A).  ApoE-/- mice were normotensive: blood pressure was 
not significantly different that in C57Bl/6 mice (ApoE-/- 101±1.5 vs C57Bl/6 
102±2.4 mmHg, P>0.05, unpaired t-test). 
 
 
Figure 4.2:  Systolic blood pressure in ApoE-/- mice (hashed), DKO mice 
(horizontal stripes) and KRDKO mice (vertical stripes).  Data are means ±S.E.M.  
Statistical analysis was performed using a one-way ANOVA and Tukey post-test.  
***P<0.001 compared to ApoE-/- mice, ###P<0.001 compared to DKO mice. 
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Renal sodium handling was evaluaed to assess its role in the hypertension observed 
in the DKO and KRDKO mice.  Fractional sodium excretion was substantially 
higher in the DKO and KRDKO mice than the ApoE-/- controls (Figure 4.3.A).  
Since amiloride’s natriuretic capacity was lost in the DKO and KRDKO mice 
(Figure 4.3.B), the increased sodium excretion may be partially attributable to 
impaired ENaC function.  Haematocrit values recorded in the DKO and KRDKO 
mice were significantly higher than those of the ApoE-/- mice, suggestive of volume 
contraction (Figure 4.3.C).  Hypokalemia, a cardinal feature of AME, was observed 
in both the DKO and KRDKO mice (Figure 4.3.D).  Since fractional potassium 
excretion was substantially higher in the DKO and KRDKO mice than the ApoE-/- 
mice, this may have contributed to the hypokalemia.  Urine osmolality was 
significantly lower in the DKO and KRDKO mice than the ApoE-/- mice indicative 
of a urine-concentrating defect, however urine flow rate was not significantly 
different between the three groups.  GFR values were not significantly different 
between the ApoE-/-, DKO and KRDKO mice (Table 4.1). 
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Figure 4.3:  Renal function and plasma status in ApoE-/- mice (hashed), 
DKO mice (horizontal stripes) and KRDKO mice (vertical stripes).  (A) 
Fractional excretion of sodium.  (B) The effect of amiloride on sodium 
excretion.  (C) Haematocrit.  (D) Plasma potassium concentrations.  Data 
are means ±S.E.M.  Statistical analysis was performed using a one-way 
Anova and Tukey post-test.  ***P<0.001, **P<0.01, *P<0.5 compared to 
ApoE-/- mice.  
 164 
 
 ApoE-/- DKO KRDKO 
GFR (µl/min) 314±25 229±27 307±57 
FEK (%) 24±9 45±9 40±6 
UV (µl/min) 3.1±0.3 4.6±0.8 5.4±1.0 
UOsm (mOsm) 991±94 652±25*** 661±10*** 
 
 
Table 4.1:  Basal renal function in ApoE-/-, DKO and KRDKO mice.  
GFR, glomerular filtration rate.  FEK, fractional excretion of potassium.  
UV, urine flow.  UOsm, urine osmolality.  Data are means ±S.E.M.  
Statistical analysis was performed using a one-way Anova and Tukey post-
test.  ***P<0.001 compared to ApoE-/- mice.  
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4.3.2.  Water and sodium homeostasis in brain 11βHSD2-/- mice 
Professor Megan Holmes and Dr Caitlin Wyrwoll performed the validation of the 
brain specific deletion of 11βHSD2 in the NestinCre.HSD2flx mice (personal 
communication).  In this model the sequence encoding β-galactosidase was inserted 
in the construct after the region of the target gene that was flanked by loxP sites.  
Consequently, β-galactosidase was expressed in tissues in which 11βHSD2 had been 
deleted.  As shown in Figure 4.4. X-gal staining occurred in the brain but not the 
kidney, confirming tissue specific targeting.  Further confirmation was provided by 
tissue specific enzyme activity assays.  The discrete location of 11βHSD2 in the NTS 
of adult mice meant that enzyme activity was too low to accurately measure in adult 
brains.  Since expression of 11βHSD2 in the brain is wide spread throughout 
embryogenesis, activity was in measured in foetal brain extracts at day E13.  Enzyme 
activity was significantly reduced (~75%) in the brain 11βHSD2-/- mice compared to 
the floxed controls (Figure 4.5.A).  In contrast there was no significant difference in 
placental or whole body enzyme activity (Figure 4.5.A).  These data substantiated 
the conclusion that 11βHSD2 deletion was specifically targeted to the brain.  
Notably, the activity of 11βHSD2 in the kidneys of adult mice was not significantly 
different in the brain 11βHSD2-/- mice and the floxed controls (Figure 4.5.B).  
Together, these data suggested that the nestin.cre was not leaky, and 11βHSD2 




Figure 4.4:  Confirmatory X-gal staining in brain 11βHSD2-/-.  Example 
staining showed from (A) The Brain and (B) The Kidney.  Images courtesy of 




Figure 4.5:  11βHSD2 enzyme activity in Floxed 11βHSD2 control mice 
(white) Brain 11βHSD2-/- mice (black) and C57Bl/6 controls (horizontal 
stripes).  (A) Enzyme activity in E13 foetus’.  (B) Enzyme activity in adult 
kidneys (n=5).  Data are means ± S.E.M.  Statistical analysis was performed 
using an unpaired t-test and one-way ANOVA as appropriate.  Data courtesy 
of Holmes and Wyrwoll (personal communication).  
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To evaluate the role of 11βHSD2 in the NTS in water homeostasis, urine flow and 
water intake were measured over a four-day baseline period in floxed control and 
brain 11βHSD2-/- mice.  In contrast to the global 11βHSD2-/-, deletion of 11βHSD2 
in the NTS did not alter basal water turnover.  Urine flow (Figure 4.6.B) and water 
intake (Figure 4.6.A) were not significantly different between the brain 11βHSD2-/- 
and the floxed 11βHSD2 control mice.  Similarly, urine osmolality, an indicator of 
urine concentrating ability, was not significantly different between the two groups 
(Figure 4.6.C).  Consequently, cumulative water balance over the four-day period 






Figure 4.6:  (A) Water Intake in floxed 11βHSD2 mice (white) and aged-
matche brain 11βHSD2-/- mice (black).  (B) Urine Flow.  (C) Urine 
Osmolality.  (D) Cumulative Water Balance calculated over the four-day 
baseline period.  Data are means ±S.E.M. Statistical analysis was performed 
using an unpaired t-test or Mann-Whitney test as appropriate.  
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Since basal water turnover was not altered by the deletion of 11βHSD2 in the brain, 
it was postulated that the response to water deprivation would also be functional in 
the brain 11βHSD2-/- mice.  Following water deprivation, urine flow reduced in both 
groups of mice, however the brain 11βHSD2-/- mice produced significantly lower 
volumes of urine than the floxed control mice during this period (Figure 4.7.A).  
These data were reflected in the water balance data, which was significantly more 
negative in the floxed 11βHSD2 mice than the brain 11βHSD2-/- mice (Figure 4.7.D).  
In response to water removal, urine osmolality increased to a similar extent in both 
groups of mice.  Consequently, there was no significant difference between the 
osmolality values recorded in the floxed controls and the brain 11βHSD2-/- mice 
(Figure 4.7.B).  Weight loss, used as an indicator of body fluid loss, was 
approximately equal in the floxed 11βHSD2 and brain 11βHSD2-/- mice.  Both 
groups lost approximately 1.5g of weight following water removal (Figure 4.7.C).  
These data suggested that both groups of mice had a functional concentration 









Figure 4.7:  Response to water deprivation in floxed 11βHSD2 mice 
(white) and aged matched brain 11βHSD2-/- (black.  (A) Urine Flow.  
(B) Urine Osmolality.  (C) Weight Loss.  (D) Water Balance calculated 
during the 24-hour water deprivation challenge.  Data are means 
±S.E.M. Statistical analysis was performed using an unpaired t-test.  
*P<0.05 compared to age matched controls. 
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Basal sodium turnover was evaluated in the control and brain 11βHSD2-/- mice.  
Urinary sodium excretion was not significantly different between the two groups of 
mice (Figure 4.8.A); both brain 11βHSD2-/- and floxed 11βHSD2 mice excreted 
approximately 0.3 mmol/24hrs.  Similarly, sodium intake, was not different between 
the two groups (Figure 4.8.B).  Cumulative sodium balance was therefore equivalent 
in the brain 11βHSD2-/- and floxed 11βHSD2 mice (Figure 4.8.C).  Plasma sodium 





Figure 4.8:  Sodium homeostasis in floxed 11βHSD2 mice (white) and 
aged matched brain 11βHSD2-/- mice (black).  (A) Urinary Sodium 
Excretion.  (B) Sodium Intake.  (C) Cumulative Sodium Balance 
calculated over the four-day baseline period.  (D) Plasma Sodium.  Data 
are means ±S.E.M.  Statistical analysis was performed using an unpaired t-
test (A,B,D) or Mann-Whitney test (C) as appropriate.   
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Table (4.2) Renal function was not affected by the deletion of 11βHSD2 in the brain. 







Phosphate Excretion  
(µmol/24hr) 
24.3±7.7 24.3±5.4 
Calcium Excretion  
(µmol/24hr) 
4.1±0.7 5.5±0.8 






Urea Excretion  
(mg/24hr) 
71.6±4.3 72.3±10.3 






Table 4.2: Data are means ±S.E.M.  Statistical analysis was performed using an 
unpaired t-test.  Urine collections were made over a 4-day baseline period.  
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Mean arterial blood pressure was not altered by the deletion of 11βHSD2 in the 
brain.  In contrast to the global deletion of 11βHSD2, specific targeting of 11βHSD2 
in the brain did not result in volume contraction; haematocrit values were not 
significantly different between brain 11βHSD2-/- and floxed control mice (Table 4.3) 
 
 Floxed 11βHSD2 Brain 11βHSD2-/- 








Table 4.3: Data are means ±S.E.M.  Statistical analysis was performed using an 
unpaired t-test.   
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11βHSD2-positive neurons in the NTS have been implicated in the behavioural drive 
to consume sodium, being activated in response to sodium deficiency (Geerling et 
al., 2006a).  Sodium appetite therefore was evaluated in the brain 11βHSD2-/- mice.  
When given the option of drinking water or 1.5% NaCl, the brain 11βHSD2-/- drank 
significantly more NaCl than the floxed control mice (Figure 4.9.A).  The increased 
consumption was specific for sodium since thirst was not altered by the deletion of 
11βHSD2 in the brain.  Brain 11βHSD2-/- mice did not drink significantly more 




Figure 4.9.A:  Salt appetite in floxed 11βHSD2 mice (white) and aged-
matched brain 11βHSD2-/- mice (black).  (A) Water and 1.5% NaCl intake.  
Data are means ±S.E.M.  Statistical analysis was performed using a one-way 
ANOVA and Tukey post-test.  ***P<0.001 compared to age matched 
controls.  ##P<0.01 compared to water intake in the same mice.   
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During the sodium preference experiment urine flow was approximately four times 
greater in the brain 11βHSD2-/- mice than the floxed control mice (Figure 4.10.A).  
Cumulative water balance over the seven-day period however was not significantly 
different between the two groups of mice (Figure 4.10.B).  Urinary sodium excretion 
was significantly higher in the brain 11βHSD2-/- mice than the floxed control mice 
(Figure 4.10.C), which suggested that the mice were not retaining sodium.  Indeed, 
although sodium balance was positive in both groups of mice, it was significantly 
less positive in the brain 11βHSD2-/- than the floxed control mice despite the 
increased salt intake (Figure 4.10.D). 
 
Figure 4.10:  Water and sodium turnover during salt preference studies in 
floxed 11βHSD2 mice (white) and aged-matched brain 11βHSD2-/- mice 
(black).  (A) Urine Flow.  (B) Cumulative Water Balance.  (C) Sodium 
Excretion.  (D) Cumulative Sodium Balance.  Data are means ±S.E.M.  
Statistical analysis was performed using an unpaired t-test (A, C) or Mann-
Whitney test (B,D) as appropriate.  ***P<0.001, **P<0.01 compared to 
age matched controls.  
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Spironolactone was used to evaluate the role of mineralocorticoid receptor activation 
in salt appetite in separate groups of mice.  The innate salt appetite in brain 
11βHSD2-/- mice was confirmed.  During the basal period, 1.5% NaCl intake was 
higher in the brain 11βHSD2-/- mice than the floxed control mice.  As previously 
demonstrated, NaCl consumption accounted for the majority of fluid intake in the 
brain 11βHSD2-/- mice.  In contrast salt aversion was evident in the floxed 11βHSD2 
control mice (Figure 4.11.A). 
 
Spironolactone administration had no effect on water intake in either the floxed 
control, or brain 11βHSD2-/-, mice.  NaCl consumption was not altered by MR 
blockade in the floxed control mice.  However, spironolactone substantially reduced 
NaCl intake in the brain 11βHSD2-/- mice; NaCl consumption was approximately 
40% lower following spironolactone (Figure 4.11.B).  As shown in Figure 4.12.A the 
effects of spironolactone on 1.5% NaCl intake in the brain 11βHSD-/- mice were 
rapid and sustained.  Although sprionolactone was administered subcutaneously, it 
was unlikely that the reduction in NaCl intake was secondary to altered renal sodium 
handling.  Blockade of MR increases natriuresis, which would be postulated to 
increase salt intake.  Indeed following spironolactone administration cumulative 
sodium balance was not significantly different in the brain 11βHSD2-/- mice and the 
floxed controls (floxed 11βHSD2 8.3±0.8 vs brain 11βHSD2-/- 10.3±0.8 mmol, 
P>0.05, Mann-Whitney test).  These data support the hypothesis that the reduced 
NaCl intake in the brain 11βHSD2-/- mice following spironolactone was not 







Figure 4.11:  1.5% NaCl Consumption Preference (A) and Fluid Intake (B) 
in floxed 11βHSD2 mice (white) and brain 11βHSD2-/- mice (black).  
Hashed bars are the consumption values following spironolactone.  Data are 
means ± S.E.M.  Statistical analysis was performed using an unpaired t-test 




Figure 4.12:  1.5% NaCl consumption in brain 11βHSD2-/- (filled 
triangles) and floxed 11βHSD2 control mice (open squares).  (Pre) 
values were recorded over 8 days prior to spironolactone and 
(Post) values over 14 days following spironolactone.  The vertical 
dotted line represents spironolactone mini pellet implantation.  
Data are presented as means ± S.E.M.  Statistical comparisons were 
made using a one-way ANOVA.  ***P<0.001 compared to floxed 
mice.  ###P<0.001 compared to pre-spironolactone. 
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4.4.  Discussion 
Global 11βHSD2-/- mice have impaired renal function, with a severe and progressive 
polyuria which, at older ages, resulted in an attenuated response to water deprivation.  
Moreover, progressive hypertension and hypokalemia have been described, in line 
with the clinical characteristics of AME (Kotelevtsev et al., 1999, Bailey et al., 
2008).  At >180 days the deranged renal function was associated with acute 
structural damage at both a gross and tubular level.  It was postulated that the 
phenotype was renal in origin and that the polydipsia was a secondary response to 
increased urine flow.  To resolve this genetically, selective targeting of 11βHSD2 in 
the kidney and brain was harnessed to permit tissue specific evaluation of 11βHSD2.  
Moreover, the restricted expression of 11βHSD2 to the NTS in the brains of adult 
mice (Holmes et al., 2006b) provided the unique opportunity to evaluate the role of 
the enzyme in salt appetite.   
 
Given the distribution of 11βHSD2 in the brain and kidney, organs pivotal in the 
modulation of salt and water homeostasis, tissue specific targeting circumvents the 
complexity of dissecting the etiology of the phenotype observed in the global 
11βHSD2-/- mice.  Within the time frame of this thesis, only KRDKO and brain 
11βHSD2-/- mice were available for physiological evaluation.  The evaluation of 
renal specific 11βHSD2-/- mice would provide further validation of the conclusions 
drawn.   
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4.4.1.  Evaluation of KRDKO mice 
Clinically, full or partial loss of 11βHSD2 activity causes AME, a condition in which 
hypertension is thought to be driven by volume expansion, occurring secondarily to 
renal sodium retention (Ferrari and Krozowski, 2000).  Moreover, AME has been 
characterised as a continuum disorder (Li et al., 1998), with the degree of enzyme 
impairment directly correlating with the severity of the phenotype.  Clinically, blood 
pressure can be normalised by kidney transplantation (Palermo et al., 2000).  The 
observation that blood pressure was reduced, but not normalised, by partial 
restoration of renal 11βHSD2 activity supports the hypothesis that blood pressure 
correlates with renal 11βHSD2 activity.   
 
In line with previous observations (Bailey et al., 2008) renal sodium excretion was 
increased, and the natriuretic response to amiloride lost, in the DKO mice aged ~180 
days.  At this age attenuated trafficking of ENaC to the apical membrane of the 
collecting duct was proposed to underpin the increased natriuresis (Bailey et al., 
2008).  Partial rescue of 11βHSD2 activity in the kidney did not restore renal sodium 
handling and hypokalemia was observed in both the DKO and KRDKO mice.  Since 
fraction excretion of potassium was substantially higher in the DKO and KRDKO 
mice than the ApoE-/- mice, renal potassium wasting likely contributed to the low 
plasma levels.  In accordance with the global 11βHSD2-/- mice, DKO and KRDKO 
mice were volume contracted; suggesting that at this age hypertension is dissociated 
from volume expansion.  In combination with the observed natriuresis, these data 
suggest that there may be extra-renal components to the hypertension at this time 
point.  In combination with published data from the heterozygous and global 
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11βHSD2-/- mice (Kotelevtsev et al., 1999, Bailey et al., 2008, Bailey et al., 2011), 
these data provide an insight into the threshold of AME as a continuum disorder. 
 
The phenotype observed in KRDKO mice, which have ~30% normal renal 11βHSD2 
function, is markedly different to the phenotype previously described in the 
heterozygous 11βHSD2 mice, which have ~50% renal 11βHSD2 function.  During 
basal conditions 11βHSD2 heterozygous mice were not hypertensive and had plasma 
potassium and haematocrit values within the normal physiological range (Bailey et 
al., 2011, Kotelevtsev et al., 1999).  These data suggest that whereas ~50% enzyme 
activity is sufficient to maintain renal function and blood pressure during basal 
conditions, ~30% is not.   
 
Although basal renal function is normal, the 11βHSD2 heterozygous mice have a salt 
sensitive phenotype.  Administration of a high salt diet resulted in hypertension, 
transient volume contraction and hypokalemia, in line with the phenotype observed 
in the global 11βHSD2-/- mice.  The phenotype induced by salt loading was not 
normalised by spironolactone (Bailey et al., 2011).  Similarly, the MR antagonist 
eplerenone had no significant effect on blood pressure in the DKO mice (Deuchar et 
al., 2011).  These data suggest the involvement of non-MR mediated mechanisms in 
the AME phenotype.  Notably, the GR receptor antagonist, RU38486, prevented the 
development hypertension and hypokalemia in the heterozygous mice (Bailey et al., 
2011), suggesting a role for GR overactivation in the AME phenotype. 
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The demonstration that the natriuretic capacity of amiloride was lost in the DKO and 
KRDKO mice at ~180 days suggests a decrease in functional ENaC at this age.  This 
may explain the observation that, although amiloride caused a significant reduction 
in blood pressure in the DKO mice, it was unable to reduce it to control levels 
(Deuchar et al., 2011).  Furthermore, that ENaC mediated sodium retention may not 
be entirely responsible for the hypertension at this age.  Indeed clinically, 
administration of amiloride does not normalise blood pressure unless given in 
combination with other drugs (Stewart et al., 1988, Knops et al., 2011).  Moreover 
the doses required are often high (Cooper and Stewart, 1998), and therefore may also 
block NHE3 in the proximal tubule (Yun et al., 1995, Orlowski, 1993) and thereby 
contribute to the depressor effects of amiloride.  In the DKO mice amiloride was 
administered chronically, and at a relatively high dose (Deuchar et al., 2011).  
Consequently, off target effects may explain the hypotensive response at an age 
when the acute natriuretic capacity of amiloride was lost.  
 
Although urine osmolality was significantly lower in the KRDKO and DKO mice 
than the ApoE-/- mice, urine flow was not different between the three groups when 
measured under anaesthesia.  The absence of polyuria in the DKO and KRDKO mice 
is in contrast to the observations made in conscious global 11βHSD2-/- mice, in 
which significantly elevated urine flow was documented.  This apparent disparity 
may be attributable to the effects of anaesthesia on renal function (Dudley et al., 
1954, Maddox et al., 1977).  In humans anaesthesia and surgery are associated with 
antidiuresis, moreover antidiuretic effects of inactin have been reported 
experimentally (Giri and Peoples, 1965).  That the absence of polyuria was the result 
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of anaesthesia is corroborated by preliminary metabolic cage data from the DKO, 
KRDKO and ApoE-/- mice.  These data demonstrated that the DKO mice were 
polyuric and polydipsic.  Deranged water handling prevailed in KRDKO mice, 
although the absolute water turnover was reduced compared to the DKO mice (Table 
4.4. Data courtesy of Dr Yuri Kotelevtsev).  This suggests that partial restoration of 
renal 11βHSD2 activity is able to reduce, but not normalise, the increased water 
turnover in the DKO mice.  
 
 
 ApoE-/- DKO KRDKO 
Urine Flow 
(ml/24hr) 
2.6±0.2 16.5±2.1*** 12.7±1.5*** 
Water Intake 
(ml/24hr) 
4.6±0.4 20.8±2.0*** 16.6±1.6*** 
 
 
Table 4.4:.  Basal water handling in ApoE-/-, DKO and KRDKO mice. Data 




A confounding factor when evaluating the DKO, and potentially KRDKO mice, is 
the extensive atherosclerosis observed at this age.  Although renal artery stenosis has 
not been characterised in the model, the possibility that lesions within the renal artery 
impede blood flow and induce renal failure should be considered.  Although, the 
close correlation with the phenotype observed in the global 11βHSD2-/- mice 
supports a pivotal role for renal enzyme function in blood pressure regulation and 
water homeostasis. 
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4.4.2.  Evaluation of brain 11βHSD2-/- mice 
4.4.2.1.  Renal function was not impaired by the deletion of 11βHSD2 in the 
brain 
Mean arterial blood pressure was not significantly different between brain  
11βHSD2-/- mice and the floxed controls.  Although in combination with the results 
from KRDKO mice these data support the hypothesis that hypertension is driven by 
the kidney, this conclusion must be treated with caution.  It may be that loss of 
11βHSD2 function in the NTS has a more predominant role when blood pressure is 
perturbed, or in situations of stress and/or physiological challenges.  In agreement 
with this hypothesis, glucocorticoid administration to the dorsal hindbrain (the region 
containing the NTS) of Sprague-Dawley rats resulted in an augmented blood 
pressure response to a novel restraint stress test.  The same effect was not observed 
following systemic glucocorticoid administration (Scheuer et al., 2007).  
Additionally, in borderline hypertensive rats, (which have an increased endogenous 
stress response), blockade of GR in the dorsal hindbrain reduced the hypertensive 
response to restraint.  GR blockade had no effect on the blood pressure response on 
control rats (Bechtold et al., 2009).  Therefore, it is postulated that although basal 
blood pressure was not altered by deletion of 11βHSD2 in the NTS, the response to 
blood pressure challenges may be impaired in the brain 11βHSD2-/- mice.  
 
Baseline water and electrolyte handling were not altered by the selective deletion of 
11βHSD in the brain; renal function and haematocrit values were all similar to the 
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floxed control mice.  Similarly, the brain 11βHSD2-/- mice also had a functional 
response to water deprivation. 
 
Previous attempts to resolve the respective roles of MR and 11βHSD2 in the brain 
and kidney have evaluated the effects of s.c. and i.c.v. drug delivery.  Accordingly, 
whereas subcutaneous aldosterone induced polyuria in unilaterally nephrectomised 
rats; i.c.v. delivery had no effect (Gomez-Sanchez, 1986).  Similar results have been 
obtained using carbenoxolone to inhibit 11βHSD2 (Gomez-Sanchez and Gomez-
Sanchez, 1992).  However, these studies are limited by the non-selective nature of 
carbenoxolone (Hult et al., 1998) and the spill over effects of i.c.v. and s.c. drug 
delivery.  The use of cre-lox technology to selectively delete 11βHSD2 permits a 
more accurate evaluation of the role of the enzyme than enabled by the global 
11βHSD2-/- mice, or the use of s.c. and i.c.v. inhibitor administration.  The studies 
described, in combination with the preliminary data from KRDKO mice, support the 
hypothesis that the altered water turnover observed in the global 11βHSD2-/- mice is 
of renal origin. 
 
4.4.2.2.  Deletion of 11βHSD2 in the brain resulted in an increased salt 
appetite 
Despite strong circumstantial evidence (Cooney and Fitzsimons, 1996, Geerling et 
al., 2006a), the role of 11βHSD2 in salt appetite is yet to be confirmed.  The 
investigations described in this chapter demonstrated that salt appetite was 
augmented in the brain 11βHSD2-/- mice.  Furthermore, the brain 11βHSD2-/- mice 
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preferred to drink 1.5% NaCl to water, with saline accounting for ~70% of their total 
fluid intake. Therefore, the loss of 11βHSD2 function in the brain, specifically the 
NTS, caused increased sodium intake.  Typically salt appetite is driven by sodium 
depletion and the resultant volume contraction (Geerling and Loewy, 2008).  
However, since basal renal sodium handling and plasma sodium concentrations were 
normal in the brain 11βHSD2-/- mice there was no physiological drive for the 
increased salt intake and it was not retained chronically.  These data are the first 
demonstration of salt appetite occurring in the absence of sodium depletion and with 
normal renal function.   
 
Since the maintenance of extracellular fluid status is essential for survival the drive 
to consume sodium during deficiency is highly motivated.    Recent data suggest that 
sodium intake can activate central reward pathways terminating in the nucleus 
accumbens (Voorhies and Bernstein, 2006), a region of the brain implicated in 
addictive behaviour.  The activation of such reward pathways may underpin the 
augmented salt intake in the brain 11βHSD2-/- mice. 
 
Interestingly, in salt deprived rats fitted with a gastric fistula to prevent sodium 
reabsorption, sodium intake activated neurons in the nucleus acccumbens.  Since the 
beneficial effects of sodium intake were prevented in this model, it was postulated 
that nucleus accumbens activation is involved in motivation to seek and ingest salt 
during sodium depletion.  Indeed, increased Fos-immuoreactivity in the nucleus 
accumbens was not found in sodium deprived rats without a gastric fistula.  In these 
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rats ingestion of sodium resulted in the normalisation of plasma sodium levels; 
consequently, the continued drive to consume salt was not necessary (Voorhies and 
Bernstein, 2006).  Dopaminergic pathways, which project to the nucleus accumbens, 
are central in the rewarding and reinforcing effects of drug abuse (Koob, 1992).  
These data raise the possibility that common neuropathways drive the motivation to 
seek salt.  In accord with this, repeated sodium deprivation and repletion induced 
morphological changes in the nucleus accumbens (Roitman et al., 2002), similar to 
the effects observed following repeated cocaine administration (Robinson et al., 
2001).  Such morphological changes are involved in sensitization, the increased 
response to a stimulus following its repeated administration.  Indeed, prior sodium 
deprivation challenges have been shown to increase salt appetite (Sakai et al., 1987, 
Sakai et al., 1989) and need free sodium consumption (Sakai et al., 1989) in rats.  
Sensitization to salt raises the possibility of salt addiction.  Microarray analysis 
demonstrated that many of the genes enriched in drug addiction models were also 
increased by sodium depletion and the resultant salt appetite.   Notably, 
dopaminergic pathways were implicated in both salt appetite and drug addiction.  
The physiological relevance of this finding was illustrated by the demonstration that 
dopamine receptor-1 antagonism selectively reduced salt intake in deplete rats 
(Liedtke et al., 2011).  The demonstration that mutisynaptic pathways project from 
the NTS to the nucleus accumbens (Shekhtman et al., 2007) add further support to 
the hypothesis that during salt appetite, NTS mediated activation of the nucleus 




4.4.2.3.  Activation of MR contributes to the increased salt appetite in brain 
11βHSD2-/- mice 
The antagonism of MR resulted in an approximately 40% reduction in sodium intake 
in the brain 11βHSD2-/- mice.  These results were specific for salt appetite since 
spironolactone had no effect on water intake in either group of mice, or on NaCl 
consumption in the floxed 11βHSD2 control mice.  These data suggested that the 
increased salt appetite was partly driven by the loss 11βHSD2 protection of MR in 
NTS.   
 
MR has been previously implicated in the drive to consume sodium.  Following 
coronary artery ligation, to induce chronic heart failure, rats developed an increased 
salt appetite.  Salt consumption was attenuated by the administration of 
spironolactone, suggesting that the increased appetite was partly driven by the over-
activation of MR (Francis et al., 2001).  These data may help explain the clinical 
observation that the concurrent administration of spironolactone with ACE inhibitors 
reduced the risk of death in severe heart failure patients (Pitt et al., 1999).  The 
mechanism by which spironolactone attenuated mortality was not determined, but it 
is possible that a reduced salt appetite contributed to its beneficial effects.  
 
In the brain 11βHSD2-/- mice spironolactone administration was unable to normalise 
NaCl consumption.  This may have been due to incomplete MR blockade in the NTS 
since the spironolactone was administered s.c.  The i.c.v. administration 
spironolactone may increase its effects on salt appetite.  Conversely, it is possible 
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that other factors contribute to the increased sodium intake.  Glucocorticoids have 
been shown to increase sodium intake in adrenalectomized rats (Kenyon et al., 
1984a).  Therefore, it is possible that the loss of 11βHSD2 function resulted in the 
overactivation of GR, which are also expressed in the NTS (Harfstrand et al., 1986).   
 
4.4.2.4.  The use of cre-lox technology to target 11βHSD2 in the NTS 
In the studies detailed the nestin promoter was used to drive cre-recombinase 
expression.  Since nestin is a neural stem cell marker, recombination is postulated to 
occur in the central nervous system, predominantly throughout neurogenesis.  This is 
illustrated in the X-gal staining, which is widespread in the brain.  Consequently, 
11βHSD2 was deleted in the brain throughout prenatal development.  During 
embryogenesis 11βHSD2 has a wide spread distribution, which restricts postnatally 
(Diaz et al., 1998, Holmes et al., 2006b).  It is possible therefore, that the increased 
salt appetite might reflect prenatally programmed changes in the brain rather than 
adult deletion of 11βHSD2 in the NTS.  Programmed changes in MR and GR within 
the brain have been observed in models of prenatal glucocorticoid overexposure, 
such as prenatal dexamethasone (Welberg et al., 2001) or carbenoxolone (Welberg et 
al., 2000) treated rats, however, such changes in receptor expression were not 
observed in the brains of global 11βHSD2-/- mice (Holmes et al., 2006a).  In this 
context, MR and GR expression in the NTS would be of particular relevance. 
 
In addition, overexposure to glucocorticoids can have detrimental effects on the 
development of the brain.  Development of the cerebellum, which continues 
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postnatally, was attenuated in 11βHSD2-/- mice (Holmes et al., 2006b).  Cerebellum 
size was reduced in the null mice, which correlated with an impaired ability to 
perform the behavioural tests used to assess neurodevelopment.  It is therefore 
possible that the increased salt appetite observed in the brain 11βHSD2-/- mice 
resulted from altered neurodevelopment rather than the loss of 11βHSD2 function in 
the NTS.  To evaluate this further, a temporally inducible cre could be used, such as 
a tamoxifen-dependent cre recombinase.  This would enable the activation of cre 
recombinase in adult mice (for discussion of the technique see (Feil et al., 1996).  
This would not only ensure specific deletion of 11βHSD2 in the NTS, but it would 
also eliminate the confounding effects of altered neurodevelopment. 
 
Enzyme activity analysis demonstrated that 11βHSD2 activity was reduced by ~75% 
in the foetal brain at E13.5.  Therefore the data from the adult mice should be 
interpreted in the context that the activity of 11βHSD2 in the NTS was substantially 
reduced, rather than entirely eliminated.  Nestin driven recombination has also been 
characterised systemically, notably in the murine kidney at E15.5 (Dubois et al., 
2006).  This raises the possibility of renal targeting of 11βHSD2 in the brain 
11βHSD2-/- mice.  However, in view of the normal enzyme activity, and the absence 
of X-gal staining in the adult kidney, it is unlikely that a significant loss of renal 











Chapter 5:  Conclusions and Perspectives 
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The studies detailed in this thesis evaluated the role of 11βHSD2 in the regulation of 
salt and water homeostasis.  The novel findings were: 
1. 11βHSD2-/- mice develop a severe and progressive nephrogenic diabetes 
insipidus like phenotype, characterized by polyuria, polydipsia and 
natriuresis.  The increased urine flow is renal in origin, driven by an impaired 
renal response to vasopressin stimulation.  As in other models of 
glucocorticoid excess, an impaired medullary concentration of urea also 
contributes to the polyuria. 
2. In >180 day 11βHSD2-/- mice the exacerbated polyuria is associated with 
severe renal injury.  The medullary atrophy observed at this age results in 
decreased NKCC2 mRNA abundance.  Therefore, the loss of the cortico-
medullary gradient augments the phenotype at this age. 
3. Mice in which 11βHSD2 has been specifically targeted in the brain have 
normal water handling and kidney function, confirming a renal origin to the 
polyuria in the global null mice 
4. Mice in which 11βHSD2 has been specifically targeted in the brain have an 
increased salt appetite.  Blockade of MR significantly and selectively reduced 
NaCl intake.  Since 11βHSD2 is exquisitely expressed in the NTS in adult 
mice these data implicate over-activation of MR on 11βHSD2 positive 
neurons in the NTS in salt appetite 
 
In this chapter these findings will be discussed in wider context of the AME and their 
potential clinical implications.  
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5.1:  Loss of 11βHSD2 in the NTS causes increased salt appetite 
The demonstration of increased salt appetite driven by the selective targeting of 
11βHSD2 in the NTS is novel and potentially, has wide clinical implications.  
Increased salt appetite has deleterious effects on the progression of many clinical 
conditions, including hypertension, congestive heart failure and chronic kidney 
disease (Strazzullo et al., 2009, Sanders, 2004).  In ~15% of hypertensive individuals 
increased aldosterone is implicated in the progression of the disease (Freel and 
Connell, 2004).  Based on the data presented in this thesis, it is likely that 
aldosterone excess, perceived or actual, accelerates hypertension through two 
mechanisms: by reducing the ability of the kidney to excrete sodium and by 
increasing the behavioural drive to consume sodium.  This may help explain the 
notoriously poor compliance to low sodium diets in patients with hypertension (Ohta 
et al., 2004, Luft et al., 1997).  It could be that the patients who would benefit most 
from a low salt diet have the highest innate salt appetite.  Chronic heart failure is 
another condition in which the consumption of a low sodium diet is recommended 
(Hunt et al., 2005).  Notably, the RALES trial demonstrated that the administration 
of spironolactone resulted in a 30% reduction in the risk of death from all cardiac 
causes (Pitt et al., 1999).  The mechanism by which spironolactone reduced mortality 
was not determined, however in the context of the data presented here it is possible 
that a reduced salt appetite was contributory to its salubrious effects.  In support of 
this hypothesis is the demonstration that spironolactone reduced salt appetite in the 
rat model of congestive heart failure (Francis et al., 2001). 
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5.2:  Nephrogenic diabetes insipidus like phenotype in 11βHSD2-/- mice 
A key finding from the current studies is the nephrogenic diabetes inspidus like 
phenotype in the 11βHSD2-/- mice.  In the null mice the increased water turnover was 
postulated to be the result of reduced AQP2 abundance, which may have been 
secondary to a renal insensitivity to AVP stimulation.  At >180 days exacerbated 
polyuria was associated with extensive medullary atrophy.  Although the overarching 
cause of the phenotype was not determined, it is postulated that hypokalemia has a 
central role.   
 
A cardinal feature of AME, and the 11βHSD2-/- mice, is hypokalemia (Bailey et al., 
2008, Kotelevtsev et al., 1999, Ferrari, 2010).  Indeed much of the phenotype 
described in the null mice can be attributed to low plasma potassium.  As discussed 
in section 3.4.1.1 the administration of a low potassium diet to rats resulted in the 
development of polyuria and polydipsia.  The increased water turnover was the result 
of reduced AQP2 abundance, in accordance with the phenotype observed in the 
11βHSD2-/- mice.  The restoration of plasma potassium resulted in the normalisation 
of urine flow in the hypokalemic rats (Marples et al., 1996).  Low plasma potassium 
is also associated with renal injury, with the induction of hypokalemia resulting in 
tubular dilation, hypertrophy, hyperplasia and local inflammation in rats (Suga et al., 
2001, Reungjui et al., 2008).  Renal injury was most pronounced within the medulla, 
possibly driven by reduced renal oxygenation.  Indeed, since pertitubular capillary 
loss correlated with the extent of hypokalemia impaired angiogenesis and local 
hypoxia were implicated in the nephropathy (Reungjui et al., 2008, Suga et al., 
2001).  It is possible therefore, that hypokalemia induced hypoxia contributed to the 
 197 
development medullary atrophy in the >180 day 11βHSD2-/- mice.  Notably, in 
humans, low plasma potassium alone may not be sufficient to induce nephropathy.  
Severe hypokalemia occurs in both Gitelman’s and Barrter’s syndromes, however, 
only in the latter is impaired renal function observed (Walsh et al., 2011).  
Consequently, it was postulated that clinically “hypokalemic nephropathy” may be 
dependent on hyperaldosteronism.  Whether hypokalemia, and the perceived 
hyperaldosteronism, result in nephropathy in AME has not been extensively studied.  
 
Finally, plasma potassium is receiving increasing attention as a key determinant of 
blood pressure, with low potassium diets implicated in the development of 
hypertension (Adrogue and Madias, 2007).  Moreover, there is clinical evidence that 
potassium supplementation can reduce blood pressure in both normotensive and 
hypertensive subjects (Braschi and Naismith, 2008, Geleijnse et al., 2003).  The 
mechanisms underlying potassium’s beneficial effects are undetermined, however 
the demonstration that potassium reduces vascular endothelium stiffness and induces 
nitric oxide release suggests that increased vascular compliance may be contributory 
(Oberleithner et al., 2009).  In the context of these data, whether the normalisation of 
plasma potassium would rescue the phenotype in the 11βHSD2-/- mice is of interest. 
 
In view of their hypokalemia, it is surprising that urinary potassium excretion was 
not significantly lower in the 11βHSD2-/- mice than aged-matched controls, and 
indeed suggests that renal losses may contribute to the potassium depletion.  There 
are two possible causes for renal potassium loss, which are not mutually exclusive: 
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impaired reabsorption and increased secretion.  The cause for the relatively high 
potassium excretion in 11βHSD2-/- mice is undetermined.   
 
Potassium is reabsorbed in the proximal tubule and thick ascending limb, and 
secreted in the ASDN.  The demonstration that NKCC2 mRNA abundance was not 
significantly different in 11βHSD2-/- and C57Bl/6 mice at <100 days suggests that 
impaired potassium reabsorption in the thick ascending limb was not causative, at 
least at this age.  This implicates increased potassium secretion in the phenotype.  In 
Type II Bartter’s syndrome the persistent kaliuresis, in the face of severe 
hypokalemia, is attributed to increased BK mediated potassium secretion in the distal 
nephron (Bailey et al., 2006).  Notably, the calcium-dependent, BK-mediated 
potassium secretion is stimulated by increased flow rates (Liu et al., 2007).  
Therefore, it is postulated that in the 11βHSD2-/- mice the sustained hypokalemia and 
normal potassium excretion may be due to flow stimulated potassium secretion in the 
distal nephron.  Hypertrophy and hyperplasia have been reported in the distal 
convoluted tubules of 11βHSD2-/- mice (Bailey et al., 2008): whether the structural 
changes are associated with altered function, namely potassium handling, is therefore 
of interest.  The paradox of this hypothesis is that hypokalemia is postulated to be 
involved in the initiation of polyuria, which itself, through the stimulation of BK, 
may augment renal potassium losses.  In view of the complexity of the phenotype, 
the evaluation of isolated perfused tubules from 11βHSD2-/- mice would help dissect 
the function of renal potassium handling in the model. 
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5.3:  Central and renal components to the phenotype in 11βHSD2-/- mice 
Severe polyuria and natriuresis were observed in the 11βHSD2-/- mice at <100 and 
>180 days.  In view of the sustained hypertension reported in the model (Bailey et 
al., 2008, Kotelevtsev et al., 1999), these data suggest that mechanisms other than 
sodium and water retention are involved in the maintenance of the elevated blood 
pressure 
 
Indirect evidence of increased sympathetic nerve activity has been documented in the 
11βHSD2-/- mice.  Urinary catecholamine excretion was approximately doubled in 
the null mice, and α1-adrenoreceptor antagonism normalised blood pressure (Bailey 
et al., 2008).  Consequently, sympathetic overdrive was implicated in the 
hypertension.  As reviewed (Grassi, 2009) sympathetic overdrive is a key component 
of hypertension.  Evaluation of neuroadrenergic function in hypertensive patients has 
demonstrated the association between increased sympathetic nerve activity and 
augmented blood pressure.  Moreover, the degree of hypertension has been shown to 
directly correlate with the extent of sympathetic nerve activity, supporting a 
cause/effect relationship between the two factors (Grassi, 2009, Grassi et al., 1998).  
Whether sympathetic overdrive is a component of both essential and secondary 
hypertension is contentious.  Although sympathetic overdrive has been consistently 
documented in essential hypertension, it has not been robustly demonstrated in 
secondary forms (Grassi, 2009, Grassi et al., 1998).  Despite this, anti-adrenergics 
have been shown to reduce blood pressure in AME, in situations where MR blockade 
and cortisol suppression were not effective (Morineau et al., 2006).  Clearly, the 
kidneys have a pivotal role in the control of blood pressure, however, it has recently 
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been postulated that there is a centrally determined set point which is implicated in 
its long term regulation.  Since the NTS receives afferent inputs from both arterial 
chemoreceptors and baroreceptors it is proposed to be a central site of blood pressure 
regulation (Zanutto et al., 2010). 
 
Increased blood pressure causes the activation of baroreceptors located in the aortic 
arch and carotid sinuses.  Afferents from these regions project to the NTS, which 
though activation of GABAergic neurons in the caudal ventrolateral medulla 
(CVLM), cause the inhibition of the sympathetic premoter neurons in the rostral 
ventrolateral medulla (RVLM) that promote vasoconstriction (Schreihofer and 
Guyenet, 2002).  Therefore, NTS mediated activation of this sympathoinhibitory 
pathway results in a depressor response.  Accordingly, bilateral carotid occlusions to 
induce hypertension have been shown to result in reduced adrenaline and 
noradrenaline release from the rostral NTS (Philippu et al., 1991).  Similarly, 
noradrenaline infusion to induce blood pressure increases resulted in reduced 
adrenaline release from the NTS (Singewald et al., 1992).  These data suggest that in 
response to increased blood pressure, the NTS mediates a reduction in sympathetic 
nerve activity, in an attempt to normalise blood pressure.  In contrast chemoreceptors 
located in the carotid and aortic bodies respond to reductions in blood pressure.  
Afferents from these regions also project to the NTS.  In this instance it is proposed 
that afferents from the commissural NTS project to the RVLM and activate the 
vasoconstrictor sympathetic premoter neurons, therefore eliciting a pressor response.  
In line with this hypothesis, inhibition of neurons within the commissural NTS 
resulted in reduced sympathetic nerve activity and subsequently arterial blood 
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pressure in SHR rats (Koshiya and Guyenet, 1996, Sato et al., 2002).  Together these 
data support the hypothesis that the NTS is a site of integration, responding to, and 
counteracting peripherally detected changes in blood pressure. 
 
In view of the increased urinary catecholamine excretion in the 11βHSD2-/- mice 
(Bailey et al., 2008), it is postulated that the loss of 11βHSD2 in the NTS results in 
an inappropriate sympathetic response to augmented blood pressure.  In this context 
the following hypotheses are proposed: in the 11βHSD2-/- mice hypertension is 
primarily renal in origin, driven by the increased retention of sodium and water, 
occurring at time points prior to those investigated.  The loss of 11βHSD2 function 
in the NTS results in an impaired countervailing response to the initial blood 
pressure increase, such that an augmented centrally determined set point is 
established.  Subsequently, inappropriate NTS driven sympathetic output and the 
resultant vasoconstriction may promote the maintenance of the hypertension.  This 
would explain the acute hypotensive response to α1-adrenoreceptor blockade in the 
11βHSD2-/- mice (Bailey et al., 2008).  At <100 days, polyuria and natriuresis may 
be a renal compensatory response to the increased blood pressure, in line with the 
Guytonian hypothesis (Figure 5.1).  Whether renal sympathetic nerve activity is 
augmented in the 11βHSD2-/- mice is of interest, in view of the fact that increased 
activity would promote renal sodium and water retention (DiBona, 2000).  By >180 
days the augmented water turnover is associated with severe renal damage, which no 
doubt contributes to the exacerbation of polyuria at this age.  Given that the NTS is 
implicated in the response to blood pressure perturbations this could explain the 
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Although basal blood pressure was not altered by the deletion of 11βHSD2 in the 
NTS, these data must be considered in the context of the increased salt appetite, and 
the impaired renal sodium handling, driven by the loss of 11βHSD2 in the brain and 
kidney respectively.  During augmented sodium intake, the brain 11βHSD2-/- mice 
were able to remain in a normal balance because of their ability to excrete the 
Figure 5.1:  Proposed mechanism of hypertension in 11βHSD2-/- mice 
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increased levels of sodium.  In line with the Guytonian view of blood pressure 
regulation, this prevented the development of hypertension.  However, the long term 
consequences of the increased salt intake are unknown.  Chronic studies in 
chimpanzees have demonstrated that the prolonged consumption of a high salt diet 
resulted in increased blood pressure (Denton et al., 1995).  These data provide a link 
between increased salt appetite/intake and the development of hypertension.  
Moreover, in the global 11βHSD2-/- mice renal sodium handling is impaired.  This 
suggests that in the 11βHSD2-/- mice, the renal ability to handle the increased sodium 
intake would be diminished: which in turn could exacerbate the observed 
hypertension.  In this context the effect of an increased salt appetite on blood 
pressure in the global 11βHSD2-/- mice is of interest.  Additionally, in view of the 
role of the NTS in the modulation of blood pressure, it is likely that the loss of 
11βHSD2 in this region would result in an impaired central regulatory response to 
such a challenge.  In line with these hypotheses is the demonstration that blood 
pressure was exacerbated by a high salt appetite in a patient with a partial loss of 
11βHSD2 function (Ingram et al., 1996).  Therefore, the tissue specific targeting of 
11βHSD2 in the kidney and brain can provide valuable insights into the complexity 
of the phenotype observed in the global 11βHSD2-/- mice and patients with AME.   
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